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Abstract 
The Wnt signalling pathways play crucial roles in development, tissue patterning, and stem cell 
fate determination. These pathways are therefore an attractive therapeutic target in the field of 
regenerative medicine and tissue engineering. Magnetic nanoparticles (MNP) are useful tools in 
bio-engineering. Previous work from our group has demonstrated the efficacy of targeting and 
activating cell signalling pathways using MNP functionalised with targeting proteins coupled with 
magnetic fields to remotely torque the MNP. Using this approach, in this work MNP were 
functionalised with ligands targeted to cell surface Frizzled receptors which are involved in Wnt 
signal transduction. The effects of remote stimulation with MNP on Wnt pathway activity were 
then assessed in human mesenchymal stem cells (hMSC).  Results demonstrated that targeting of 
Frizzled receptors with MNP and remote stimulation using magnetic fields remotely activated Wnt 
signalling pathways. This was indicated by nuclear mobilisation of β-catenin and activation of a 
TCF/LEF luciferase reporter. The effect of remote Wnt pathway activation on hMSC osteogenesis 
was subsequently assessed. Activation was shown to augment hMSC differentiation in monolayer 
experiments where expression of osteogenic markers increased. This strategy also had beneficial 
effects on bone formation in an ex vivo foetal chick femur model as indicated by μCT and 
histology. The role of spatial Wnt gradients on bone formation is also important in development 
and was investigated using a tissue engineering platform utilising immobilised Wnt protein. In 
conclusion, these studies demonstrate the use of MNP to remotely activate Wnt signalling 
pathways and have shown potential in directing hMSC differentiation. This provides proof of 
concept for new injectable therapies that modulate cell signalling pathways with applications in 
regenerative medicine. 
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Introduction 
Increasing life expectancy has resulted in a shift in the world’s demography towards an 
ageing population. This is a testament to the success of medical advancements but has 
also led to increased incidence of chronic disease which is now putting increasing strain 
on healthcare systems. A major part of this problem is the incidence of bone fractures. 
Current treatments often involve fixing afflicted limbs for prolonged periods or 
performing bone transplants. One particular problem is that these interventions often 
require multiple rounds of invasive surgery which can have long-term effects on patient 
outcome.  
As such there is growing interest in the development of novel therapies to improve the 
clinical outcome for patients afflicted with orthopaedic pathologies. One area of research 
that strives to meet the developing need for new orthopaedic healthcare treatments is 
tissue engineering and regenerative medicine (TERM). The aims of TERM are to develop 
new tissue engineered constructs that utilise stem cells in combination with advanced 
materials which can be implanted into the patient to promote tissue regeneration.  There 
are many such systems in development that are geared towards driving stem cell 
differentiation towards lineages that are involved in tissue formation.   
One novel approach which has gained interest over recent years is the use of magnetic 
nanoparticles to condition stem cells. This can be achieved by tailoring the functionality of 
the nanoparticle surface to enable control over where the nanoparticles bind.  Magnetic 
fields can then be used to remotely induce direct mechanical forces to the cells via 
twisting of the nanoparticles. Recent work has demonstrated the feasibility of using 
nanoparticle targeted to specific cell receptors and ion channels to remotely stimulate 
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cell signalling pathways in order to influence stem cell behaviour. This strategy has been 
demonstrated to have beneficial effects on stem cell differentiation towards bone 
forming osteoblasts that results in putative bone formation. 
One signalling pathway that is known to regulate stem cell differentiation towards the 
bone lineage is Wnt signalling. This pathway is therefore an attractive target for 
modulation in a bone tissue engineering context. To date, the potential for targeting Wnt 
signalling pathways in stem cells using nanoparticles has not been investigated. Neither 
have the effects of mechanoactivation of these pathways on stem cell behaviour or 
osteogenesis. 
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Aims of this thesis 
The primary aim of this thesis was to determine the feasibility of targeting the Wnt 
signalling pathway for remote activation in a clinically relevant stem cell type, human 
mesenchymal stem cells (hMSC). Wnt signalling pathways are involved in the regulation 
of stem cell fate including hMSC, therefore novel strategies for the modulation of this 
pathway are of particular relevance to stem cell biology and tissue engineering. This aim 
was explored with the use of magnetic nanoparticles (MNP) that were functionalised with 
ligands targeted to the Wnt receptor Frizzled. This is a novel way of targeting and 
controlling cell signalling pathways in order to influence cell behaviour.  
The secondary aim was to assess the effects of functionalised MNP mediated Wnt 
pathway activation on the osteogenic differentiation of hMSC. This is particularly relevant 
to bone tissue engineering where new treatments are currently needed. With this in 
mind, the aim was to demonstrate the feasibility of a magnetic stem cell activation 
approach which can inform the development of future injectable cell therapies. This aim 
was assessed in two ways. Firstly the osteogenic response of hMSC to MNP in vitro was 
assessed in monolayer cell culture experiments. Secondly, the translational applications 
of this strategy was assessed using an ex vivo foetal chick femur model of bone 
development. The third aim of this thesis was to introduce and briefly explore the role of 
Wnt gradients presented in a spatial manner in maintaining the MSC niche. This facet of 
cell signalling is often overlooked but plays critical roles in regulating tissue development. 
This aim was investigated with the use of a novel tissue engineering platform featuring 
immobilised Wnt protein overlaid with cells and collagen hydrogel. 
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1. Chapter 1: Literature Review
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This thesis will be focusing on the osteogenic differentiation of stem cells and bone 
formation strategies in tissue engineering. An understanding of bone structure, re-
modelling and repair is therefore required and will be provided in the following sections.   
1.1 Bone 
1.1.1 Role and components of bone 
Bone is a specialised form of connective tissue which has multiple roles in the body. The 
principle role of bone is to provide support and stability for the body; it also provides 
protection for vital organs and acts as a framework that allows movement. Bone also acts 
as a store for ions such as calcium, magnesium and phosphorus (Hull, 2011). Bone tissue 
is mainly composed of collagen fibres which constitute around 85% of bone protein and a 
crystalline matrix of calcium phosphate (Currey, 2013). Together these constituents 
enable bone to resist externally applied tensile stresses and compressional forces (Khan, 
2001). Other constituents of bone include proteoglycans and non-collagenous proteins 
such as osteopontin and osteocalcin which play a number of roles in regulating bone 
formation. These constituents act as nucleators for calcium phosphate deposition, bind to 
and control the bio-availability and activity of growth factors and regulate cellular 
processes which control bone metabolism. Bone also contains multiple cell types which 
control tissue development, these cell types include osteoblasts, osteoclasts, osteocytes 
as well as osteoprogenitor and stem cells (Bilezikian et al., 2008), (Hollinger et al., 2004).  
1.1.2 Structure of bone 
Bone is categorised into four classes: long, short, flat and irregular bone. Examples of 
these four types include the femur, carpals, cranium and vertebrae respectively. On a 
macro scale bone is broadly organised into two types, cortical and cancellous bone. These 
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bone types are classified according to their strength, structure and porosity. Cortical 
bone, also known as compact bone is much denser, less porous (less than 5%) and 
stronger than cancellous bone. Cortical bone is mainly found along the shafts of long 
bones and covering cancellous bone at the epiphyseal ends of long bones. The micro 
structure of cortical bone consists of tightly packed Haversian systems which contain 
blood vessels and are surrounded by canaliculi and concentric lamellae which all together 
form osteons. Cancellous bone, which is also known as trabecular bone is more porous in 
structure and mechanical weaker than cortical bone. Cancellous bone consists of an 
interconnected matrix of mineralised rods and plates which together form an inter-
connected network known as a trabecular network. The pores in between the trabeculae 
contain the bone marrow. Cancellous bone is mainly found in the centre of long bones 
and makes up approximately 20% of the human skeleton. Bones are lined by a periosteal 
layer which is involved in bone repair and consists of a cell layer which harbours 
osteoblasts, osteoclasts and osteoprogenitor cells and an outer fibrous layer mainly 
consisting of  collagen fibres as well as vasculature and nerve fibres (Clarke, 2008), 
(Mortensen, 2006), (Steele and Bramblett, 1988), (Singh, 2014).  The macro- and 
microscopic structure of bone is illustrated in Figure 1.1. 
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Figure 1.1. Structure of bone. 
Illustration depicting the micro- and macroscopic structure and components of long 
bones. Image reproduced with permission from Mescher 2009 (Mescher, 2009)  
 8 
 
1.1.3 Bone formation mechanisms 
There are two mechanisms of bone formation, these are known as intramembranous and 
endochondral ossification. Intramembranous formation describes bone that is directly 
synthesised by differentiated mesenchyme tissue and is the prominent process behind 
flat bone formation. This process is controlled by mesenchymal stem cells (MSC) which 
first proliferate, form aggregations, then differentiate down the osteogenic lineage to 
become bone forming osteoblasts. These cells are responsible for synthesis of new bone 
matrix (Gilbert, 2000).  The second mechanism of bone formation, endochondral 
ossification, is a multi-step process that involves deposition of new bone by osteoblasts 
over a pre-established cartilaginous matrix. This matrix is deposited by chondrocytes. This 
mechanism of bone formation plays a major role in the formation of long bones (Claes 
and Willie, 2007), (Gilbert, 2000). An important part of later bone formation is 
angiogenesis which initiates vascularisation of the developing tissue and allows nutrient 
transfer for the propagation of bone formation (Wohl et al., 2009). 
1.1.4 Limb bud formation during development  
In vertebrate embryogenesis, limb development begins with cell outgrowths from the 
embryonic body wall. These outgrowths are known as limb buds and consist of a 
condensation of mesenchymal cells belonging to the mesoderm lineage. At their distal 
ends, the limb bud is covered by an epithelial layer of the ectoderm lineage known as the 
apical ectodermal ridge (AER) (Pownall and Isaacs, 2010). The cells of the AER are 
involved in maintaining the development and outgrowth of the limb bud by creating 
temporal and spatial signalling gradients of fibroblast growth factor (FGF) members which 
orchestrate limb development (Martin, 1998), (Niswander et al., 1993). The cells proximal 
to the AER, under the influence of FGFs, remain in an undifferentiated state during 
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outgrowth. Conversely, the mesenchymal cells distal to the AER and proximal to the body 
wall fall under the influence of Retinoic acid and begin to form condensations. 
Mesenchymal condensation is followed by specification and differentiation of these 
mesenchymal cells distal from the AER progress zone  (Yashiro et al., 2004), (Mercader et 
al., 2000). The next stage of development involves limb patterning. This process is fine-
tuned by expression of a variety of other signalling factors including members of the Sonic 
hedgehog (Shh), Wingless related integration site (Wnt), Homeotic (HOX) gene family 
members (Ahn and Joyner, 2004), (Riddle et al., 1995), (Kengaku et al., 1998). At later 
stages of development members of the Bone morphogenetic protein family (BMP), such 
as BMP2 and 7, are involved in inducing differentiation of stem cell progenitors towards 
the bone and cartilage forming lineage. This process is required for bone formation to 
progress through endochondral ossification (Kang et al., 2004), (Hogan, 1996).      
1.1.5 Bone remodelling 
Bone remodelling is a continual and crucial process throughout life. This process adapts 
the architecture of bone structure according to the magnitude of mechanical forces 
applied to the tissue. This phenomenon was first suggested by Julius Wolff in the 19th 
century and is known as Wolff’s law. The bone remodelling process helps to preserve 
bone integrity by enabling the tissue to withstand increased loads (Maquet et al., 2012). 
Bone remodelling ultimately ensures appropriate bone turnover and maintains tissue 
homeostasis by removing old or damaged bone and depositing new bone to load-bearing 
regions. The bone remodelling process consists of three phases: resorption, reversal and 
synthesis. Bone resorption involves the removal of old bone and is mediated by 
osteoclast cells, which release hydrogen ions and lysosomal enzymes to break down and 
remove old bone. The resorption phase may last for up to two weeks. The second phase 
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is known as the reversal stage. During this time mononuclear cells prime the bone surface 
and secrete signals that cause the recruitment and differentiation of osteoblast cells; this 
stage last for around five weeks. The final stage of remodelling is the bone formation 
stage, this is where new bone is synthesised by osteoblasts. Osteoblasts synthesize and 
secrete new matrix which is eventually mineralised. The formation stage may continue for 
months (Hadjidakis and Androulakis, 2006). At the cellular level, bone remodelling is 
controlled by the action of bone resorbing osteoclasts and bone forming osteoblasts.  The 
remodelling process is delicately balanced and tightly regulated by multiple factors. The 
action and activity of osteoblasts and osteoclasts is regulated by many signals such as 
growth, hormonal and cytokines as well as the genetic, nutritional and mechanical 
environment. Imbalances in the activity between these cells has serious consequences on 
tissue integrity and mechanical stability. If the action of osteoclasts is higher than 
osteoblasts, this inevitably leads to lower bone mass and is the major pathology behind 
Osteoporosis and Paget’s disease (Tanaka et al., 2005), (Kini and Nandeesh, 2012), (Raisz, 
1999), (Fraher, 1993). In the opposite scenario, where osteoblast activity is higher than 
osteoclast activity, this leads to a high bone mass phenotype and is seen in conditions 
such as Sclerosteosis and Van Buchem disease (Ahituv, 2012).   
1.1.5.1 Mechanical forces in bone remodelling 
The bone remodelling process is particularly sensitive to environmental factors, especially 
externally applied forces which are present during normal activities such as exercise. 
Mechanical forces cause small deformations in the shape of bone which results in 
pressure changes and oscillatory fluid flow in the canaliculi network (Klein-Nulend et al., 
2005). These changes are sensed by osteocytes embedded in bone matrix which release 
numerous signalling factors such as Nitric Oxide (NO), BMPs, Wnts and Prostaglandin E2 
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(PGE2). These signalling factors direct the activation and differentiation of osteoblasts and 
Osteoprogenitor cells and regulate the behaviour of osteoclasts (Robling et al., 2008), 
(Tan et al., 2007), (You et al., 2008), (Santos et al., 2009), (Santos et al., 2011), (Jiang and 
Cheng, 2001), (Kitase et al., 2010). Osteoblasts are also mechanosensitive and respond to 
external forces by proliferating and increasing matrix protein production (Liedert et al., 
2006). Ultimately, external forces have profound effects on bone homeostasis, 
remodelling and the load bearing capacity of the tissue (Chen et al., 2008), (Knothe Tate 
et al., 2008). 
1.1.6 Bone repair mechanism 
 Bone tissue can be damaged through many mechanisms such as disease or trauma. The 
bone repair process is divided into three main phases and is depicted in Figure 1.2. Phase 
one is known as the inflammatory phase which lasts for approximately one week and is 
characterised according to the inflammatory response caused by an injury. This stage 
involves formation of a haematoma and recruitment of immune cells and subsequent 
initiation of angiogenesis which precedes the repair phase. The next phase is the repair 
phase and commences within days after injury and lasts for several weeks. This phase 
involves callous tissue formation which consists of fibrous connective tissue that provides 
support and stability for the injury site. This stage also sees the recruitment and 
differentiation of mesenchymal stem cells which eventually differentiate into osteoblast 
cells which synthesis new bone via intramembranous ossification. At the callous 
periphery, mesenchymal cells differentiate towards the chondrocyte lineage and form a 
cartilaginous matrix. New bone is synthesized over the cartilaginous matrix through the 
process of endochondral ossification. By this point the calcified callous becomes more 
rigid, is invaded by blood vessels and begins to resemble woven bone. The final stage of 
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bone repair is known as the remodelling phase and involves resorption of excess bone 
and conversion of woven bone to lamellar bone. This process may be active for several 
years and is fine-tuned according to the mechanical stability of the remodelled bone at 
the fracture site (Sfeir et al., 2005).  
Figure 1.2. Fracture repair mechanism.  
Illustration of the fracture repair process. The repair process consists of three distinct 
phases, an inflammatory phase, a reparative phase and a final remodelling phase. Image 
reproduced with permission from Sfeir et al. 2005 (Sfeir et al., 2005) 
 13 
 
The bone repair process is also affected by the mechanical environment present during 
healing. If a fractured bone is given the correct support and fixed in place then callous 
formation and intramembranous bone formation leads to properly mineralised and 
repaired tissue. However complications can occur during the healing process that can 
lead to extended healing times, inadequate re-mineralisation, tissue regeneration and 
mechanical instability (Gomez-Benito et al., 2011). This is exemplified by the observation 
that healing is delayed when load is applied to fractured limbs too soon after injury 
(Gardner et al., 2006). 
 
1.2 The embryonic chick as a model of bone formation 
One well studied model of limb development that has been prominently used in research 
is the chick embryo. Later models of post-natal chick bone development have also been 
adopted to study the processes underpinning bone development. One example here is 
the embryonic femur which is now a well-established tool for studying bone development 
in vitro and ex vivo. Due to the ease of isolation and capability for high throughput 
experiments, this model is especially useful as a screening tool in the development of new 
therapies. Another advantage of this model is that the underlying developmental 
similarities, particularly in the signalling process, between vertebrate species means that 
the knowledge gained from these models can inform the developmental process in 
humans. Many groups have applied the embryonic chick model to study the process of 
embryonic bone and cartilage formation and repair (Anderson and Reynolds, 1973), (Todt 
and Fallon, 1984), (Roach, 1990), (Takahashi et al., 1991). Subsequent work has revealed 
the network of signalling processes such as Wnt and FGF signalling that underpin limb 
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growth, patterning and bone formation in vertebrates (Satoh et al., 2010), (Yonei-Tamura 
et al., 1999), (Maruyama et al., 2010), (Jin et al., 2012). The foetal chick model has 
remained an invaluable research tool today where it is used as a screening tool to inform 
the development of new treatments, especially in the field of bone tissue engineering  
(Smith et al., 2012), (Smith et al., 2015), (Smith et al., 2014a), (Smith et al., 2014b), 
(Kanczler et al., 2012).   
 
1.3 Orthopaedic pathologies 
The advances of modern medicine have continued to extend life expectancy and have 
subsequently led to an ageing population. Unfortunately quality of life has not kept pace 
with this extension in lifespan. One of the major impactors on this is mobility, which is 
compromised by orthopaedic pathologies. Osteoarthritis is a major problem caused by a 
loss of articular cartilage and friction between bones. This causes significant pain and 
discomfort in affected joints and affects 13.9% of adults aged 25+  and 33.6% (12.4 
million) of people aged 65+ in the US (Helmick et al., 2008). Bone can also be damaged as 
a result of malignancies such as Ewing sarcoma, Osteosarcomas and Multiple Myeloma (Li 
and Siegal, 2010). Bone fractures are also particular problems. Fractures are caused by 
trauma or arise as a result of Osteoporosis, and are the most common bone pathology in 
adults. In the US there are approximately 58 million people considered to be at risk of 
Osteoporosis and over 6 million cases are reported annually. 5-10% of these cases result 
in complications in healing that frequently require multiple surgical interventions. 
Orthopaedic pathologies such as osteoporosis are particular problems in the elderly and 
women especially.  This is due to many factors; the bone formation and repair 
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mechanisms become less efficient with age due to physiological changes in hormone 
production. Decreased osteoblast activity and decline of stem cell populations or 
differentiation is also observed. As such, bones gradually lose mass, become more 
porous, the healing process takes considerably longer and is less efficient (Gruber et al., 
2006), (Claes and Willie, 2007), (Saxon et al., 2014). An added complication of bone 
fractures is the incidence of delayed and non-union fractures which have been reported 
to affect between 4-48% of Tibial fractures (Bhandari et al., 2001) and 1.7-7.5%  of 
Femoral shaft fractures depending on treatment (Canadian Orthopaedic Trauma, 2003). 
All of these pathologies require extensive and expensive surgical intervention.   
1.3.1  Current treatments 
The optimal treatment for orthopaedic conditions depends on the causes, site and extent 
of the injury to the tissue. The risk of bone fractures due to osteoporosis can be mitigated 
to a certain extent by altering life style factors such as increasing physical activity and by 
administering calcium supplements or hormone replacement therapy (in post-
menopausal women) in order to reduce bone loss (Saxon et al., 2014). However, when 
fractures do occur, the current gold standard treatments involve immobilisation of the 
afflicted limb using internal or external fixators and / or some form of reparative surgery. 
This may be achieved through bone grafts or implants which may consist of steel or 
titanium screws and plates which are used to stabilise damaged limbs. However, these 
treatments involve invasive surgery, usually require replacement or refinement at some 
stage and frequently lead to unsatisfactory clinical outcome for the patient (Stannard et 
al., 2007), (Park, 2012). With increasing cases of bone pathologies there is now a clear 
need for new scalable, effective and affordable treatments in order to meet the growing 
clinical need. These treatments will now be discussed. 
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1.3.2 Tissue engineering strategies 
One thriving area of research for the development of new clinical treatments is Tissue 
engineering and regenerative medicine (TERM). The aim of TERM is to develop new 
treatments that recreate the in vivo environment and developmental niche in order to 
provide the optimal conditions for tissue repair. The tools for TERM include the use of 
stem cells, biomaterials and growth factors. These tools can also be combined with 
bioreactor systems in order to provide an optimal growth environment for specific 
tissues. A crucial and central aim of TERM is to develop treatments that promote 
integration of grafts or implanted scaffolds and newly formed tissue with existing host 
tissue (El Haj et al., 2005).  
1.3.2.1 Growth factor delivery 
One aspect of TERM based treatments involves the application of growth factors to 
injured tissue in order to enhance host tissue formation. Growth factors provide 
biochemical cues to cells and are instrumental in guiding cell function and fate by 
influencing cell proliferation and differentiation. This strategy has shown promise in 
fracture and spinal injury repair where delivery of growth factors belonging to the Bone 
Morphogenetic protein (BMP) family e.g. BMP2 and BMP7 in conjunction with a collagen 
carrier have been shown to enhance bone repair and induce new bone formation. BMP 
based treatments have since been translated to the clinic and commercialised as a 
treatment for non-union fractures (Laursen et al., 1999), (White et al., 2007). Other 
growth factor treatments include Parathyroid hormone (PTH) which has been used in a 
number of models and translated to the clinic where it was shown to enhance bone 
repair for fracture healing (Barnes et al., 2008), (Ellegaard et al., 2010). A comprehensive 
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review of the growth factors used for in vivo bone repair in animal and clinical studies is 
discussed further by Gothard et al. (Gothard et al., 2014).  
1.3.2.2 Scaffolds 
Lots of current research has focused on the development and application of 
biocompatible biomaterials in tissue engineering. Biomaterials are defined as non-toxic, 
inert substances that can be implanted into living systems. A primary requirement for 
biomaterials is that they must have the capacity to integrate with host tissue; it is also 
advantageous if the materials are mechanically stable and easy to fabricate (Park, 2012). 
Biomaterials are especially useful as scaffolds which can be used to support and bridge 
damaged tissue that enable or enhance tissue repair by the host. In the context of bone 
tissue engineering, common scaffold materials that are used to support bone repair 
include inorganic materials such as tricalcium phosphate (TCP), hydroxyapatite based 
materials or bio-active glasses. Synthetic polymers such as Polylactic acid (PLA), 
Polyglycolic acid (PGA) or combinations of polymer materials are also popular due to their 
versatility. These materials are also relatively cheap and easy to fabricate and their shape 
and surface characteristics can be modified according to the desired application. 
Hydrogels such as polyethylene glycol (PEG) are also useful due to their elastic properties 
which mean they can be tailored to fit different defects. Also, their high water content 
means they can be delivered easily. Natural polymers such as collagen are also of interest 
in bone tissue engineering. Collagen is a major component of bone, and provides optimal 
cell attachment motifs although sourcing large scale amounts can be problematic 
(Stevens, 2008), (Bose et al., 2012), (Hutmacher, 2000). 
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1.3.2.3 Cell therapies 
 Another key element of TERM therapies revolves around the expansion and delivery of 
cells to the sites of injury.  Indeed there are established treatments already available in 
orthopaedics that utilise cell populations which can be directly injected to the site of 
injury or diseased tissue. An example here is cartilage repair by autologous chondrocyte 
implantation (ACI). Here chondrocytes are extracted from a patient, expanded in vitro 
and re-transplanted into the site of repair to promote new hyaline articular cartilage 
synthesis (Kon et al., 2012), (Roberts et al., 2003). This treatment has been extensively 
evaluated in high impact joints such as the knee, where ACI has been shown to be 
effective in restoring joint function and reducing pain (Macmull et al., 2012), (Beris et al., 
2012), (Bhosale et al., 2009). Bone tissue engineering cell therapies tend to focuses on the 
use of adult stem cells, such as the mesenchymal stem cell (MSC) derived from bone 
marrow or adipose tissue. Both sources of MSC have been shown to promote new bone 
growth for the repair of bone defects and necrotic bone tissue (Quarto et al., 2001), 
(Lendeckel et al., 2004), (Pak, 2012). The use of stem cells and mesenchymal stem cells 
will be discussed in the following sections. 
 
1.4 Stem Cells 
By definition Stem cells are undifferentiated cells that are capable of self-renewal, which 
preserves the stem cell population, or differentiation into other cell types, which gives 
rise to new tissue. Stem cells can be further classified according to their potency. In this 
regard embryonic stem cells, which can be isolated from the inner cell mass of a 5-6 day 
old blastocyst, are considered to be the archetypal stem cell due to their pluripotent 
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nature. Embryonic stem cells have the capacity to differentiate into any cell type from the 
three germ layers (Lanza and Atala, 2013), (Bongso and Lee, 2005). In contrast adult stem 
cells are more differentiated stem cell types that express characteristic surface markers 
and retain capacity for self-renewal but have limited multipotency. In this respect adult 
stem cells are more limited in their differentiation capacity and so are committed to cell 
types of certain lineage. One such example of an adult stem cell is the mesenchymal stem 
cell which forms tissue of the mesenchyme lineage (Lanza et al., 2004).    
1.4.1 Mesenchymal stem cells 
Mesenchymal stem cells (MSC) are stromal cells with fibroblastic morphology and are 
derived from the mesoderm germ layer (Vodyanik et al., 2010). MSC were first isolated 
from bone marrow but have since been isolated from other tissues such as muscle, 
umbilical cord and adipose tissue. When MSC are isolated and expanded in vitro they 
form colonies, this led to the term attribution of the term Colony forming units-
Fibroblasts (CFU-F). MSC are multipotent in nature, with a capacity for self-renewal or 
differentiation into other cell types. According to the Mesenchymal and Tissue Stem Cell 
Committee of the International Society for Cellular Therapy, in order to be classified as 
MSC cells must be adherent and express surface markers CD105, CD90, CD73. Conversely, 
MSC populations must also be negative for haematopoietic lineage surface markers CD45, 
CD34, CD14, CD19 and HLA-DR. Other recently suggested markers for MSC include STRO1, 
VCAM1 and CD106. Cells expressing these markers can be detected and isolated using 
fluorescent cell sorting techniques. The final requirement for MSC classification is that 
cells must be capable of tri-lineage differentiation down the osteogenic, chondrogenic 
and adipogenic lineages by forming osteoblasts, chondrocytes and adipocytes 
respectively (Dominici et al., 2006), (Boxall and Jones, 2012), (Oreffo et al., 2005). Interest 
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around MSC has grown since their stem cell and differentiation capacities were 
discovered. Previous work has demonstrated the capacity for MSC to form putative 
cartilage, bone and other connective tissues (Castro-Malaspina et al., 1980), (Prockop, 
1997), (Caplan and Bruder, 2001). More recently, MSC have been shown capable of 
differentiating into a wider range of cell types such as endothelium and myogenic cell 
lineages (Wu et al., 2013), (Gang et al., 2004), (Oswald et al., 2004). The tissue forming 
potential of MSC is illustrated in Figure 1.3.  The bone and cartilage forming capabilities of 
MSC’s as well as their ease of isolation from a range of tissues makes them a particularly 
attractive cell type for orthopaedic tissue engineering. In this context MSC already have a 
proven potential to be utilised as cell therapies particularly in orthopaedics and 
connective tissue  repair (Oreffo et al., 2005), (Ling et al., 2009). 
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1.4.2 The MSC Niche 
The Stem cell niche was a concept first introduced by Schofield in 1978 and refers to the 
cellular, extracellular and molecular microenvironment that governs stem cell 
maintenance and differentiation (Ehninger and Trumpp, 2011), (Schofield, 1978). MSC 
reside in a number of anatomical locations but are typically located in the endosteum and 
in the blood vessels that line the bone marrow (Gronthos et al., 2003), (Shi and Gronthos, 
2003). The stem cell niche is composed of multiple cell types including stem cells, 
progenitor and differentiated cells. In the case of bone marrow this includes cells of the 
haematopoietic lineage as well as differentiated mesenchymal progenitors (Ehninger and 
Trumpp, 2011), (Kolf et al., 2007). These different cell populations interact with each 
Figure 1.3. The mesenchymal lineage. 
Mesenchymal stem cells (MSC) arise from the mesenchyme lineage. MSC can self-
renew or differentiate into cells that give rise to connective tissue including bone, 
cartilage and adipose tissue. Image reproduced with permission from Caplan 2010, 
(Caplan, 2010). 
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other and secrete many signalling factors such as Wnt and FGF which regulate stem cell 
differentiation and proliferation. Another important aspect of the stem cell niche is the 
extracellular matrix (ECM), this consists of proteins such as Collagen 1 and Fibronectin. 
These proteins not only provide points of attachment for cells but also present signalling 
molecules in a spatially specific manner. The main function of the niche micro-
environment is to maintain the stem cell populations that reside there (Kolf et al., 2007), 
(Lichtman, 1981), (Gattazzo et al., 2014). An illustration showing the different 
components of the niche environment is shown in Figure 1.4. 
 
1.4.3 MSC osteogenic differentiation 
The bone forming capabilities of MSC are of particular interest in the development of new 
orthopaedic treatments. The process of osteogenic differentiation of MSC has been 
Figure 1.4. The MSC niche. 
Illustration of the MSC niche. This consists of multiple differentiated cells (DC1, DC2), 
Blood vessels (BV), Extracellular matrix components (ECM) as well as soluble signalling 
factors. Image reproduced from Kolf et al. 2007 (Kolf et al., 2007), (Published by 
BioMed central). 
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extensively studied in vitro and can be initiated with culture media supplemented with 
Dexamethasone, Ascorbic acid and β-Glycerophosphate (Pittenger et al., 1999), (Jaiswal 
et al., 1997). In vivo, the commitment and regulation of MSC differentiation to the 
osteogenic lineage is controlled by multiple growth factor signalling pathways. Amongst 
these, BMP, Wnt, and Platelet Derived Growth Factor (PDGF) signalling pathways have all 
been shown to play prominent roles in this process (Rickard et al., 1994), (Liu et al., 2009), 
(Quarto et al., 2010), (Kratchmarova et al., 2005), (Ng et al., 2008). Integration of these 
signalling pathways leads to expression of many transcription factors which regulate the 
expression of bone related genes. With regards to osteogenic differentiation, Runt-
Related Transcription Factor 2 (RUNX2), a member of the runt domain family and Osterix 
(SP7), a zinc-finger containing transcription factor both behave as master regulators of 
osteogenic differentiation (Schroeder et al., 2005), (Sinha and Zhou, 2013). These 
transcription factors regulate the expression of multiple bone-related and matrix 
associated genes such as Collagen 1 (COL1), Osteopontin (SPP1), Osteocalcin (BGLAP) and 
Alkaline Phosphatase (ALP). The proteins encoded by these genes are all components of 
bone and play roles in matrix maturation and mineralisation. The changes in gene 
expression during osteogenesis lead to changes in cell phenotype, lineage commitment 
and differentiation of  osteoblasts (Ziros et al., 2008), (Ducy et al., 1997), (Langenbach and 
Handschel, 2013), (Kulterer et al., 2007). The osteogenic differentiation process in MSC is 
shown in Figure 1.5. 
 24 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.4.3.1 Markers of MSC osteogenic differentiation  
Osteogenic differentiation of MSC leads to characteristic changes in cell phenotype. As 
differentiation progresses the cells begin to resemble mature osteoblasts. Enhanced 
matrix synthesis and subsequent mineralisation are typical indicators of differentiation 
and can be easily identified using histological stains such as Alizarin red which reveals 
Figure 1.5. Osteogenic differentiation pathway of MSC. 
Osteogenic differentiation of MSC to osteocytes is controlled by multiple signalling 
pathways such as the BMP, Wnt and EGF pathways. These pathways regulate expression 
of osteogenic transcription factors such as RUNX2 and Osterix (Osx) and up-regulate 
bone markers such as alkaline phosphatase (ALP), Collagen 1 (Col1), Osteopontin (OPN) 
and Osteocalcin (OCN). Image adapted from Giuliani et al. 2013 (Giuliani et al., 2013). 
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mineralised matrix by binding to the calcium ions present in the matrix (Puchtler et al., 
1969). Collagen production can also be visualised using Picro-Sirius red which binds to 
basic groups in collagen fibrils via sulphonic acid groups (Junqueira et al., 1979), 
(Junqueira et al.), (Tullberg-Reinert and Jundt, 1999). The expression of other matrix 
protein markers such as osteopontin and osteocalcin, which indicate late-stage 
osteogenic differentiation, can also be investigated using Immunofluorescent techniques 
(Marom et al., 2005). Another well-established marker of osteogenic potential is the 
enzyme alkaline phosphatase (ALP). The role of ALP in bone formation is not fully 
understood but is thought to be involved in initiating mineralisation by cleaving inorganic 
pyrophosphate, an inhibitor of mineralisation, whilst providing a source of inorganic 
phosphate for mineralisation (Orimo, 2010), (Harmey et al., 2004). ALP expression can be 
simply determined using biochemical assays that assess enzyme activity (Bednarska et al., 
2006). 
1.4.4 MSC in cell therapies 
MSC have many useful properties that have prompted interest in developing them as cell 
based therapies. MSC have been shown to be immune privileged cells that do not elicit a 
response from the host immune system.  The immune privileged nature of MSC can be 
partly attributed to their secretion of soluble factors including transforming growth factor 
beta 1 (TGF-β1) and hepatocyte growth factor (HGF) that are thought to regulate immune 
cell activity and proliferation. As such, the immune regulatory role of MSC is particularly 
advantageous in allogeneic cell therapies (Bartholomew et al., 2002), (Di Nicola et al., 
2002). The most exciting property of MSC stems from their multipotent nature and tissue 
forming capabilities. Added to this is their relative ease of isolation and expandability 
which presents MSC as an attractive cell type for new cell therapy treatments. The 
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multipotent nature of MSC endows the capability of directing their differentiation into 
multiple useful cell types such as  osteoblasts, chondrocytes as well as cells of other 
mesenchymal lineages including tendon and muscle (Krampera et al., 2006), (Pittenger et 
al., 1999). In the clinic, implantation of bone marrow which contains MSC, or isolated 
bone marrow stromal cells in conjunction with biocompatible scaffolds has been shown 
to be a promising treatment of non-union fractures and bone defects (Quarto et al., 
2001), (Connolly, 1995), (Bajada et al., 2007). MSC have also been applied in the 
treatment of osteoarthritis where injection of MSC into articular cartilage has been 
shown to enhance cartilage regeneration (Baghaban Eslaminejad and Malakooty Poor, 
2014), (Horie et al., 2012). Furthermore, transplants of bone marrow derived 
osteoprogenitor cells into children with osteogenesis imperfecta has been shown to 
increase bone formation as a result of MSC differentiation to osteoblasts (Horwitz et al., 
1999). A further example is the treatment of spinal cord injuries where MSC have been 
shown to promote neural regeneration (Dasari et al., 2014).  In conclusion, this highlights 
the promise of stem cells such as MSC, Regenerative medicine and tissue engineering 
based approaches in addressing current clinical challenges in orthopaedic medicine. 
 
1.5 Wnt signalling components and mechanisms 
1.5.1 The Wnt family of proteins 
Wnt proteins are an evolutionary conserved class of proteins of which there currently 19 
known members in mammals. The broad range of Wnt ligands is an indicator of the 
degree of complexity of the Wnt signalling pathway and infers how specificity between 
Wnt signalling pathways is obtained.  Wnt proteins are between 350-400 amino acids in 
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length with a notable occurrence of conserved cysteine rich domains (MacDonald et al., 
2009), (Logan and Nusse, 2004). The N-terminus contains a signalling peptide which 
targets the protein for secretion and there are numerous post translational modifications 
including glycosylation’s and lipid modifications (e.g. palmitoylation) which aids binding of 
Wnt ligands to the Wnt receptors (Cong et al., 2004), (Komekado et al., 2007). These lipid 
modifications also confer the distinctive hydrophobic properties of Wnts which, 
incidentally, also present problems when trying to obtain biochemically active Wnt 
proteins (MacDonald et al., 2009), (Logan and Nusse, 2004). Of the 19 known Wnt ligand’s 
Wnt 3A and Wnt 5A have been the most extensively studied. Wnt 3A is generally 
considered to mediate β-catenin activation via Low-density lipoprotein receptor-related 
proteins (LRP) co-receptors and promote canonical Wnt signalling. In contrast Wnt 5A has 
been extensively associated with β-catenin independent non-canonical signalling 
pathways which are transduced through other co-receptors such as Rho-associated 
protein kinase 2 (ROR2) (Grumolato et al., 2010). 
1.5.2 Wnt receptors 
1.5.2.1 Frizzled 
Wnt signalling has been shown to be mediated through a multitude of different receptors 
of different classes as well as a multitude of Wnt ligands. The signalling plasticity of Wnt 
receptors underlines the scale of pleiotropy in Wnt signalling (Logan and Nusse, 2004). 
The principal class of receptors that Wnt proteins signal through are known as Frizzled 
receptors. Frizzleds are 7 transmembrane spanning proteins that together form a 
separate class of G-protein coupled receptors. There are 10 members of the Frizzled 
family currently identified in mammals. Most Frizzleds show varied capabilities in 
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activating canonical Wnt signalling, especially when co-expressed with LRP5/6 (Binnerts 
et al., 2007) although it is thought that there is a degree of functional redundancy 
amongst the Frizzled family in respect to Wnt signalling activation. Structurally, Frizzleds 
have an extended N-terminal region that contains a cysteine rich domain (CRD); it is to 
this CRD domain that the Wnts primarily bind in order to initiate signalling (Logan and 
Nusse, 2004), (MacDonald et al., 2009), (Wang et al., 2006). Propagation of Wnt signals is 
mediated through the intracellular c-terminus of most Frizzled receptors. This process 
involves the interaction between conserved KTXXXW motifs located at the c-terminus of 
frizzled and PDZ domains contained within intracellular mediators such as Dishevelled. 
This leads to localisation of these mediators to Frizzled at the cell membrane and 
activation of downstream signalling (Wong et al., 2003), (Umbhauer et al., 2000). An 
illustration depicting the structural domains of Frizzled receptors is shown in Figure 1.6. 
 
 
 
 
 
Figure 1.6. Schematic of the Frizzled receptor. 
Illustration depicting the structural domains of Frizzled receptors. The extracellular 
Cysteine rich domain is involved with Wnt reception. The transmembrane domains 
span the lipid bilayer. The intracellular terminus has binding sites for interaction with 
intracellular mediators such as Dishevelled (Dvl). Image reproduced with permission 
from Schulte 2010 (Schulte, 2010). 
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1.5.2.2 LRP 
Besides Frizzled receptors, Wnt reception has also been shown to require recruitment 
and dimerisation of various co-receptors in order to initiate signalling. Chief amongst 
these co-receptors are members of the single-pass transmembrane low density lipo-
protein receptor-related proteins (LRP) family, namely LRP5/6. It is widely thought that 
Wnt molecules form a trimeric complex with a Frizzled receptor and a LRP5/6 receptor to 
signal pathway activation (Logan and Nusse, 2004). In the presence of a Wnt ligand and 
dimerisation with Frizzled, the LRPs become phosphorylated at a number of sites at their 
C-terminal.  During activation LRP6 becomes phosphorylated at Thr1479, Ser1490, and 
Thr1493 by kinases such as Glycogen synthase kinase 3 (GSK-3) and Casein Kinase 1 (CK1) 
upon stimulation by Wnt (Tamai et al., 2004), (Zeng et al., 2005), (Davidson et al., 2005). 
LRP6 seems to be more prevalent in Wnt signalling, particularly during embryogenesis 
whereas LRP5 has been shown to be crucial for the maintenance of adult bone 
(MacDonald et al., 2009). 
1.5.2.3 Other related receptors 
In addition to Frizzled and LRP5/6, there is an array of other cell surface receptors that 
play roles in Wnt signalling. A number of these receptors belong to the receptor tyrosine 
kinase (RTK) family of receptors. One such example is Receptor Tyrosine Kinase-Like 
Orphan Receptor 2 (ROR2), a transmembrane receptor that is primarily associated with 
non-canonical Wnt signalling. Like the Frizzled receptors, ROR2 contains a CRD in the 
extracellular portion of the receptor that is involved in Wnt protein reception. The 
intracellular C-terminal domain contains the tyrosine kinase domain required for signal 
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transduction (Oishi et al., 2003), (Kani et al., 2004). ROR2 has been shown to interact with 
Wnt5A and transduce non-canonical Wnt signalling whilst at the same time antagonising 
canonical Wnt signalling via Wnt3A (Oishi et al., 2003). RYK is another single pass 
transmembrane RTK receptor. The extracellular domain of RYK contains a Wnt inhibitory 
factor (WIF) sequence to which Wnt proteins are presumed to bind. RYK is involved in 
canonical Wnt signalling and has been shown to play roles in pattern formation and axon 
guidance (Yoshikawa et al., 2003), (Inoue et al., 2004). 
Another Wnt pathway related receptor family are the leucine-rich repeat-containing G 
protein-coupled receptors (LGR). LGRs are a subgroup of receptors that belong to the 
Rhodopsin family. They are characterised by their large leucine rich extracellular domains 
and have been shown to be a receptors for R-spondin. LGR5 is known to be expressed in 
stem cells and is associated with cell proliferation and has been implicated in numerous 
cancers (Carmon et al., 2011), (Van Hiel et al., 2012), (Van Loy et al., 2008). 
1.5.3 Inherent complexity of Wnt signalling pathways 
Wnt signalling is a complex web of inter-connected pathways all of which show cross-talk 
with each other. The first layer of complexity can be found with Wnt proteins. Some Wnt 
proteins (e.g. Drosophila Wnt) are capable of binding to multiple frizzled receptors with 
different affinities (Hsieh et al., 1999). Despite there being evidence of Wnt promiscuity in 
terms of signal specificity, there is also evidence to suggest that certain Wnt proteins 
have a tendency for signal preference. For example, Wnt 3a is commonly associated with 
canonical signalling whereas Wnt 5a is usually associated with non-canonical signalling 
(Grumolato et al., 2010). It is also apparent that most frizzled receptors are capable of 
signalling through the canonical or non-canonical pathways (MacDonald et al., 2009). The 
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current model of Wnt signalling indicates that the expression of different co-receptors is 
the most important factor determining signal specificity and pathway activation (van 
Amerongen et al., 2008). 
1.5.4 Canonical Wnt signalling 
In Canonical signalling Wnt proteins interact with target cells by binding to a receptor 
complex comprised of Frizzled and LRP5/6 located at the cell surface. Wnt is critical in 
initiating formation of this complex and previous work has demonstrated that an 
engineered complex of Frizzled and LRP5/6 is sufficient to activate canonical signalling 
(Cong et al., 2004), (Holmen et al., 2005), (Tolwinski et al., 2003). The complex of Fz/LRP 
and Wnt transduces the Wnt signal to the scaffold protein Dishevelled (Dvl). Dvl functions 
by binding to and sequestering several other intracellular proteins including glycogen 
synthase kinase-3 (GSK-3β), Axin and Adenomatous Polyposis Coli (APC) to the cell 
membrane.  This complex of proteins form what is termed the ‘destruction complex’ and 
serves to regulate the cytoplasmic pool of a signalling protein known as  -catenin, which 
is a transcriptional regulatory factor in the nucleus (Logan and Nusse, 2004). -catenin is a 
large multifunctional signalling molecule that consists of a central region of twelve 
repeats of three helices, this structure allows binding of a wide range of proteins besides 
GSK-3β including T-Cell Factor (TCF), APC, Axin and cadherin (Bullions and Levine, 1998), 
(Huber et al., 1997), (Kimelman and Xu, 2006). In the absence of a Wnt signal, the 
destruction complex successively phosphorylates -catenin at its N-terminal residues 
Ser33, Ser37 and a neighbouring aspartate residue. This provides a docking site for E3 
ubiquitin ligases which in turn labels Lys19 and Lys49 residues of β-catenin with ubiquitin. 
 32 
 
This marks -catenin for proteasome degradation and thereby prevents Wnt signalling 
activation (Wu et al., 2003), (Kimelman and Xu, 2006).  
In the presence of a Wnt signal the destruction complex is sequestered by Dvl, and as a 
result becomes deactivated. This results in accumulation of the active, hypo-
phosphorylated form of -catenin in the cell cytoplasm and nucleus. In the nucleus -
catenin acts as a transcriptional regulator and interacts with the T-cell factor / lymphoid 
enhancer factor 1 (TCF/LEF) family of transcription factors (Logan and Nusse, 2004). These 
transcription factors bind to and activate transcription of Wnt responsive genes that 
harbour TCF/LEF responsive elements.  -catenin propagates this process  by replacing 
transcriptional co-repressors such as Groucho and CtBP which associate with TCF/LEF and 
aids the recruitment of transcriptional activators such as Swi/SNF (Rao and Kuhl, 2010). A 
schematic of canonical Wnt signalling is shown in Figure 1.7.   
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Figure 1.7. Diagram of the canonical Wnt signalling pathway. 
Reception of Wnt proteins occurs at the cell membrane and involves binding to Frizzled 
and LRP5/6 co-receptors. In the cytosol this causes recruitment of Dishevelled to the 
activated receptor complex. This leads to inactivation of the destruction complex which 
consists of Axin, GBP, APC, CK1 and GSK-3β. Consequently, this leads to stabilisation and 
nuclear translocation of β-catenin and transcription of TCF/LEF responsive genes.  
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1.5.5 Wnt target gene transcription 
The activation complex regulates the transcription and expression of a multitude of Wnt 
target genes with TCF/LEF binding sites (Logan and Nusse, 2004), (Schuijers et al., 2014), 
(Nusse, 1999) and is involved in the regulation of many cell processes. Some of the genes 
regulated by Wnt signalling include genes regulating the cell cycle, cell proliferation and 
oncogene expression. Examples here include c-Myc, Cyclin D1 (He et al., 1998), (Shtutman 
et al., 1999), (Rohrs et al., 2009), (Herbst et al., 2014)  and COX2 (Nuñez et al., 2011), 
(Howe et al., 1999). Other Wnt responsive genes include regulatory proteins in the Wnt 
pathway such as LEF1 (Filali et al., 2002), TCF7 (Roose et al., 1999) and Wnt signalling 
inhibitors such as Dickkopf (Dkk1) (Rao and Kuhl, 2010). Feedback loops such as this help 
to provide a further level of control over Wnt pathway activity (Logan and Nusse, 2004). 
1.5.6 Non-canonical Wnt signalling 
Non-canonical Wnt signalling is a collective term for the Wnt signalling pathways that do 
not signal through -catenin. There are multiple non-canonical Wnt pathways that use 
different intracellular messengers and result in a multitude of cellular effects including 
changes to the cell cytoskeleton, cell polarity and differentiation. The effects of non-
canonical signalling vary depending on the cell type and species (Rao and Kuhl, 2010). The 
non-canonical pathways are characterised according to their intracellular mediators. The 
Wnt/JNK pathway proceeds through intracellular mediators such the Ras homolog (Rho) 
family of small GTPases and Jun N-terminal kinase (JNK) proteins whilst the Calcium 
pathway involves activation of calcium dependent enzymes and release of intracellular 
calcium.  
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1.5.6.1 Wnt/JNK pathway 
The Wnt/JNK pathway strongly overlaps with the planar cell polarity pathway observed in 
Drosophila. JNK pathway activation occurs through Frizzled receptors in conjunction with 
Dishevelled. This pathway activates small GTPases e.g. Rho and other downstream 
kinases e.g. JNK and results in changes to protein localisation and cell polarity. In 
Drosophila the planar cell polarity pathway  regulates cellular functions involved with 
polarised cell movements. e.g. gastrulation (Rao and Kuhl, 2010). The JNK pathway is also 
involved in ciliogenesis (Ross et al., 2005).   
1.5.6.2 Calcium pathway 
Wnt proteins can also activate calcium signalling, the evidence of this pathway was first 
observed in Zebrafish and Xenopus (Slusarski et al., 1997a), (Slusarski et al., 1997b). Wnt 
5A has been shown to activate the calcium pathway in a number of cell types. This branch 
of Wnt signalling is dependent on small heterotrimeric G-proteins to propagate the signal 
and activate calcium dependant enzymes e.g. CAMK2, Protein kinase C (PKC), Calcineurin 
(Kremenevskaja et al., 2005), (Dejmek et al., 2006), (Ma and Wang, 2006), (Safholm et al., 
2006), (Kuhl et al., 2000a), (Kuhl et al., 2000b). Non-canonical signalling in this manner 
(i.e. through CAMKII) can lead to inhibition of -catenin signalling (Ishitani et al., 2003), 
(Ishitani et al., 1999). Furthermore, the type of calcium dependant enzyme activated 
determines which downstream transcription factors are activated. The 
Calcium/Calcineurin pathway, which acts through Nuclear factor of activated T-cells 
(NFAT) transcription factors, has important roles to play in cardiac development and has 
been associated with cardiac hypertrophy (Rao and Kuhl, 2010), (Dejmek et al., 2006), 
(Belema Bedada et al., 2005), (Heineke and Molkentin, 2006). 
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1.5.7 Wnt pathway antagonists 
1.5.7.1 Dkk  
The most widely studied Wnt pathway inhibitors are the Dickkopf WNT Signalling 
Pathway Inhibitor (Dkk) proteins. There are four known Dkk genes expressed in humans 
of which Dkk1 is the most widely studied (Krupnik et al., 1999), (Monaghan et al., 1999). 
Dkk is postulated to inhibit Wnt pathway activation through two mechanisms, both of 
which involve binding to and inhibition of Wnt co-receptors LRP5/6 and/or Kremen. This 
process is mediated through the cysteine rich domains harboured within Dkk. One 
proposed mechanism behind Dkk mediated Wnt pathway inhibition involves disruption of 
the Wnt induced LRP and Frizzled complex formation which prevents downstream 
pathway activation. The second mechanism involves internalisation of LRP into the cell 
cytosol, which therefore reduces the availability of LRP receptors for Wnt binding at the 
cell membrane. As these mechanisms involve LRP co-receptor inhibition, Dkk proteins are 
therefore able to specifically antagonise the canonical β-catenin pathway due to the 
requirement for LRP co-receptors in canonical pathway activation  (Mao et al., 2002), 
(Bafico et al., 2001), (Mao et al., 2001), (Mao and Niehrs, 2003), (Krupnik et al., 1999), 
(Semenov et al., 2001). However, it should be noted that Dkk mediated LRP6 
internalisation and degradation may not be the main mechanism of action in mammalian 
cells with endogenous LRP6 expression. In this scenario disruption of the Wnt-Frizzled-
LRP complex may be the main effect of Dkk (Semenov et al., 2008).  
Interestingly, Dkk2 has been shown to act as an agonist or antagonist of Wnt signalling 
depending on the cell type. For instance, agonistic activity of Dkk2 on LRP6 activity and 
Wnt pathway activation was observed in 293 fibroblasts. However this was only the case 
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in the absence of Kremen 2 expression, co-expression of Kremen 2 re-introduced the 
antagonistic effects of Dkk2 (Mao and Niehrs, 2003).   
1.5.7.2 Other notable antagonists 
Other major antagonistic proteins that regulate Wnt signalling include the secreted 
frizzled related proteins (sFRP) and Wnt inhibitory factors (WIF). Both of these classes of 
proteins act by binding to Wnt proteins and sequester the Wnt protein away from the cell 
surface receptors. This suggests that sFRP and WIF regulate Wnt stability and control 
extracellular distribution (MacDonald et al., 2009). It has also been reported that sFRP is 
capable of binding to Frizzled receptors. As canonical and non-canonical Wnt signalling 
both signal through Frizzled receptors, this renders sFRP capable of inhibiting both 
canonical and non-canonical pathways (Bovolenta et al., 2008). Five sFRP genes have 
currently been identified in mammals and they all share structural similarities to the 
extracellular domain of Frizzled receptors, including the presence of a cysteine rich 
domain (Chang et al., 1999), (Leimeister et al., 1998), (Rattner et al., 1997). Knock-out 
studies of sFRP have demonstrated that there is also functional redundancy amongst the 
sFRP family much like the Frizzled family of receptors (Satoh et al., 2008). 
Another Wnt pathway modulator is known as Wise, which is a secreted protein that 
interacts with LRP6 and can act as a Wnt pathway inhibitor or activator. Wise has been 
shown to be involved in posterior neuron formation (Itasaki et al., 2003). Sclerostin is 
another LRP5/6 antagonist. Similar to Dkks, Sclerostin prevents Fz-LRP6 complex 
formation by binding to the extracellular domains of LRP5/6 thereby preventing 
formation of the receptor complex that is ordinarily formed as part of Wnt / -catenin 
signalling (Semenov et al., 2005). Shisa proteins are also a distinct family of Wnt 
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antagonists. Shisa proteins act by trapping Frizzled receptors in the Endoplasmic 
Reticulum and by doing so prevents them from being transported and expressed at the 
cell membrane. This therefore prevents Wnt pathway activation by ablating Wnt signal 
reception at the cell membrane (Yamamoto et al., 2005). 
1.5.7.3 Pharmacological antagonists of Wnt Pathways 
Excessive or unrestricted Wnt pathway activation is involved in a wide array of diseases 
especially cancers (Herr et al., 2012). As a response there is great interest in developing 
pharmacological inhibitors of Wnt signalling. Currently, most antagonists of Wnt 
pathways act by promoting β-catenin degradation. This can be achieved using molecules 
that increase Axin expression which stabilises the destruction complex and promotes β-
catenin degradation. One example of this type of compound is endo-Inhibitors of Wnt 
response 1 (endo-IWR1)  (Lu et al., 2009), (Chen et al., 2009). Alternative mechanisms of 
inhibition target downstream transcription of Wnt responsive genes, which can be 
blocked by interfering with β-catenin binding to TCF/LEF responsive elements. One 
example here are the inhibitors of catenin responsive transcription (iCRT) compounds e.g. 
iCRT-14 (Gonsalves et al., 2011). 
1.5.8 Wnt pathway agonists 
Besides Wnt protein, there are multiple other protein ligands which are known to have 
agonistic effects on Wnt pathways. Norrin and R-spondin (Rspo) proteins are two classes 
of canonical pathway agonists. Norrin is a specific ligand for Frizzled 4 and acts in 
accordance with LRP6; this complex has been observed during retinal vascularisation (Xu 
et al., 2004). Similarly, R-spondin also has synergistic relationships with Wnt, Frizzled and 
LRP6 (Kazanskaya et al., 2004), (Kim et al., 2005), (Nam et al., 2006), (Wei et al., 2007) and 
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is involved in development during embryogenesis (Bell et al., 2008). R-spondins are often 
co-expressed with and may in fact depend on Wnt for expression. This suggests that R-
spondin may act as part of a positive feedback loop that serves to reinforce a Wnt signal 
(Kazanskaya et al., 2004). Having said this, the finer elements behind R-spondins 
mechanism of action remains poorly understood. An alternative model suggests that R-
spondin binds to Kremen and in this way prevent Dkk/Krm controlled LRP6 internalisation 
(Binnerts et al., 2007).  
1.5.8.1 Pharmacological agonists of Wnt pathways  
There is a growing array of synthetic molecules that have been developed as agonists or 
antagonists of Wnt pathways. The most widely used class of agonists of canonical Wnt 
signalling are GSK-3β inhibitors of which Lithium Chloride (LiCl) is most well-known. LiCl is 
a long established treatment for bi-polar disorder but has also been associated with high 
bone mass conditions (Zamani et al., 2009).  LiCl acts as an activator of Wnt signalling by 
inhibiting the action of GSK-3β which is required to phosphorylate -catenin which is 
necessary for initiating proteasomal degradation. As a result active -catenin is able to 
mobilise to the nucleus to activate Wnt responsive genes (Freland and Beaulieu, 2012). 
Another class of GSK-3β inhibitors is 6-bromoindirubin-3'-oxime (BIO), which is a potent 
and selective inhibitor of GSK-3β. BIOs mode of action involves binding the Adenosine 
triphosphate (ATP) binding pocket of GSK-3β. It has also been shown to inhibit the 
phosphorylation of tyrosine residues in the GSK-3β active site. Like LiCl, the inactivation of 
GSK-3β allows the nuclear accumulation of -catenin and activation of Wnt responsive 
genes. In vivo studies have shown that BIO can mirror the effects of Wnt signalling in 
Xenopus embryos (Meijer et al., 2003).  
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1.5.9 Peptide mediated modulation of Wnt pathways 
There is a growing interest in developing upstream modulators of Wnt pathways that act 
on Wnt receptors at the cell membrane.  One such peptide that has been shown to 
interact with Frizzled receptors is known as UM206 and was developed by Blankesteijn et 
al. (Blankesteijn Wessel Matthijs, 2010). The amino acid sequence of UM206 is based on a 
fragment of Wnt3A and Wnt 5A proteins (amino acids 296 - 307 and 324 - 335 
respectively). The peptide sequence of UM206 is shown below:  
Ac-Cys-Asn-Lys-Thr-Ser-Glu-Gly-Met-Asp-Gly-Cys-Glu-Leu-NH2 
UM206 is a high affinity ligand for Frizzled 2 receptors and, to a lesser extent, Frizzled 1. 
The peptide has been shown to initiate activation of canonical Wnt signalling as 
demonstrated by increased Wnt reporter activity when the peptide is present in a cyclical 
conformation (EC50 2.10-
8M). The cyclic conformation of UM206 can be formed by 
inducing a disulphide bridge between the two cysteine residues in the peptide.  In 
contrast, when the peptide is presented in its linear conformation it has been shown to 
act as an inhibitor of Wnt pathway activity (IC50 10
-10 M). Restriction of Wnt signalling 
using UM206 in its linear conformation has been shown to be beneficial in preventing 
infarct expansion and heart failure after myocardial infarction (Blankesteijn Wessel 
Matthijs, 2010), (Laeremans et al., 2011).  
 
1.6 Role of Wnt signalling in bone 
Wnt signalling pathways play vital roles in regulating bone formation at all stages of 
development, from limb formation during embryogenesis, to bone remodelling and 
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fracture repair in adult bone (Regard et al., 2012). The important roles of Wnt signalling in 
bone are highlighted by the bone pathologies arising from mutations in the genes 
involved in Wnt signal transduction. For example, some patients displaying a high bone 
mass phenotype have been shown to harbour a mutation in the gene for the Wnt co-
receptor LRP5 known as G171V. This mutation prevents the Wnt inhibitor Dkk1 from 
blocking Wnt pathway activation (Little et al., 2002), (Boyden et al., 2002). Another 
inactivating mutation of the SOST gene which encodes the LRP5/6 inhibitor Sclerostin is a 
cause of Sclerosteosis, which is also characterised by a high bone mass phenotype 
(Balemans et al., 2001). This suggests that increased Wnt pathway activity is a driver 
behind bone formation. In contrast loss of function mutations of LRP5 (e.g. frameshift and 
nonsense causing mutations) have been shown to cause low bone mass. This is observed 
in Osteoporosis Pseudoglioma syndrome which results in low trabecular bone volume 
(Gong et al., 2001). At the cellular level Wnt signalling has been shown to either promote 
or restrict osteoblast differentiation depending on the stage of cell differentiation. For 
instance, stimulation of Wnt signalling in early stage osteoblasts has been reported to 
enhance differentiation at later stages, whilst in mature osteoblasts mineralisation was 
inhibited (Eijken et al., 2008). Active Wnt signalling is also known to be prevalent in 
osteoblast precursor cells where β-catenin has been shown to be prevalent in the 
nucleus, an indication of Wnt pathway activity (Day et al., 2005). Wnt activity is also 
present during bone repair. For example, inducing a transcortical Tibial defect in 
transgenic mouse models expressing the TOPgal Wnt reporter was shown to induce 
reporter activity. This indicates that Wnt signalling is a response to injury and is required 
for bone repair (Kim et al., 2007). Conversely, impaired Wnt signalling has been 
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implicated in a range of diseases such as osteoporosis and osteopenia (Dimitriou et al., 
2011), (Hoeppner et al., 2009).  
1.6.1.1 Roles of Wnt signalling in regulating MSC fate 
Wnt signalling is an important signalling pathway in development and in particular Stem 
cell proliferation and differentiation. This had made the Wnt signalling pathways a 
therapeutically relevant target not only in cancer but in the field of tissue engineering and 
regenerative medicine in which MSC are playing an important role. Fine tuning of Wnt 
signalling activity is also an important factor in the regulation of the developmental niche, 
including the MSC niche. One way of controlling Wnt activity is by establishing and 
presenting cells with Wnt gradients (Heller and Fuchs, 2015), (Kim et al., 2015). MSC are 
known to express a number of Wnt ligands including Wnt 2, 4, 5a, 11 and 16. Expression 
of a number of Frizzled receptors (Frizzled 2-6), co-receptors and pathway inhibitors has 
also been observed (Etheridge et al., 2004). This suggests that Wnt signalling has roles to 
play in MSC fate and lineage specificity. Wnt signalling has been shown to elicit different 
outcomes depending on the cell type and Wnt concentration, this is  also evident  in the 
context of osteogenesis (Quarto et al., 2010), (De Boer et al., 2004b). Activation of 
canonical Wnt signalling by Lithium or Wnt3A in hMSC has been shown to inhibit 
differentiation, decrease mineralisation and ALP activity but increase other bone-related 
markers whilst promoting proliferation and maintaining MSC multi-potency (de Boer et 
al., 2004a), (Boland et al., 2004), (Cho et al., 2006). These observations are presumably 
linked to the activation of Wnt responsive genes involved in cell cycle and proliferation 
like Cyclin D1 and c-Myc (Baek et al., 2003). One advantage of the proliferative effects of 
Wnt signalling is that this could allow the scale-up and banking of huge numbers of stem 
cells that are required for cell-based therapies, whilst maintaining stem cell multi-
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potency. A dose response effect of Wnt signalling has also been observed. For instance, 
low levels of canonical Wnt signalling have been reported to promote cell proliferation 
(including in hMSC), whilst higher doses were shown to have suppressive effects (Gong et 
al., 2001), (De Boer et al., 2004b), (Qiu et al., 2007). Previous work has also demonstrated 
a differential expression pattern of Wnt related genes during hMSC osteogenesis. For 
instance, upregulation of the genes encoding Frizzled 6, ROR2, sFRP2/3 and Wnt 11 whilst 
down-regulation of the Wnt 9a and Frizzled 7 genes have been observed (Boland et al., 
2004). Activated canonical Wnt signalling has been shown to promote osteogenesis in 
certain cellular contexts. For example canonical Wnt3A has been shown to promote 
osteogenesis in calvarial osteoblasts (Quarto et al., 2010) whilst LiCl has been shown to 
induce ALP activity in hMSC (De Boer et al., 2004b). In murine MSC and osteo-progenitor 
cells canonical Wnt signalling has been shown to promote osteoblastogenesis via up-
regulation of RUNX2, DLx5 and SP7 (Bennett et al., 2005), (Gaur, 2005). Furthermore, the 
induction of relatively high activity of canonical Wnt signalling through addition of 
exogenous Wnt3a, overexpression of LRP6 or stabilised -catenin has been shown to 
enhance hMSC osteogenesis (Gong et al., 2001), (De Boer et al., 2004b), (Qiu et al., 2007). 
It is also apparent that the stage of the target cell is also important when determining the 
cellular response to Wnt signalling. MSC committed to osteogenesis have been shown to 
exhibit enhanced osteogenesis in response to canonical Wnt signalling whilst this also 
inhibits their terminal differentiation in to osteoblasts (Kahler and Westendorf, 2003), 
(Kahler et al., 2006), (Eijken et al., 2008), (Kahler et al., 2008). The non-canonical pathway 
has also been associated with MSC osteogenic differentiation. The non-canonical pathway 
associated Wnt5a has been shown to promote osteogenic differentiation whilst at the 
same time blocking the effects of Wnt3a (Baksh et al., 2007), (Boland et al., 2004). 
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Furthermore, non-canonical associated Wnt11 has been shown to be up-regulated during 
osteogenic and chondrogenic differentiation (Lako et al., 1998). Evidently, there is a clear 
role for both canonical and non-canonical Wnt signalling pathways in controlling MSC 
differentiation. A comprehensive review detailing the roles of Wnt signalling on MSC 
proliferation and differentiation is provided by Ling et al. and is summarised in Table 1.1  
(Ling et al., 2009). 
 
  Wnt pathway 
MSC fate Canonical   Non-canonical   
Self-renewal Stimulatory Inhibitory Inhibitory   
Low Wnt activity High Wnt 
activity 
   
(Subject to cellular context) (Subject to cellular context) 
Osteogenic 
Differentiation 
Stimulatory Inhibitory Stimulatory   
High Wnt activity: 
Lineage commitment 
Lineage 
commitment 
   
Early differentiation Terminal 
differentiation 
   
Mouse MSC       
Chondrogenic 
differentiation 
Stimulatory Inhibitory Stimulatory Inhibitory 
Lineage commitment Chondrocyte 
differentiation 
Chondrocyte 
differentiation 
Lineage 
commitment 
Maturation     Maturation 
Adipogenic 
differentiation 
Inhibitory   N/A   
Myogenic 
differentiation 
Stimulatory   Stimulatory   
Table. 1.1. The effects of Wnt signalling on MSC fate. 
Wnt signalling has both stimulatory and inhibitory effects on MSC self-renewal and 
differentiation. The outcome on cell fate is dependent on the Wnt dosage and the cellular 
context. Adapted from Ling et al. 2009 (Ling et al. 2009).  
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1.6.1.2 Use of Wnt in bone tissue engineering 
The use of Wnt proteins in vivo for tissue engineering and regenerative medicine has 
been extremely limited to date. This is due to many factors including the multiplicity of 
Wnt ligands and their contextual effects which hinder the implementation of 
standardised dosing. These problems are also compounded by the difficulties in purifying 
substantial amounts of active Wnt protein with the appropriate post-translational 
modifications and hydrophobicity which are required for bio-activity (Willert et al., 2003), 
(Kikuchi et al., 2007), (MacDonald et al., 2009), (Logan and Nusse, 2004). Despite these 
issues there are some studies which have demonstrated the efficacy of Wnt delivery for in 
vivo bone repair. For example, direct delivery of Wnt protein or liposome encapsulated 
Wnt protein has been shown to increase bone volume and enhance bone repair in mouse 
models (Zhou et al., 2009), (Minear et al., 2010). Other groups have utilised transduced or 
transfected cells which over-express Wnt, these cells can then be delivered to sites of 
repair in vivo. This approach has also been shown to cause increases in bone density and 
formation in Severe combined immunodeficiency (SCID) mice models (Nalesso et al., 
2011), (Qiang et al., 2008), (Liu et al., 2009), (Chang et al., 2007). Clearly new treatments 
that regulate Wnt signalling could be beneficial for bone regeneration. However one 
important aspect to consider is that potential treatments would have to be carefully 
controlled due to the role of Wnt pathways in tumourgenesis (Dimitriou et al., 2011), 
(Wagner et al., 2011). 
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1.7 Mechanotransduction 
Mechanotransduction is the process of converting a physical force into a biological signal. 
This process is instrumental in development and governs many processes in 
embryogenesis and tissue patterning. Mechanotransduction at the cell occurs through so 
called mechano-sensitive proteins and receptors. Examples of mechanosensitive proteins 
include Integrins, ion channels and growth factor receptors. The central premise behind 
mechanotransduction is that applied forces induce conformational changes in these 
mechano-sensitive receptors. This leads to changes in their activation state and 
subsequent signalling to downstream intracellular signalling pathways (Kirkham et al., 
2010), (Ingber, 2006), (Farge, 2003). Many cell types express mechano-sensitive receptors 
including bone cells, and mechanotransduction is a critical signalling mechanism 
controlling bone development. Activation of mechanosensors leads to downstream 
activation of  many second messenger systems and signal transduction pathways such as 
Nitric oxide (NO) and Calcium signalling as well a host of growth factor signalling 
pathways (Liedert et al., 2006), (Ingber, 2006). Activation of these signalling pathways 
ultimately leads to transcription of mechano-sensitive genes and changes in gene 
expression that alter cell  proliferation, migration, differentiation and the production of 
signalling molecules such as BMPs and cytokines (Mammoto et al., 2012), (Santos et al., 
2011). 
1.7.1 Mechanosensors 
Mechanical forces are detected by the cell through mechanosensitive molecules. An 
overview of the molecules involved in Mechanotransduction is shown in Figure 1.8. Many 
mechanosensitive proteins are activated as a result of changes in their conformation and 
activity in response to external forces. A principle site for sensing mechanical forces is the 
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cell membrane where forces are detected by proteins such as primary cilia, growth factor 
receptors, ion channels, integrins and cadherins amongst others. Mechanical forces are 
also sensed via intracellular mediators such as the cell cytoskeleton and chromatin 
(Ingber, 2006). Mechanotransduction elicits different effects on cell behaviour depending 
on where the force is targeted.  Some mechanosensitive molecules such as stress 
sensitive ion channels cause fluxes in ion transport across the cell in response to force. 
This occurs as a result of changes in their conformation which causes opening and closing 
of the channels and subsequent activation of downstream signalling that leads to changes 
in gene expression (Sukharev and Corey, 2004), (Itano et al., 2003). Other proteins such as 
integrins are linked to the cell cytoskeleton. When forces are applied to these structures 
this leads to cytoskeletal and organelle rearrangements and activation of signalling 
pathways such as nuclear factor kappa-light-chain-enhancer of activated B cells (NF-β) 
pathway (Wang et al., 1993), (Matthews et al., 2006), (Ralphs et al., 2002), (Maniotis et 
al., 1997), (Tzima et al., 2005). Alternatively, when forces are directly applied to 
transmembrane molecules that are not directly linked to the cell cytoskeleton, such as 
growth factor receptors, this results in localised effects on cell signalling (Ingber, 2006). 
For example, shear stress has been shown to activate the vascular endothelial growth 
factor receptor 2 (VEGFR2) which led to downstream activation of Akt and Mitogen 
Activated Protein kinases (MAPK) (Jin et al., 2003), (Shay-Salit et al., 2002). G-protein 
coupled receptors (GPCRs) have also been implicated in mechanotransduction. For 
instance, application of fluid shear stress to endothelial cells has been shown to cause 
changes in the activity of the GPCRs bradykinin B2 and Gαq/11 (Chachisvilis et al., 2006), 
(dela Paz et al., 2015). Furthermore, membrane stretch has been shown to cause 
activation of transient receptor potential (TRP) ion channels and was shown to be 
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mediated through Gq/11 –coupled receptors in vascular smooth muscle cells (Mederos y 
Schnitzler et al., 2008). 
 
 
 
 
 
 
 
 
1.7.1.1 Integrins 
Integrins are a family of cell surface receptors that consist of two subunits known simply 
as α and β. Together, the α and β subunits form a functional dimer complex. Integrins link 
the extracellular matrix (ECM) to the cell cytoskeleton via focal adhesions and are 
involved in cell adhesion. The integrin complex facilitates mechanotransduction of 
external mechanical forces to the nucleus via the cell cytoskeleton (Hynes, 2002). This 
results in focal adhesion assembly via Rho signalling and actin polymerisation (Riveline et 
Figure 1.8. Mechanosensors. 
Overview of mechanosensors. Mechanical forces are detected by many 
mechanosensitive proteins and receptors such as primary cilia, surface receptors, ion 
channels, Integrins, Cadherins, cell cytoskeleton etc. Image reproduced with 
permission from Ingber 2006 (Ingber, 2006).  
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al., 2001) as well as causing changes  in mechanosensitive pathways mediated through c-
fos, c-myc and MAPK (Benaud and Dickson, 2001), (Schwartz, 1997). Integrin mediated 
signalling has been implicated in the determination of cell fate, polarity, proliferation and 
differentiation through multiple intracellular pathways including Rho, Rho-associated 
protein kinase (ROCK), extracellular-signal-regulated kinases (ERK) and Akt signalling 
amongst others (Hynes, 2002). 
1.7.1.2 Ion Channels 
Mechanotransduction is also mediated through stretch activated ion channels. 
Mechanical perturbation of the cell membrane causes conformational changes in ion 
channels, which control ion flow across the cell membrane. Subsequently, these 
conformational changes cause opening and closing of the ion channels. This results in ion 
flux across the cell that results in changes to cell activity (Ingber, 2006). One such example 
is the MscCa channel which regulates cation flux across the cell membrane and is involved 
in the regulation of cell volume and movement. The gating of this channel has been 
shown to be regulated by changes in membrane tension (Maroto et al., 2005). Another 
example is the Twik-related potassium channel 1 (TREK1), an outwardly rectifying 
potassium channel that regulates the resting membrane potential of the cell (Lesage and 
Lazdunski, 2000), (Patel and Honore, 2001), (Fink et al., 1996). TREK1  is expressed in 
most tissues and is particularly prevalent in tissues of the nervous system, lung, heart and 
smooth muscle (Fink et al., 1996), (Medhurst et al., 2001), (Aimond et al., 2000), (Koh et 
al., 2001). TREK1 is known to be sensitive to a number of stimuli including heat, lipids and 
pH. TREK1 channels are also known to be mechanoresponsive and forces such as stretch 
can cause opening and closing of the channels. This results in movement of potassium 
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ions across the cell membrane that leads polarisation of the cell (Hughes et al., 2006), 
(Patel et al., 1998).  
1.7.1.3 Growth factors  
Growth factors and their receptors have also been implicated in mechanotransduction. 
The activity of the signalling pathways involved is known to be altered by mechanical 
forces. For example members of the Wnt pathway, insulin-like growth factor (IGF), 
Transforming growth factor-β (TGF-β) and BMP have all been shown to be induced in 
osteoblasts in response to loading (Liedert et al., 2006). A diagram illustrating the cell 
signalling pathways involved in mechanotransduction is shown in Figure 1.9. 
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1.7.2 Biological responses to mechanical force in bone 
Mechanical loading is a key factor that regulates many physiological processes and is 
required for tissue morphogenesis and, at the cellular level, regulates cell behaviour and 
fate. This review will focus on the effects of forces in bone and bone cells; comprehensive 
reviews of the role of mechanical forces in development have been previously discussed 
(Heisenberg and Bellaiche, 2013), (Patwari and Lee, 2008). At the cellular level, bone cells 
have been shown to be sensitive to various mechanical stimuli. Fluid flow has been 
demonstrated to cause release of NO and PGE2 from bone cells (Mullender et al., 2004). 
Figure 1.9. Mechanotransduction associated signalling pathways. 
Mechanotransduction is mediated through multiple signalling pathways including 
integrins, growth factor receptors; G-protein coupled receptors (GPCRs) and ion 
channels. This leads to changes in gene expression that determines cell fate. Image 
reproduced with permission from Liedert et al. 2006 (Liedert et al., 2006). 
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Furthermore, direct stimulation of integrin receptors using magnetic nanoparticles has 
been shown to elucidate a number of responses in bone cells including changes to the 
cytoskeleton, MAPK activity, intracellular pH changes, and generation of calcium fluxes 
(Hughes et al., 2005). As well as causing activation of bone cells, mechanical stresses are 
known to influence the differentiation, proliferation and matrix production of progenitor 
and stem cells too. For instance, cyclic strain applied to MSC via substrate deformation 
has been shown to stimulate ERK1/2 signalling. This strain led to decreased cell 
proliferation and enhanced matrix mineralisation (Simmons et al., 2003). Fluid shear 
stress has also been reported to activate MAPK and calcium signalling in hMSC which also 
led to increased cell proliferation (Riddle et al., 2006). It has been shown that relatively 
small magnitudes of force are required to illicit a biological response at the cell and tissue 
level. For instance, stimulation of polyurethane based scaffolds seeded with hMSC was 
shown to promote cell proliferation and increase type 1 procollagen production. These 
effects were observed in response to perfusion applied at a rate of 10ml/min or 
compression strain applied at 10% strain (Liu et al., 2012). Furthermore, when 7-8 day old 
neonatal mouse tibia were stimulated with cyclic compression using forces in the 
magnitude of 500-7000 microstrain, DNA and protein synthesis were found to increase 
with peak effects observed at 1000 microstrain at a frequency of 1Hz  (Kunnel et al., 
2002). Low magnitude high frequency strains have also been shown to increase bone 
formation and density and inhibit osteopenia in various animal models (Rubin et al., 2001) 
1.7.3 Mechanical stimulation systems in bone tissue engineering 
Many bioreactor systems have been developed in recent years and used to apply loading 
regimes in order to mechanically condition cells and cell seeded constructs. This strategy 
is used as a means of optimising cell differentiation and tissue formation and is 
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particularly relevant in a bone tissue engineering context. Mechanical forces can be 
applied to cells or tissues in a passive and non-specific manner to cause generic 
membrane shear stresses to activate mechanotransduction pathways (Thompson et al., 
2012). One type of generic stimulation system is compressive systems which can be used 
to apply generic compressive forces to a whole construct. This type of system has been 
used to investigate the osteogenic response of chick tibiotarsi in response to intermittent 
compressive loading provided by a simple piston system attached to a cam and weights. 
In this system ALP expression was maintained in comparison to the control and Collagen 1 
expression was found to be increased (Zaman et al., 1992). Mechanical forces in the form 
of strain and stretching applied to osteoblast cells have also been shown to cause 
activation of the RUNX2 transcription factor through MAPK and ERK1/2 pathways 
resulting in upregulation in the expression of other osteogenic and bone related genes 
including ALP, Osteocalcin and Osterix (Kanno et al., 2007). The application of substrate 
strain to cells or cell seeded scaffolds has been shown to enhance the osteogenesis of 
hMSC by many groups (Haasper et al., 2008), (Friedl et al., 2007), (Ward et al., 2007). 
Perfusion based systems that utilise fluid-flow to induce shear stress are particularly 
common mechanical stimulation systems. This type of system has been shown to be 
beneficial for conditioning induced pluripotent stem cell (iPS)-derived mesenchymal 
progenitors cultured on osteo-conductive scaffolds. These cells showed a decrease in 
proliferation and an increase in lineage specific genes. This subsequently enabled the 
production of a functional bone substitute (de Peppo et al., 2013). Many groups have 
investigated the effect of shear stresses on the osteogenic differentiation of MSC. 
Perfusion systems that impart shear stresses on cell monolayers and cell seeded scaffolds 
have been found to increase bone marker gene expression and calcium deposition by 
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MSC  (Kreke et al., 2008), (Bancroft et al., 2002), (Stiehler et al., 2009). A comprehensive 
review of the role of mechanics in directing MSC differentiation is provided by Potier et al. 
(Potier et al., 2010). One important aspect concerning the application of mechanical force 
is the relationship between cyclical and static strains. Studies have shown that cyclical 
force is the most important factor determining the scale of the biological response and 
that cyclical force appears to have a greater effect on the anabolism of tissue than static 
loading of higher magnitudes (Hsieh and Turner, 2001), (Liu et al., 2012). Cyclic forces 
have been shown to promote new bone deposition and tissue remodelling in conjunction 
with implanted scaffolds in vivo (Roshan-Ghias et al., 2011). Many hydrostatic force based 
stimulation systems have also been used to impart mechanical loads to cells and tissues. 
This approach has been shown to mimic fracture repair and upregulate osteogenic and 
angiogenic genes in a stress fracture rat model (Mosley and Lanyon, 1998), (Holtorf et al., 
2005), (Wohl et al., 2009). Hydrostatic conditioning of chick femurs cultured ex vivo  and 
cell seeded hydrogels has also been shown to be beneficial in driving new bone formation 
(Henstock et al., 2013). As an alternative to generically applied forces, controlled forces 
can be directionally applied to cells and target proteins using tools such as magnetic 
nanoparticles. This strategy has been shown to stimulate cell signalling pathways and 
promote the osteogenic differentiation of hMSC  (Kanczler et al., 2010), (Hughes et al., 
2008). This approach is discussed in more detail in section 1.8. 
1.7.4 Mechano-activation of Wnt signalling 
There is a clear link between mechanical forces, Wnt signalling and bone formation. There 
is growing evidence that the Wnt signalling pathway is activated in response to 
mechanical forces and that this is an important mechanism regulating bone remodelling 
(Huang and Ogawa, 2010), (Tu et al., 2012), (Crockett et al., 2011). As discussed 
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previously, the Wnt co-receptor LRP5 has long been associated with bone mass. For 
example, LRP knockout mice show significantly lower bone strength and mineral density 
and their osteogenic response to mechanical loading of the Ulna was found to be 
reduced. In vitro experiments also showed an inability of LRP5 knockout osteoblasts to 
synthesize Osteopontin after mechanical strain. This suggests that LRP5 is an important 
mediator of osteoblast activity in response to loading (Sawakami et al., 2006).  Other In 
vitro experiments have investigated the link between Wnt pathway activity and 
mechanical loading. The application of fluid shear stress and mechanical strain by 4-point 
bending has been shown to initiate nuclear translocation of -catenin and activation of a 
TCF reporter gene in Mouse MC3T3-E1 osteoblasts, ROS 17/2.8 cells and primary 
osteoblasts (Norvell et al., 2004), (Armstrong et al., 2007). Other in vivo models have 
demonstrated that mechanical loading of mouse tibias results in increased expression of 
Wnt pathway and Wnt target genes. Furthermore, there was a concomitant increase in 
this response from mice displaying the high bone mass phenotype LRP5 G171V. These 
results were corroborated in vitro where mechanical loading of MC3T3-E1 osteoblasts 
which were subjected to 5h of loading showed similar increases in Wnt gene activation 
including up-regulation of Frizzled 2 (Robinson et al., 2006). These studies suggest that 
the application of mechanical strain to influence Wnt signalling may be of benefit to bone 
formation for tissue engineering.   
 
1.8 Magnetic Nanoparticles 
The development of nano-scale technologies has opened up new fields of discovery in 
science and technology, and subsequently, new avenues of treatment in medicine 
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(Chakraborty et al., 2011). One particularly versatile set of tools in nanotechnology are 
magnetic nanoparticles (MNP). Broadly speaking, MNP are magnetic particles with 
dimensions in the nanometre scale. One type of MNP, known as superparamagnetic iron 
oxide nanoparticles (SPIONs), have proven to be useful in a wide range of biomedical 
fields such as imaging, diagnostics and biotechnology (Riehemann et al., 2009). There are 
also emerging applications for MNPs in tissue engineering and regenerative medicine; 
these applications will be discussed in section 1.8.6. 
1.8.1 Composition of MNP 
MNP typically consist of a magnetic core material, which is commonly iron oxide in the 
form of magnetite or maghemite (Mahmoudi et al., 2011). The magnetic core is often 
surrounded by a protective layer or biocompatible polymer e.g. dextran. This helps to 
prevent degradation of the core and reduce the cytotoxic effects of iron oxide based 
nanoparticles which has previously been observed in both in vitro (Hoskins et al) and in 
vivo studies (Hanini et al). The biocompatible MNP coating can then be functionalised 
with reactive groups such as carboxyl, hydroxyl or biotin. These reactive groups can then 
be used for attachment of biomolecules such as antibodies, therapeutic drugs and genes 
(Mahmoudi et al., 2011), (Fouriki et al., 2014), (Hoskins et al., 2012), (Hanini et al., 2011). 
1.8.2 Magnetic properties of MNP 
MNP are particularly useful as engineering tools because of their magnetic properties. 
The materials that make up the magnetic core of MNP can be varied to produce particles 
with different magnetic susceptibilities. Magnetic susceptibility occurs in materials with 
unpaired electrons and is defined as the ratio between the induced magnetisation and 
the applied magnetic field. Magnetite is a common core material used in MNP. When 
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magnetite based MNP are produced in the nano-scale dimension, this may cause the 
formation of single magnetic domains. Under these parameters magnetite based MNP 
may display superparamagnetic properties. Superparamagnetic materials only display 
magnetic susceptibility in the presence of an external magnetic field. In the absence of a 
magnetic field Brownian motion randomises the magnetic dipoles of the material and the 
particles retain no net magnetism. Superparamagnetic materials are particularly useful in 
medical applications where their colloidal stability and magnetic susceptibility need to be 
carefully controlled (Levy, 2012), (M. Hofmann-Amtenbrink, 2009), (Meng Lin et al., 
2010), (Kumar, 2009). 
1.8.3 MNP surface coatings 
After synthesis of MNP, it is necessary to apply organic or inorganic coatings to the 
surface in order to stabilise the particle and help prevent particle aggregation. The 
surface coating can be modified to vary the physical properties of the MNP like surface 
charge, topography and protein binding capacity.  For in vivo applications it also becomes 
necessary to coat the MNP with biocompatible substances such as Bovine Serum Albumin 
(BSA), Dextran or pullulan to reduce toxicity in the host (Gupta and Gupta, 2005), 
(Mehvar, 2000), (Hughes et al., 2005).      
1.8.4 Particle Internalisation 
Most cells (including MSC) will internalise micro- or nano- sized particles through 
endocytotic mechanisms such as caveolin and clathrin mediated endocytosis as well as by 
phagocytosis. The rate and method of internalisation is dependent on many factors such 
as the cell type, particle size, surface functionality etc. (Hughes et al., 2005), (Farrell et al., 
2008). With respect to particle size, nanometre sized MNP in the range of 50-500nm have 
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been observed to be internalised more efficiently whilst larger particles above 1μm take 
longer to be internalised (Prabha et al., 2002), (Desai et al., 1997), (Foster et al., 2001). 
Surface functionality also affects the degree of MNP internalisation. For example, cationic 
functionalised gold nanoparticles have  been shown to be more readily internalised than 
particles with anionic functionality (Jiang et al., 2015), (Jambhrunkar et al., 2014). The 
immediate fate of particles is dependent on the size and method of particle 
internalisation. MNP may be retained in the endosome or lysosome, or may be released 
and dispersed throughout the cytosol (Panyam et al., 2002).       
1.8.5 Functionalisation of MNP 
One of the attractive properties of MNP is their magnetic versatility and their capability to 
be functionalised with ligands. Ligands can be attached to MNP via functional groups 
located on the surface coating of the MNP (Lin et al., 2008). One common mechanism 
involves the covalent conjugation of the amine groups of proteins or peptides to carboxyl 
groups presented by MNP. This can be achieved using 1-Ethyl-3-(3-dimethylaminopropyl)-
carbodiimide (EDAC) as a cross-linking agent which reacts with carboxyl groups to form a 
reactive O-acylisourea intermediate. This reactive intermediate can be stabilised using 
sulfo-N-hydroxy succinimide (NHS) to convert the O-acylisourea to a sulfo-NHS ester. The 
sulfo-NHS ester intermediate then reacts with primary amines to form a stable peptide 
bond between the particle and the ligand (Grabarek and Gergely, 1990), (Conde et al., 
2014). A schematic depicting the conjugation process through carbodiimide activation is 
shown in Figure 1.10. 
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Figure 1.10. Carbodiimide cross-linking of carboxy-MNP with biomolecules. 
Reaction schematic illustrating cross-linking of Biomolecules to MNP. Reaction of 
carboxy-functionalised MNP with EDC and Sulpho-NHS results in a formation of a 
reactive sulpho-NHS intermediate. This intermediate reacts with amine groups present 
in biomolecules to form a peptide bond linking the biomolecule to the MNP. Image 
reproduced from Conde et al. 2014 (Conde et al. 2014), (Originally publsihed by 
Frontiers in Chemistry).  
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Other conjugation mechanisms include maleimide coupling. This involves the use of 
maleimide which reacts with sulfhydryl groups to form a thioether link and is used to 
conjugate primary amines to thiol groups (Brinkley, 1992), (Conde et al., 2014). Click 
chemistry based reactions such as the copper-catalysed azide-alkyne cycloaddition 
(CuAAC) reaction can also be used for bio-conjugation. These reactions rely on the 
reactivity of the Azide and alkyne functional groups for conjugation and have been used 
to conjugate various proteins to gold nanoparticles (Zhu et al., 2012). Alternatively, non-
covalent methods can be used for MNP-ligand conjugation, these methods are discussed 
further by Conde et al. (Conde et al., 2014).  
1.8.6 Biomedical applications of MNP 
The physical properties of MNP such as size, composition, surface functionality and 
biocompatibility can be easily tailored to the intended purpose during production 
(Akbarzadeh et al., 2012). MNP can also be functionalised with a wide range of biological 
ligands such as small peptides or antibodies which allows targeting of MNP to specific 
tissues or cell populations via surface proteins (Conde et al., 2014) as shown in Figure 
1.11. The versatility of these tools means that MNP can be applied to an enormous range 
of biomedical applications. In the field of nano-medicine MNP have been utilised for 
applications such as targeted gene or drug delivery, hyperthermia treatment of tumours 
and stem cell tracking by magnetic resonance imaging (MRI) (Lin et al., 2008). 
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1.8.6.1 Tracking and Tagging 
MNP are particularly useful as tracking agents. For instance, MNP tagged cells that have 
been injected into the body can be easily located by magnetic resonance imaging (MRI). 
When cells are labelled with MNP, the MNP are eventually internalised by the cell. By 
doing so the magnetic properties of the MNP are effectively transferred to the cell. This 
makes it possible to track the cells by MRI (Ramaswamy et al., 2009). This strategy is 
useful in areas such as tissue engineering where the monitoring of the location and 
distribution of injected cells for cell therapies is important (Markides et al., 2012). 
Furthermore, MNP have been shown to be useful MRI contrast agents due to their high 
relaxation times and slow renal clearance. This is especially true for MNP sized <50nm in 
diameter (Talelli et al., 2009), (Mahmoudi et al., 2011). The use of SPION also tends to 
enable imaging of deeper tissues and often give superior image resolution  when 
Figure 1.11. Schematic of MNP and surface coatings. 
MNP typically consist of a magnetic core material surrounded by a protective 
matrix of biocompatible substrate such as Dextran. The MNP surface can be 
functionalised with various biomolecules including peptides, antibodies via 
surface functional groups or organic linkers.  
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compared to gadolinium based contrast agents (Talelli et al., 2009), (Jin et al., 2010). 
Examples of MNP that have made it to clinical use as contrast agents include Feridex and 
Endorem (Meng et al., 2009), (Martin et al., 2012). The tagging of cells with MNP also 
enables cells to be remotely guided and retained at the desired location. This can all be 
achieved using an external magnet. The applications of this strategy are clear in 
regenerative medicine where stem cells can be guided to damaged or hypertrophic tissue 
where they can then orchestrate repair of the tissue (Kyrtatos et al., 2009), (Arbab et al., 
2004). 
1.8.6.2 Cancer 
Tumours have been shown to be particularly susceptible to heating compared to healthy 
tissue. Most cancer cells undergo cell death when heated to temperatures of 45oC. The 
application of high temperatures causes many kinds of cell stress and results in protein 
denaturation, cytoskeleton and membrane damage and alters the activity of the enzymes 
involved in DNA replication and repair. In combination, these factors can lead to 
irreparable damage and cause apoptosis (Thanh, 2012). One way of generating localised 
heat at tumour sites is by using MNP. When tumours are loaded with MNP and exposed 
to an alternating magnetic field, the electromagnetic energy is converted to heat 
(Gneveckow et al., 2004). This results in controlled, localised heating of the tumour and 
subsequent tumour necrosis. Improved targeting of tumours can be achieved by 
combining antibody therapy with Hyperthermia treatment (Ito et al., 2004).  
Hyperthermia treatment of tumours is showing great promise in in vivo mouse models for 
a number of cancers (Hilger et al., 2005).  
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1.8.6.3 Drug delivery 
MNP have also found applications as drug delivery vehicles. In this instance a high 
gradient external magnetic field can be used to guide and concentrate a drug loaded MNP 
that is intravenously or intra arterially injected to the desired location. At this point the 
drug or gene is then delivered using mechanisms such as enzymatic cleavage or changes 
in physiological condition e.g. pH, temperature (Shubayev et al., 2009), (Fouriki et al., 
2014), (Lemke et al., 2004). This strategy has obvious benefits for reducing the doses 
required for chemotherapy where currently the administration of systemic (and often 
high) doses of a therapeutic agent are required for therapeutic efficacy but which can also 
induce side-effects. Targeted delivery systems that use MNP can help to maximise drug 
efficacy whilst minimising side effects, lowering the required dosage and therefore the 
cost of treatment (Alexiou et al., 2003). Drug delivery using this system has been assessed 
in rabbits with squamous cell carcinoma where it was demonstrated that Ferro-fluids 
loaded with Mitoxantrone could be manipulated to deliver the drug to the desired site 
using an external magnet (Alexiou et al., 2000).  
1.8.6.4 Magnetofection 
It is also possible to efficiently deliver therapeutic genes using MNP as a gene vector. This 
strategy has many applications in medicine e.g. treatment of genetic defects, cancer etc.  
The aim of gene therapy is to replace or introduce missing or faulty genes by the insertion 
of DNA. However, achieving successful and efficient transfection is notoriously difficult 
and current viral and non-viral methods frequently suffer from poor transfection 
efficiency (Dobson, 2006).  Magnetic transfection has an advantage over other 
transfection systems that often impact cell viability or suffer from poor transfection 
efficiency (Durán et al., 2011). Furthermore, magnetic transfection requires shorter 
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incubation times, offers improved transfection of non-permissive cells and the potential 
for in vivo transfections (Dobson, 2006), (Scherer et al., 2002). For example, in vitro 
experiments have demonstrated improved transfection efficiency of MG63 cells without 
reducing cell viability (Fouriki et al., 2014). Also it has been shown that it is possible to 
transfect human umbilical vein endothelial cells (HUVECs) with VEGF in order to improve 
cell viability, this offers a novel method of treating heart ischemia (Cho et al., 2012). 
1.8.7 MNP for cell activation 
Another exciting application of MNP is remote activation of cell signalling pathways using 
MNP targeted to specific cell receptors. MNP can be functionalised with biomolecules and 
used to target specific cell receptors and signalling pathways. Signalling activity can then 
be modulated by applying external magnetic fields to the MNP. Under these conditions 
high gradient magnetic fields can be used to pull down, drag or oscillate the MNP in a 
given direction as illustrated in Figure 1.12. The magnetic field induces a translational 
force on the MNP which results in tension and deformation of the cell membrane or 
mechanosensitive receptor to which the MNP is attached or clustering of multiple 
receptors.  
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1.8.7.1 Forces exerted by MNP 
The force exerted by MNP can be estimated by mathematical modelling by taking into 
account to the particles size and magnetic field gradient. It has been shown that relatively 
low magnitude forces, in the order of piconewtons (pN), are required to induce magnetic 
activation. For instance, 250nm ferric-based MNP exerting forces ranging from 0.2pN-2pN 
have been shown to activate TREK1 channels and PDGF receptors respectively whilst 
ferro-based microparticles exerting 6pN forces have been shown to cause activation of BK 
channels in MSC (Dobson et al., 2006), (Hughes et al., 2008), (Kirkham et al., 2010) (Hu et 
al., 2014). One benefit of this strategy is that the force transduced by the MNP can be 
regulated by controlling parameters such as magnetic field strength, size and the number 
of attached particles (Hughes et al., 2005).  
1.8.7.2 Magnetic force bioreactor 
MNP can be controlled using external magnetic fields, which can be provided by 
permanent magnets or electromagnetic fields (Marcos-Campos et al., 2011), (Polyak et 
Figure 1.12. Magnetic activation of ion channels and receptor clustering. 
Illustration of magnetic particle mediated ion channel activation and receptor 
clustering after application of magnetic fields. Magnetic nanoparticles can be 
targeted to ion channels (c) or surface receptors (d) using antibodies. Application of 
magnetic fields causes opening of the channel and flux of ions across the cell 
membrane (C) or clustering of surface receptors that can activate signalling 
pathways. Image adapted with permission from Dobson, 2008 (Dobson, 2008).   
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al., 2008). The magnetic force bioreactor used in this work, provided by MICA Biosystems, 
consists of arrays of permanent magnets. The magnets can be remotely positioned to 
move the arrays toward and away from culture plates in a vertical plane to impart 
magnetic field gradients. The system can be housed inside a standard tissue culture 
incubator maintained at physiological conditions. The apparatus is controlled by software 
which regulates parameters such as the speed, frequency and number of loops of the 
arrays.  When used in conjunction with MNP this system can be used to stimulate MNP 
labelled cells and tissues. An illustration showing an overview and principle behind the 
magnetic force bioreactor system is shown in Figure 1.13. The applications of this strategy 
are discussed in the following sections.   
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1.8.7.3 Magnetic stimulation of Integrin receptors 
The RGD binding domain is prominently expressed by most integrin receptors. This 
enables proteins or peptides containing the RGD motif to bind Integrins at an interface 
between the α and β subunits (Ruoslahti, 1996), (Humphries et al., 2006). MNP can be 
easily functionalised with RGD peptides to allow attachment of MNP to Integrin receptors 
thereby enabling directed magnetic stimulation of Integrins. This approach has been 
shown to enhance proteoglycan and extracellular matrix protein synthesis by hMSC 
Figure 1.13. Schematic of the Magnetic force bioreactor system. 
Tissue culture plates sit on place holders over the top of the magnetic arrays. The 
arrays move in the vertical plane underneath the culture plates. The apparatus is 
connected to a computer system operating software which controls the travelling 
speed, distance and cycling parameters of the arrays (A). Cells and tissues can then be 
remotely stimulated by magnetic particles using magnetic fields provided by the 
permanent magnetic arrays (B) 
 68 
 
(Kanczler et al., 2010) and increase endothelin-1 expression in endothelial cells (Chen et 
al., 2001). Furthermore, stimulation of Integrins using MNP functionalised with antibodies 
raised against α2 or β1 subunits has been shown to instigate changes in the actin 
cytoskeleton, formation of adhesion complexes, increased MAPK activity and generation 
of calcium fluxes in U-2 OS cells (Schmidt et al., 1998), (Pommerenke et al., 1996).  
1.8.7.4 Magnetic activation of TREK1 channels 
Twik-related potassium channel 1 (TREK1) is another target which has been shown to be 
mechanosensitive. TREK channels belong to the two pore domain potassium channel 
family (Ketchum et al., 1995), (Goldstein et al., 2001). As discussed previously, TREK 
channels are involved in the regulation of potassium transport across the cell membrane. 
In doing so they regulate the resting membrane potential of the cell (Lesage and 
Lazdunski, 2000), (Patel and Honore, 2001). Proof of concept studies have previously 
demonstrated that TREK channels are amenable to stimulation with magnetic 
nanoparticles. In these studies stimulation of discrete regions of TREK1 using MNP 
targeted to an extracellular loop region were able to cause membrane depolarisation 
consistent with ion channel activation. In contrast, this response was not seen when 
control particles or magnetic field stimulation were applied alone (Hughes et al., 2008).   
1.8.7.5 Magnetic activation of Platelet Derived Growth Factor receptors 
Platelet Derived Growth Factor receptors (PDGFR) belong to the receptor tyrosine kinase 
(RTK) family and play crucial roles in embryonic development. The PDGF growth factor is 
involved in the regulation of many cell processes including migration and proliferation. 
PDGF ligands signal through homo or hetero dimers of PDGF receptors alpha (PDGFRα) 
and beta (PDGFRβ) (Tallquist and Kazlauskas, 2004), (Lemmon and Schlessinger, 2010). 
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Previous work has demonstrated that PDGF receptors are mechanoresponsive (Hu et al., 
1998), (Tanabe et al., 2000). The feasibility of using MNP to target PDGFRα has recently 
been demonstrated where receptor stimulation with antibody-functionalised MNP 
resulted in phosphorylation of PDGFRα and enhanced SMA expression in hMSC (Hu et al., 
2014). Furthermore, this approach was also shown to enhance osteogenic marker 
expression and increased the mineral to matrix ratio when hMSC were subjected to three 
weeks of magnetic stimulation in vitro (Hu et al., 2013).  
1.8.8 MNP and bone tissue engineering 
Magnetic activation strategies using MNP have been extensively studied both in vitro and 
in vivo, particularly in a bone tissue engineering context. In vitro studies have investigated 
labelling of human osteoblasts with RGD tri-peptide coated MNP which bind to integrin 
receptors. When this was coupled with magnetic stimulation over 7-21 days an increase 
in mineralized bone matrix and up-regulation of osteopontin and osteocalcin was 
observed. Furthermore, it was shown that cells with attached particles were proliferative 
and viable at 21 days (Cartmell et al., 2002), (Dobson et al., 2006), (Hughes et al., 2005). 
Also, hMSC have been shown to be load responsive when targeting the mechano-
responsive ion channel TREK1 and integrin receptors using MNP functionalised with anti-
TREK1 antibodies or RGD tri-peptide respectively. In this scenario, after 7 days of TREK1 
stimulation it was shown that expression of chondrogenic and osteogenic related genes 
Sox9, core binding factor alpha1 (Cbfa1), and osteopontin were up-regulated. After 21 
days expression of type 1 collagen and proteoglycan matrix was also increased (Kanczler 
et al., 2010). Remote activation of TREK channels has been shown to have beneficial 
effects on bone formation in an ex vivo foetal chick femur model of bone development.  
In this work, magnetic activation of TREK channels on hMSC that were injected into the 
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epiphyseal regions of the femurs was shown to cause an increase in bone production and 
induce areas of secondary mineralisation at the injection sites  (Henstock et al., 2014). 
This strategy has also been translated In vivo. Studies in rats have shown that mechanical 
stimulation of TREK1 ion channels on hMSC increased proteoglycan matrix, expression of 
core binding factor alpha1 (Cbfa1), extracellular matrix production and led to elevated 
expression of type 1 and type 2 Collagen after 21 days. Additionally, the magnetic 
stimulation of hMSC labelled with RGD tri-peptide MNP enhanced proteoglycan and 
collagen synthesis, extracellular matrix production and elevated the expression of 
Collagen type 1 and type 2 both in vitro and in vivo. Importantly, hMSC labelled with MNP 
were also shown to be viable in these experiments (Kanczler et al., 2010). These studies 
highlight the potential benefits of MNP and magnetic activation strategies in bone tissue 
engineering. 
 
1.9 Research Hypothesis and Objectives 
The main hypothesis underpinning this work is that targeting Frizzled receptors with MNP 
may have an effect on Frizzled signalling activity. Therefore the primary objective of this 
research is to investigate the targeting and activating capabilities of functionalised MNP in 
conjunction with magnetic fields on Wnt signalling pathway activity in hMSC. As Wnt 
signalling is involved in the regulation of stem cell behaviour and is important in bone 
formation it is also hypothesized that magnetic activation of Frizzled receptors and Wnt 
signalling may have an effect on stem cell behaviour. Therefore the next objective is to 
assess the magnetic activation strategy in directing MSC osteogenic differentiation. 
Another objective is to characterise the MNP functionalisation process and to assess the 
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effects of functionalised MNP on stem cell toxicity. The role of directional signalling 
gradients is known to be important for regulating stem cell maintenance and 
differentiation. It is therefore possible that directional presentation of signalling cues to 
stem cells may provide a more contextually relevant environment for tissue formation. 
Therefore the final objective of this research is to explore the role of spatial and 
directionally presented Wnt cues on hMSC migration and osteogenic differentiation.   
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2 Chapter 2: Nanoparticle and 
magnetic field characterisation 
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2.1 Introduction 
Magnetic Nanoparticles (MNP) have gathered much attention in recent years and have 
now become useful and popular tools in various fields of biomedical research and 
medicine (Q A Pankhurst, 2003). A major advantage pertaining the use of MNP is their 
adaptability for different applications. MNP can be positioned and bound to different 
cellular targets or surface proteins by functionalising their surface with biomolecules such 
as peptides and antibodies (Conde et al., 2014). The superparamagnetic properties of 
nano-scale MNP, which confers  magnetic susceptibility only in the presence of magnetic 
field gradients, also presents unique opportunities for their spatial control and precise 
positioning. This particular feature of superparamagnetic nanoparticles is especially 
useful in medical applications that demand precise control of magnetic particles in vivo 
(Akbarzadeh et al., 2012), (Kumar, 2009). 
Before MNP based treatments can be translated to the clinic however, the safety of these 
materials must first be demonstrated. In particular, the toxicity of MNP must be 
determined and the biocompatibility of MNP based treatments must be proven with 
clinically relevant cell types. One way of aiding MNP biocompatibility is by coating the 
magnetic core with a biocompatible substrate such as dextran. The safety of dextran 
based iron oxide MNP has previously been demonstrated by a number of groups, 
particularly in the context of MRI studies for tracking of MNP labelled cells (Huang et al., 
2009), (Lalande et al., 2011), (Loebinger et al., 2009). A comprehensive review of MNP 
based toxicity in the broader context of regenerative medicine is discussed by (Markides 
et al., 2012).   
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One specific application of magnetic nanoparticles is the selective application of 
mechanical forces to mechanosensitive receptors. This has an added benefit of being able 
to exercise a level of control over the activation of mechanosensitive receptors and cell 
signalling pathways. Previous work has demonstrated that imparting comparatively low 
magnitude force in the order of 0.2-6pN using MNP is capable of altering the activation 
state of mechanosensitive proteins. Specifically, remotely torqueing MNP attached to 
TREK1 ion channels, Integrins and Platelet Derived Growth Factor receptors (PDGFR) using 
the same magnetic force bioreactor system introduced in chapter 1  has been shown to 
induce activation of signalling pathways associated with  these targets (Dobson et al., 
2006), (Kirkham et al., 2010), (Hughes et al., 2007), (Hughes et al., 2008), (Cartmell et al., 
2002), (Hu et al., 2014). However, to date MNP mediated mechanical stimulation of the 
Wnt signalling pathway through direct application of mechanical forces to Frizzled 
receptors is still lacking. 
The aims of the experiments presented in this chapter were to firstly characterise the 
biological ligand (i.e. peptides and antibodies) and MNP functionalisation process which 
was used to target Frizzled receptors. This is required in order to determine the efficacy 
of MNP functionalisation with these particular Frizzled targeting modalities. The next aim 
was to characterise the magnetic field profiles of the bioreactor system used to apply 
oscillating magnetic fields, in order to determine the magnitude of the magnetic fields 
applied. The third aim was to examine the toxicity profiles of the MNP and associated 
magnetic field treatments used in these experiments in a clinically relevant stem cell type, 
hMSC. These effects were examined in order to assess the safety and biocompatibility of 
these treatments. The fourth aim was to attempt tracking of the MNP, to determine the 
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longevity of hMSC-MNP labelling in vitro. The final aim was to provide an estimation of 
the forces transduced by the MNP onto the cells using mathematical modelling.  
  
2.2 Methods 
2.2.1 Cell culture 
Fresh human bone marrow (Lonza, cat. no. 1M-125) was sourced from healthy volunteers 
with written, informed consent obtained by Lonza. No ethical approval was required for 
this project as the human tissue (bone marrow aspirate) was acquired from a 
commercially available source. The donor program is approved annually by a commercial 
institutional review board and Lonza Walkersville Inc. is a licensed tissue bank. The 
adherent cell population was selected from fresh bone marrow by culturing aliquots of 
aspirate for 2 weeks in Low glucose DMEM with 5% FBS, 1% L-glutamine and 1% Penicillin 
and Streptomycin with Media changes performed once per week.  MSC were routinely 
characterised for expression of surface markers (CD73+, CD90+, CD105+ and  CD45-, 
CD34-, CD14-, CD19- and HLA-DR-) and histological staining for osteogenic (Alizarin red), 
chondrogenic (Alcian blue) and adipogenic differentiation (Oil red O) (see appendix A). 
For cell expansion MSC were cultured in High glucose DMEM supplemented with 10% 
FBS, 1% L-glutamine and 1% Penicillin / Streptomycin (All reagents Lonza). Cells were 
passaged once per week and cells between passage 2 and 5 were used in all experiments. 
2.2.2 MNP coating 
250nm SPIO carboxyl functionalised magnetic nanoparticles (Micromod) were covalently 
coated with anti-Frizzled 2 (Abcam), TREK1 (Alomone labs), UM206 peptide (Pepceuticals, 
UK) or IgG-FITC antibodies by carbodiimide activation as described previously (Hu et al., 
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2014). Briefly, 1mg of particles (for each ligand) were activated using EDAC and NHS 
dissolved in 0.5M MES buffer pH6.3 (All Sigma) for 60 mins. at room temperature with 
constant mixing. The particle suspension was washed and re-suspended in 0.1M MES 
buffer containing 20g of anti-rabbit secondary antibody (Abcam) or 10g of either L-
UM206 or C-C-UM206 peptide. The particle suspensions were continuously mixed 
overnight at 4oC then the antibody coated suspensions were washed and re-suspended in 
0.1mL MES buffer containing 10g of either anti-Frizzled 2 antibody (Abcam) or Anti-
TREK1 antibody (Alomone labs). Particle suspensions were mixed for a further 3h at room 
temperature then all suspensions were blocked with 25mM Glycine (Sigma) for 30mins 
before final washing and re-suspension in 0.1% BSA (Fisher) in PBS (Sigma). In order to 
test the coating efficiency of MNP, samples of the coating solutions containing the 
antibodies or peptides described above were taken before and after incubation with 
MNP. The total protein content of each sample was determined using a BCA assay 
(Fisher). The amount of protein taken up by the MNP was determined according to the 
difference in protein concentrations between samples. As a control to determine the level 
of protein adhesion to reaction tubes, a 0.5mg/mL solution of BSA in 0.1M MES buffer 
was prepared, with samples taken before incubation in a 1.5mL eppendorf tube and after 
3h incubation. 
2.2.3 Total protein assay 
Total protein was assessed using a BCA assay kit (Fisher). Samples were diluted 2x with 
d.H2O and 25μL of each sample was aliquoted into 96 well plates. A working solution of 
BCA assay reagent was prepared using 10mL of reagent A and 200μL of reagent B. 200μL 
of working reagent was added to each sample and incubated for 30mins at 37oC. The 
absorbance of the resulting solutions was measured at a wavelength of 562nm using a 
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Synergy 2 plate reader. The total protein concentration of the samples was determined 
by comparison to a standard curve of BSA dissolved in 0.1M MES buffer (see appendix B).   
2.2.4 Zeta sizing and Zeta potential 
Functionalised nanoparticles were analysed for surface charge and size by dynamic light 
scattering using a Zetasizer 3000 HSa (Malvern Instruments). Particles were diluted 500x 
in dH20 and measurements performed at 25
oC. The size and surface charge of coated 
nanoparticles was compared to uncoated activated nanoparticles. 
2.2.5 Magnetic Field Mapping 
The magnetic fields for each magnetic array were mapped using Magscan 300 instrument 
(Redcliffe) at a resolution of 0.2 x 0.2 mm. The field maps and polarities at varying 
distances were determined by altering the distance between the magnetic arrays and the 
detector up to a maximum distance of 84mm from the array.  
2.2.6 Cell labelling with MNP 
Media was aspirated and cells washed with PBS. All cells were cultured in basal serum-
free MSC expansion media for 3h before addition of MNP. Particles were added to 
appropriate groups at approximately 3g MNP/cm2 of culture surface area, and 
incubated for a further 1.5h with intermittent agitation. Media was aspirated, cells were 
washed with PBS to remove unbound particles before addition of fresh media (0% FBS for 
western blotting experiments, 2.5% FBS for luciferase experiments, 10% FBS for gene 
expression experiments).  
2.2.7 Magnetic stimulation 
Magnetically stimulated groups were placed in a vertically oscillating magnetic force 
bioreactor (MICA Biosystems) which was situated inside an incubator maintained at 37oC, 
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5% CO2. Non-stimulated control groups were kept in identical conditions (without 
magnetic field). Magnetically stimulated groups were exposed to a magnetic field of 25-
120mT  from an array of permanent magnets (NdFeB) situated beneath the culture plates 
at a frequency of approximately 1Hz. Magnetic field treatment was applied in 3x 1hr 
weekly sessions on alternate days. An image showing the magnetic bioreactor apparatus 
is shown in Figure 2.1. 
 
2.2.8 Cell viability staining 
Cells were labelled with MNP and treated with magnetic field stimulation as described 
above. After each time point, cells were washed with PBS then stained with a Live/dead 
assay solution (Sigma) consisting of Calcein AM (diluted 1:500) and Propidium iodide 
(diluted 1:1000) in PBS. Samples were stained for 15mins at 37oC. Samples were then 
imaged on an Olympus IX83 confocal microscope operating Flourview 10 software.  
Figure 2.1. Magnetic force bioreactor apparatus. 
Photograph showing the key components of the magnetic bioreactor system. Tissue 
culture plates are situated over the permanent magnetic arrays (6-well and 24-well 
arrays shown). The magnetic arrays are driven in a cyclic motion underneath the 
culture plates plane using a motorised drive-shaft. The apparatus is connected to 
software which controls the movement of the arrays (not shown). 
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2.2.9 MTT assay 
Cells were labelled with MNP and treated with magnetic field stimulation as described 
above. After each time point, cells were washed with PBS then incubated with fresh 
media containing 0.5mg/mL Thiazolyl Blue Tetrazolium Bromide (MTT) (Sigma). Cells were 
incubated for 3h at 37oC. After which media was aspirated and the purple formazan salt 
produced by the cells was extracted by adding 0.5mL DMSO (Sigma), samples were placed 
on an orbital shaker for 15mins during dye extraction. 100μL of extracted dye was 
aliquoted into a 96 well plate and the absorbance at wavelength 570nm was read, 
readings were corrected by measuring absorbance at 690nm. Readings were obtained 
using a Biotek Synergy 2 plate reader.  
2.2.10 Prussian blue staining 
Cells were labelled with MNP as described above. After which media was aspirated, cells 
washed with PBS then fixed using 90% methanol (Fisher) for 10mins. Samples were 
washed with PBS before staining for Iron deposits using a solution of 20% Conc. HCl 
(sigma) with 10% Potassium Ferrocyanide (Sigma). Samples were stained for 20mins then 
washed 3x with distilled H2O. Samples were imaged on a Leica DMIL microscope 
operating LAS software. 
2.2.11 Immunocytochemistry  
For MNP staining, cells were fixed with 4% PFA in PBS (Sigma) for 10mins before blocking 
with 2% BSA/PBS for 1h. Cells were incubated with anti-Dextran (Stem cell technologies) 
diluted 1:1000 in 1% BSA / PBS overnight at 4oC. Cells were washed with PBS then 
incubated with anti-Mouse-FITC secondary antibody (Sigma) diluted 1:1000 in 1% BSA / 
PBS for 1h at room temp. Cells were washed in PBS, and F-actin stained with Phalloidin-
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Atto 565 (Sigma). Cells were washed with PBS before counterstaining with DAPI. 
Fluorescence microscopy was performed on a Nikon Eclipse Ti-S microscope operating NIS 
elements software. 
2.2.12 Microscopy 
Samples of MNP coated with IgG-FITC antibodies or uncoated MNP were aliquoted into 
wells of a 96-well plate (100μL of each particle type). Samples were diluted with 100µL 
PBS then imaged using Nikon Eclipse Ti-S microscope operating NIS elements software. 
2.2.13 Forces exerted by MNP 
The forces exerted by individual MNP in response to magnetic fields were estimated 
according to a mathematical model as previously described by (Dobson et al., 2006).  
2.2.14 Statistical analysis 
All data is presented as means +/- SEM or standard deviation as indicated. Statistical 
significance at 95% confidence level was determined using 1-way ANOVA with post-hoc 
Tukey tests using Mini-tab (v16) software. 
 
2.3 Results 
2.3.1 MNP functionalisation 
The size and surface charge of peptide and antibody coated nanoparticles were analysed 
by zeta-sizing and zeta-potential and compared to uncoated MNP (Table 2.1). The size of 
uncoated MNP was measured as approximately 300nm whereas the size of functionalised 
MNP increased by at least 10% after conjugation with protein ligands. The surface charge 
(zeta potential) of uncoated-MNP was measured as approximately -19mV whereas the 
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charge of the protein functionalised MNP increased to between -16 to -7.2 mV after 
conjugation. 
 
2.3.2 MNP coating efficiency 
The amount of protein conjugated to MNP was indirectly determined by measuring the 
protein content of the respective MNP coating solutions before and after incubation with 
activated MNP (Table 2.2).  The protein concentration of the coating solutions for each 
MNP coating type (peptides or antibodies) was found to decrease by between 5% and 
25% after incubation with the activated MNP. The protein content of a control solution of 
BSA in MES buffer incubated for 3h in an eppendorf tube showed no difference in protein 
concentration (1.87±0.02 Abs) compared to the starting concentration (1.86±0.01 Abs).  
Table 2.1. MNP size and surface charge after functionalisation. 
Uncoated particles had a measured diameter of approximately 300nm and 
surface charge (Zeta Potential) of approximately 19mV. Functionalisation of MNP 
with UM206 peptides (L-UM206 or C-C-UM206), anti-Fz2 antibodies (Fz2-IgG) or 
anti-TREK1 antibodies (Trek-IgG) all increased the diameter of the MNP to 
between 333-346nm. Peptide or antibody Functionalisation also increased the 
Zeta potential to between -15.8 and -7.3mV. Samples read in triplicate, error 
represents standard deviation. 
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2.3.3 MNP coating with IgG-FITC 
In order to confirm that the MNP bio-functionalisation process resulted in the presence of 
protein on the MNP, model fluorescently tagged antibodies were coated onto MNP (IgG-
FITC-MNP) and analysed by fluorescent microscopy (Figure 2.2). MNP coated with the 
IgG-FITC antibodies displayed a clear fluorescent signal after coating; in contrast no 
fluorescent signal was detected from uncoated MNP. 
 
 
Table 2.2. MNP coating efficiency. 
Functionalisation of MNP with L-UM206, C-C-UM206, Anti-Fz 2 antibodies (Fz2-
IgG), anti-TREK1 antibodies (Trek-IgG) or anti-Rabbit-IgG (Rabbit-IgG) all led to 
decreases in the total protein content of the coating solution supernatant of 
between 5-27%. Samples read in triplicate, error represents standard deviation. 
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2.3.4 Characterisation of permanent magnetic arrays 
Next, the magnetic field strengths, polarities and gradients produced by the permanent 
magnetic arrays were mapped and modelled using a Magscan 300 instrument (Redcliffe). 
This allowed estimations of the magnetic field gradients that were applied to the MNP to 
be calculated.  
 
Figure 2.2. MNP coating with IgG-FITC. 
Immunofluorescence and light microscopy images for antibody-FITC coated and un-
coated-MNP. MNP functionalised with IgG-FITC antibodies displayed clear 
fluorescence after coating (A). No Fluorescence signal was observed for uncoated-
MNP (C). Light microscopy images are shown in (B) and (D). Representative images of 
n=3 shown, scale bar represents 50µm. 
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2.3.4.1 6-well array field map 
Using the 6-well magnetic arrays (Figure 2.3), at the level of the sample, the magnetic 
field profiles appeared to be regular and well defined as shown by cross-sections of the 
magnetic field array. The peak field strength was estimated to be 75mT. In contrast, when 
the magnetic array was moved away from the sample, the magnetic field profile became 
irregular and the field strength was reduced to approximately 1.4mT.   
2.3.4.2 24-well array field map 
Using the 24-well magnetic arrays (Figure 2.4), at the level of the sample, the magnetic 
field profiles again appeared to be regular and well defined as shown by cross-sections of 
the magnetic field array. The peak field strength was estimated to be 108mT. But when 
the magnetic array was moved away from the sample the magnetic field profile became 
irregular and the field strength was reduced to approximately 0.7mT. 
2.3.4.3 Magnetic array field gradients 
The magnetic field strengths across a range of distances were measured for both 
magnetic array types in order to simulate the applied magnetic field gradients 
experienced by cells in vitro (Figure 2.5).  The 6-well array displayed overall stronger 
magnetic field strengths that peaked at approximately 300mT, whilst the 24-well array 
displayed weaker magnetic field strengths that peaked at approximately 120mT. The 
magnetic fields for both arrays decreased exponentially as a function of distance from the 
detector with minimum field strengths of approximately 1mT measured for each array.
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Figure 2.3. 6-well array magnetic field mapping. 
2D model representations of magnetic field strength and polarity of 6-well permanent 
magnet arrays. When the magnetic array was closest to the samples (approx. 18mm) 
the peak magnetic field strength was ±75mT (A), the peak field strength and field 
polarity is shown in (C), A representative cross-section of the magnetic fields and 
polarity is shown in (E). When the magnetic array was the furthest (measurable) 
distance from the samples (approx. 84mm) the magnetic field strength was reduced 
to ±1.4mT (B), the field strength and field polarity is shown in (D), A representative 
cross-section of the magnetic fields and polarity is shown in (F). 
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Figure 2.4. 24-well array magnetic field mapping. 
2D model representations of magnetic field strength and polarity of 24-well 
permanent magnet array. When the magnetic array was closest to the samples 
(approx. 7mm) the peak magnetic field strength was ±109mT (A), the field strength 
and field polarity is shown in (C), A representative cross-section of the magnetic fields 
and polarity is shown in (E).  When the magnetic array was the furthest (measurable) 
distance from the samples (approx. 84mm) the magnetic field strength was reduced 
to ±1.0mT (B), the field strength and field polarity is shown in (D), A representative 
cross-section of the magnetic fields and polarity is shown in (F). 
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Figure 2.5. Magnetic field gradients. 
Graphical representation of the magnetic field gradients of the 6-well and 24-well permanent arrays. For the 6-well array (A), when the 
array was positioned towards the samples (approx. 18mm distance) this resulted in a peak magnetic field range of 68-76mT. Away from 
the sample, at a distance of 84mm, the magnetic field strength was reduced to 1-2mT. For the 24-well array (B), when the array was 
positioned towards the samples (approx. 6mm distance) this resulted in a peak magnetic field range of 93-117mT. Away from the sample, 
at a distance of 84mm, the magnetic field strength was reduced to approximately 1mT. 
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2.3.5 Cytotoxic effects of MNP on hMSC 
The cytotoxic effects of the MNP, their respective surface coatings and the effect of 
magnetic field stimulation were all assessed using two well established cytotoxicity assays 
measuring cell viability and metabolism.   
2.3.5.1 Effects of MNP on hMSC viability  
Changes to cell viability were assessed by Live/Dead staining to determine intracellular 
esterase activity and cell membrane integrity 24h (Figure 2.6) and 14 days (Figure 2.7) 
after MNP labelling and intermittent magnetic field stimulation. All MNP types with 
different surface coatings had no noticeable effect on hMSC viability 24h after labelling. 
Furthermore, application of magnetic field stimulation alone or in conjunction with all 
MNP had no noticeable effect on cell viability. After 14 days, a negligible degree of cell 
death was observed after treatment with MNP (regardless of MNP coating) with and 
without intermittent magnetic field stimulation. Treatment with magnetic fields alone 
had no observable effects on cell viability. 
2.3.5.2 Effects of MNP on hMSC metabolism  
The effects of MNP on cell metabolism 24h and 14 days after MNP labelling with 
intermittent magnetic field stimulation was also assessed by MTT assay (Figure 2.8). After 
24h, no overall effect on cell metabolism was observed when cells were treated with 
magnetic field alone or when treated with either Fz-MNP or L-UM206-MNP with or 
without magnetic field stimulation. A marginal decrease in cell metabolism (not 
significant) was observed when cells were treated with C-C-UM206-MNP alone but no 
effect was observed in response to these MNP with magnetic field stimulation. After 14 
days no overall effect on cell metabolism was observed when cells were treated with 
 89 
 
either magnetic field alone or when treated with MNP of any types with or without 
magnetic field stimulation.  
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Figure 2.6. Effects of MNP and magnetic field on cell viability at 24h. 
Immunofluorescence images showing Calcein-AM (Live) and Ethidium homodimer 
(Dead) staining after treatment with different MNP types with and without magnetic 
field after 24h. Cells treated with MNP alone with different surface coatings (B-D) or 
in conjunction with magnetic field (F-H) had no discernible effect on cell viability 24h 
post treatment compared to controls (A, E). Magnetic field treatment alone also had 
no discernible effect on cell viability after 24h (E). Representative images of n=3 
shown, scale bar represents 100µm. 
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Figure 2.7. Effects of MNP and magnetic field on cell viability after 14 days. 
Immunofluorescence images showing Calcein-AM (Live) and Ethidium homodimer 
(Dead) staining after treatment with different MNP types with and without magnetic 
field after 14 days. Cells treated with MNP alone with different surface coatings 
caused negligible increases in cell death (B-D) compared to non-treated control cells 
(A). Addition of magnetic field stimulation also caused a negligible effect (F-H) 
compared to magnetic field treated cells (E). No observable effects were observed for 
cells treated with magnetic field alone after 14 days (E). Representative images of 
n=3 shown, scale bar represents 100µm.  
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Figure 2.8. Effects of MNP and magnetic field on cell metabolism. 
Graphs showing MTT metabolism in hMSC 24h and 14 days after treatment with MNP with or without magnetic field. No overall effect 
on cell metabolism over both time-points was observed for cells treated with Magnetic field alone, Fz-MNP (with or without magnetic 
field) or L-UM206-MNP (with or without magnetic field) (A, B). A minor decrease in cell metabolism (not significant) was observed in 
cells treated with C-C-UM206-MNP alone after 24h (A), but no effect was observed after 14 days. No overall effect was observed for cells 
treated with C-C-UM206-MNP with magnetic field after 24h and 14 days (B). Average absorbance values are shown, n=3, error bars 
represent SEM.   
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2.3.6 Tracking MNP distribution 
MSC labelling with different MNP types was confirmed by biochemical staining to detect 
the iron oxide core of the MNP and by Immunofluorescence to detect the dextran shell 
coating. Cells were labelled with Fz-MNP, L-UM206-MNP or C-C-UM206-MNP then the 
iron oxide component of the MNP was visualised using Prussian blue staining. The 
reaction between Potassium Ferrocyanide with the iron oxide in the MNP causes 
formation of a blue precipitate (Ferric Ferrocyanide) which can be visualised. Figure 2.9 
shows the presence of MNP and association of each MNP type with MSC after 1.5h 
incubation, the cell morphologies are shown in the polarised light images. MNP labelling 
of hMSC was also tracked over the course of 7 days using Immunofluorescence to identify 
the dextran component of the MNP, cells were counter-stained with Phalloidin and DAPI 
to locate the cell nuclei and cytoskeleton. A clear association between cells and MNP was 
observed for each MNP type. Cells labelled with Fz-MNP (Figure 2.10) showed clear 
labelling over 7 days with peak staining observed after 24h after which staining intensity 
decreased. Cells labelled with L-UM206-MNP (Figure 2.11) showed notable labelling over 
7 days with peak staining observed after 3 days, staining intensity decreased after 7 days. 
Cells labelled with C-C-UM206-MNP (Figure 2.12) showed notable labelling up to 3 days 
after labelling with peak staining observed after 3 days, staining intensity decreased to 
negligible levels after 7 days. 
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Figure 2.9. Prussian blue staining for MNP.  
Transmitted and polarised light microscopy images showing presence of Iron (Prussian blue staining) localised with hMSC. Unlabelled 
cells were negative for Iron (A). Cells labelled with Fz-MNP (B), L-206-MNP (C) and C-C-206-MNP (D) were all positive for Iron post-
labelling with MNP. Polarised light images showing cell morphology are shown E-H. Representative images of n=4 shown, scale bar 
represents 100µm.  
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Figure 2.10. Fz-MNP tracking over 7 days. 
Time-course of Immunofluorescence images showing presence of Fz-MNP over 7 
days. Dextran staining (Green) for Fz-MNP was detectable over 7 days post-
labelling (A-D). Peak Fz-MNP staining was observed after 24h (B), Fz-MNP staining 
decreased after 3 Days (C) and 7 days (D). Cell morphology is shown by Phalloidin 
staining (Red) for Actin (E-H), Nuclei (Blue) are shown by DAPI staining (I-L). Merge 
channel is shown (M-P). Representative images of n=3 shown, scale bar represents 
100µm. 
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Figure 2.11. L-UM206-MNP tracking over 7 days. 
Time-course of Immunofluorescence images showing presence of L-UM206-MNP 
over 7 days. Dextran staining (Green) for L-UM206-MNP was detectable over 7 
days post-labelling (A-D). Peak L-UM206-MNP staining was observed after 3 days 
(C), L-UM206-MNP staining decreased after 7 days (D). Cell morphology is shown 
by Phalloidin staining (Red) for Actin (E-H), Nuclei (Blue) are shown by DAPI 
staining (I-L). Merge channel is shown (M-P). Representative images of n=3 shown, 
scale bar represents 100µm.  
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Figure 2.12. C-C-UM206-MNP tracking over 7 days. 
Time-course of Immunofluorescence images showing presence of C-C-UM206-
MNP over 7 days. Dextran staining (Green) for C-C-UM206-MNP was detectable up 
to 7 days post-labelling (A-D). Peak C-C-UM206-MNP staining was observed after 3 
days (C), staining decreased after 3  days  with negligible C-C-UM206-MNP staining 
observed after 7 days (D). Cell morphology is shown by Phalloidin staining (Red) for 
Actin (E-H), Nuclei (Blue) are shown by DAPI staining (I-L). Merge channel is shown 
(M-P). Representative images of n=3 shown, scale bar represents 100µm.  
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2.3.7 Force imparted by MNP 
The force imparted by the MNP on to cells can be estimated using mathematical models. 
The model describing the force transduced (Fmag) is described in (Equation 2.1). This 
equation takes into account the size of the magnetic particle, the magnetic susceptibility 
of the magnetic core (in this case iron oxide), the relative magnetic susceptibility of the 
surrounding medium (effectively zero) and the magnitude and field gradient of the 
applied magnetic field. By this method the force imparted by the magnetic particles was 
estimated to be 0.1-1.7 pN per particle when particles were exposed to the magnetic field 
gradients originating from the 24 well magnetic array or the 6 well magnetic array 
respectively. 
 
 
 
 
 
 
 
2.4 Discussion 
2.4.1 MNP functionalisation 
The process of MNP functionalisation with bio-ligands (Peptides and Antibodies) was 
investigated by profiling the physical and biochemical changes in MNP properties before 
Equation 2.1. Force estimation by MNP  
The forces exerted by MNP can be estimated using an equation described by 
Dobson et al   (2006).  
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and after coating. The protein-MNP conjugation process was shown to affect both the 
size and surface charge of MNP. This change in the physical properties of MNP after 
coating suggests the presence of protein on the MNP surface. Changes in the physical 
properties of MNP after functionalisation have previously  been observed (Sader et al., 
2015). Interestingly, although MNP size was increased after coating with either linear 
UM206 (L-UM206) or cyclic UM206 (C-C-UM206), coating with L-UM206 had a reduced 
effect on MNP zeta potential compared to coating with C-C-UM206. This may be an 
artefact of the change in conformational shape of UM206 induced by di-sulphide bond 
formation. Linear UM206 contains two cysteine residues harbouring negatively charged 
thiol groups, which may cause an overall decrease in zeta-potential. Conversely, in C-C-
UM206 disulphide bond formation between the thiol groups would remove the net 
negative charge of these groups and may lead to an increase in the observed zeta-
potential.  
One particular advantage of using covalent attachment of bio-ligands to MNP is that the 
resulting peptide bond formed between the ligand and MNP is very stable (Radzicka and 
Wolfenden, 1996). Previous work has demonstrated the long-term stability bio-ligand 
functionalised MNP. For example Premaratne et al. showed that the peroxidase-like 
activity of Myoglobin which was coated onto MNP was detectable 4 months after coating 
(Premaratne et al., 2016)  and Sui et al. showed that lipase functionalised-MNP retained 
70% of its enzymatic activity 30 days after coating  (Sui et al., 2012). The MNP-antibody 
conjugation process was also validated by conjugating fluorescently labelled secondary 
antibodies to the MNP. This resulted in a clear fluorescence signal from the FITC-IgG 
coated MNP. This provided a visual confirmation that the coating process results in 
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functionalisation of MNP with antibodies. Next, the amount of protein conjugated to 
MNP was estimated by measuring the changes in the supernatant protein concentration 
of the MNP coating solutions before and after incubation with carbodiimide activated 
MNP. It was found that the protein concentration of the coating solution decreased after 
incubation with activated MNP for all coating types. This difference may be expected and 
has been previously observed by many groups (Puertas et al., 2010), (Wang and Lee, 
2003), (Kouassi and Irudayaraj, 2006b), (Kouassi and Irudayaraj, 2006a) and can be 
explained by increased conjugation of protein to the MNP surface thereby removing free 
protein from the coating solution. Interestingly, there was a clear difference in 
conjugation efficiency between L-UM206 and C-C-UM206. A reduction in conjugation 
efficiency was observed when MNP were coated with C-C-UM206, indicating that the 
peptide in this conformation binds less efficiently to the MNP. This could be due to steric 
hindrance effects caused by multiple cyclic peptides competing for the binding sites of the 
MNP. This would therefore result in lower levels of C-C-UM206 bound to the MNP 
surface.    
2.4.2 Magnetic field characterisation 
The magnetic field profiles of the magnetic arrays used in the experiments were also 
characterised by magnetic field mapping at different distances. As expected, the highest 
magnetic field strengths were observed closest to the magnetic array with the magnetic 
field gradient degrading exponentially as a function of distance. The field strengths 
applied in these experiments have been shown to be comparable to the field strengths 
applied in previous work for the activation of other cell surface receptors (Hu et al., 
2013).  
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2.4.3 MSC labelling with MNP 
The presence of MNP and association with cells was determined using biochemistry to 
detect the iron oxide core of the MNP and Immunocytochemistry to detect the dextran 
matrix. Both techniques confirmed that MNP were associated with MSC after labelling 
and MNP association with cells was shown to persist up to 7 days. This may be an 
indication that MNP internalisation has commenced and is consistent with previous work 
with other MNP which showed that endocytosis commences within days after labelling 
with complete internalisation of most adhered MNP after one week (Cartmell et al., 
2005). Other work has identified the mechanism behind MNP internalisation to be 
clathrin and caveolae dependent endocytosis (Cores et al., 2015). However, the rate of 
MNP internalisation is dependent on numerous factors including the cell type, particle 
size, surface charge and particle coating (Hughes et al., 2005).  The results from this work 
suggest that the MNP used here may be internalised after 3-7 days, although It is 
indeterminable whether these MNP are intact or to discern their intracellular or 
extracellular location using the methods shown here. Further work should investigate the 
intracellular location and fate of MNP which could be achieved high resolution or electron 
microscopy techniques. These results may suggest that a window of opportunity may 
exist for mechanical stimulation by MNP before internalisation of the MNP-target 
complex occurs. Having said this, some signalling pathways including the Wnt pathway 
require internalisation of surface receptors in order to propagate signalling. For example, 
caveolin and clathrin-mediated internalisation of Wnt and LRP6 initiated has been shown 
to be necessary for accumulation of β-catenin and Wnt pathway activation (Blitzer and 
Nusse, 2006), (Yamamoto et al., 2006). In this scenario internalisation of the MNP-
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receptor complex may not preclude abrogation of signalling activity. Therefore the effect 
of MNP internalisation on signalling activity should be studied further.  
2.4.4 Cytotoxic effects of MNP and Magnetic field 
The effects of coated MNP on cell toxicity were investigated using two widely used 
methods. Firstly, the effect of MNP on short and medium term cell viability was 
determined using a Live/Dead assay. Fluorescent microscopy indicated that treatment of 
cells with coated MNP remained viable and metabolically active suggesting that there are 
no obvious adverse effects of functionalised MNP on cell membrane integrity or cell 
viability. This agrees with previous work which has shown that dextran-based MNP do not 
significantly affect MSC viability (Jasmin et al., 2011), (Moraes et al., 2012). Furthermore, 
the addition of magnetic field stimulation appeared to have no adverse effects on cell 
viability, this is unsurprising given that previous work has shown that both static and 
oscillating magnetic field gradients up to 600mT in magnitude have no deleterious effects 
on MSC viability (Schäfer et al., 2010), (Ross et al., 2015), (Fouriki and Dobson, 2013). 
Secondly, the effects of MNP on cell metabolism were assessed using an MTT assay. All 
MNP types regardless of surface functionality had no clear effect on cell metabolism 
indicating that they do not induce detrimental effects on cell metabolism and, once again, 
addition of magnetic field stimulation had no detrimental effects on cell metabolism. 
These findings also agree with previous work which has demonstrated that iron oxide-
based MNP have negligible effects on MSC metabolism  (Markides et al., 2013), (Sibov et 
al., 2012). Overall these results suggest that, at the doses used in these experiments, 
functionalised-MNP and applied magnetic fields are biocompatible and non-toxic to 
hMSC. Despite there being no clear effects of these MNP on cell viability at this dose and 
over this time-frame, a longitudinal study examining the toxicity of these MNP over a 
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broad dose range and using a greater variety of methods is needed. The toxicity of these 
MNP in other cell types both In vitro and in vivo should also be assessed.  
2.4.5 Force transduced by MNP 
Finally, the force exerted by the MNP used in these experiments was modelled according 
to an equation described by (Dobson et al., 2006) which estimated force transduction 
according to magnetic field strength, gradient and particle size. The force exerted by the 
MNP was estimated to be in the range of 0.1-1.7pN per particle. Although this may be 
considered to be a broad range for eliciting biological effects, previous work examining 
MNP mediated magnetic activation of cell surface receptors suggests that forces in this 
range do influence cell signalling behaviour. For example, Hughes et al demonstrated that 
250nm ferric based MNP exerting forces of 0.2pN and targeted to the TREK1 ion channel 
caused changes to whole-cell currents in COS7 cells consistent with TREK channel 
activation (Hughes et al., 2008). Also, The application of 6pN forces using ferro-magnetic 
microparticles targeted to Integrin receptors was shown to cause hyperpolarisation of 
MSC which was mediated through BK channels (Kirkham et al., 2010).  
The simplified mathematical model applied in this work may be appropriate for 
estimating the magnitude of force transduced by MNP in a vertical direction. However, 
this assumes that MNP act as single entities and does not take into account MNP 
aggregation which may inflate the applied forces. Furthermore, the orientation and 
angles at which MNP bind to target cells is also a factor when considering force 
transduction as these parameters will determine the direction of the applied force and 
may influence the magnitude of the force experienced by the cell. Further work should 
involve experimental validation of the forces applied by MNP to confirm this. 
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2.5 Conclusions 
The use of MNP has revolutionised many areas of engineering and medicine. This is due, 
in part, to the adaptability of MNP which can be functionalised with biomolecules for 
specific applications. In these experiments it was shown that the bio-functionalisation 
process of MNP successfully resulted in conjugation of antibodies and peptides to the 
MNP surface. Functionalised MNP were also shown by a range of techniques to attach to 
human mesenchymal stem cells, a clinically relevant stem cell type that has already been 
adopted for cell therapies. The MNP used in these experiments were mechanically 
torqued using a magnetic force bioreactor that imparts magnetic field gradients on to the 
MNP. The magnitude and profile of the applied magnetic fields were elucidated and 
shown to be in the range of 60-120 mT. Further mathematical modelling, which takes into 
account the MNP used and magnetic field gradients, allowed the magnitude of the force 
transduced by the MNP to the cells to be estimated at approximately 0.1-1.7 pN/particle. 
The safety and biocompatibility of nano-materials is also an important consideration 
which must be proven before the translation of novel cell treatments to clinical practice. 
To this end, the biocompatibility and cytotoxic effects of MNP with different surface 
coatings was also investigated using well established methods. The MNP used in these 
experiments were shown to be non-toxic to hMSC at the applied doses over short and 
medium terms and the addition of magnetic field stimulation to MNP and cells also had 
no obvious effect on cell cytotoxicity. Finally, tracking of MNP in vitro using 
Immunocytochemistry suggested that MNP labelling of MSC persists up to 7 days. 
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3 Chapter 3: Remote activation of Wnt 
signalling pathways using magnetic 
nanoparticles 
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3.1 Introduction 
Wnt signalling is a complex pathway involved in the regulation of a range of biological 
processes ranging from cell proliferation and differentiation to embryogenesis, tissue 
formation and regulation of stem cell niches (Nusse, 2008) (Clevers, 2006).  The primary 
receptor for Wnt ligands are Frizzled receptors (Binnerts et al., 2007). Frizzleds have an 
extended N-terminal region harbouring a cysteine rich domain (CRD) which is required for 
Wnt reception (Logan and Nusse, 2004), (MacDonald et al., 2009), (Wang et al., 2006). In 
Canonical Wnt/-catenin signalling, Wnt proteins interact with a receptor complex 
comprised of Frizzled (Fz) and Low density lipoprotein (LDL) receptor-related protein 
(LRP) located at the cell membrane (Cong et al., 2004), (Holmen et al., 2005), (Tolwinski et 
al., 2003). When activated by Wnt, LRP becomes phosphorylated at multiple sites. The 
activated Fz/LRP receptor complex recruits Axin to the cell membrane (Tamai et al., 
2004), (Zeng et al., 2005), this causes the sequestration of several other intracellular 
proteins required for Wnt signalling modulation. In the absence of an external Wnt signal, 
GSK-3, Dvl and APC form a destruction complex that regulates the cytoplasmic pool of the 
transcriptional regulator -catenin (Logan and Nusse, 2004). In the presence of a Wnt 
signal the destruction complex dissociates and is deactivated, as a result active -catenin 
accumulates in the cytoplasm and nucleus. Nuclear -catenin acts as a transcriptional 
regulator and interacts with the lymphoid enhancer-binding factor 1/T-cell specific 
transcription factor (LEF/TCF) family of transcription factors (Logan and Nusse, 2004) 
which bind to and activate Wnt responsive genes with TCF/LEF binding sites (Logan and 
Nusse, 2004).  
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Human Mesenchymal Stem Cells (hMSC) are multipotent stem cells involved in bone and 
cartilage formation during development and are of particular interest in tissue 
engineering (Oreffo et al., 2005), (Ling et al., 2009). Human MSC have been shown to 
exhibit Wnt pathway activity and are known to express a number of Wnt ligands and 
Frizzled receptors including Frizzled 2 and co-receptors such as LRP (Etheridge et al., 
2004), (Kolben et al., 2012), (Okoye et al., 2008). There is also a clear role for mechanical 
forces in MSC and Wnt signalling. Previous work has shown that hMSC are responsive to 
mechanical loading both in vitro and in vivo (Kanczler et al., 2010), (Henstock et al., 2014). 
The Wnt signalling pathway has also been shown to be activated in response to fluid flow 
(Arnsdorf et al., 2009). This suggests that mechanical loading of MSC may be a viable and 
alternative way of targeting and modulating Wnt signalling pathways.  
The main drawback of using recombinant Wnt protein for bioengineering applications is 
the limited ability to obtain large quantities of bio-active Wnt (Coudreuse and Korswagen, 
2007), (Willert and Nusse, 2012). As a result there is now great interest in the 
development of modulators of Wnt receptors using small molecules such as peptides. 
This approach allows a more targeted method of regulating pathway activity compared to 
pharmacological modulators such as the GSK-3β inhibitor LiCl (Freland and Beaulieu, 
2012). One such example of peptide mediated modulation of Wnt signalling is the 
synthetic peptide UM206 which is based on a conserved fragment of Wnt3A and Wnt 5A. 
UM206 is a high affinity ligand for Frizzled 2 receptors (and to a lesser extent Frizzled 1) 
with the capability of acting as an agonist of canonical Wnt signalling in HEK293 cells 
when present in a cyclical conformation (EC50 of 2.10
-8M). Alternatively UM206 has been 
shown to behave as a Wnt pathway antagonist when present in its linear conformation 
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(IC50 of 10
-10 M). Conversion of linear UM206 to its cyclic conformation is possible with 
disulphide bond formation between its Cysteine residues. This therefore allows an 
element of control over peptide activity (Blankesteijn Wessel Matthijs, 2010). 
Representational models of the peptide sequence and conformations of UM206 are 
shown in Figure 3.1. 
Figure 3.1. Representational models of UM206 peptide. 
The amino acid sequence of UM206 is shown in the top diagram; the Cysteine residues 
involved in disulphide bond formation are indicated by lines and circled. Ball and stick 
models of the two conformation of UM206 are shown in the bottom panels. UM206 in 
the linear conformation is shown bottom left, the cyclic conformation is shown on the 
bottom tight image. Atoms are colour coded as follows, Grey = carbon, Red = Oxygen, 
Blue = Nitrogen, Yellow = Sulphur, White = Hydrogen atoms.   
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A further strategy for Wnt pathway modulation is to target Wnt receptors using MNP 
technology. When MNP are coupled with oscillating magnetic field gradients, this causes 
a translational torque on the MNP which results in changes in target receptor 
conformation. This strategy has previously been demonstrated for the activation of other 
mechanosensitive receptors (Hughes et al., 2005), (McBain et al., 2008), (Yiu, 2011). The 
main aim of the experiments presented in this chapter was to investigate the effects of 
Frizzled 2 targeting using antibodies and UM206 peptides bound to MNP, and to assess 
the effects of magnetic stimulation of these targeted MNP on canonical Wnt pathway 
activity in hMSC. 
 
3.2 Methods 
3.2.1 Cell culture 
Bone marrow derived human MSC were sourced as described in chapter 2. For cell 
expansion MSC were cultured in high glucose DMEM supplemented with 10% FBS, 1% L-
glutamine and 1% Penicillin & Streptomycin (All reagents Lonza). Cells were passaged 
once per week and cells between passage 2 and 5 were used in all experiments. For 
UM206 peptide treated groups, cells were cultured in basal media containing 1μg/mL of 
either L-UM206 or C-C UM206 peptide. For positive Wnt signalling control groups, either 
recombinant Wnt 3A (20ng/mL) (R&D systems) or diluted Wnt 3A conditioned media 
collected from Wnt 3A overexpressing L-M(TK-) cells (LGC standards) was used (see 
appendix C). 
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3.2.2 Transient transfections 
For Wnt luciferase reporter studies, hMSC (P3-5) were transiently transfected with a 
Gaussia Luciferase reporter gene under control of an 8x TCF/LEF promoter (provided by 
Dr Hu Bin and Neil Farrow, Keele University). Cells were seeded at 1X104 cells /well in 24-
well plates and cultured in reduced serum opti-MEM media without the addition of 
antibiotics during transfection. Cells were transfected according to the manufacturer’s 
instructions. Briefly, 100μL of transfection solution consisting of 0.5g of TCF/LEF reporter 
plasmid, 2.25L of Lipofectamine LTX and 0.5L of Plus reagent (All Invitrogen) was added 
to each well. 4h after transfection media was aspirated and replaced with fresh antibiotic 
free media.  
3.2.3 MNP coating 
250nm SPIO carboxyl functionalised magnetic nanoparticles (Micromod) were covalently 
coated with anti-Frizzled 2 (Abcam), Trek1 (Alomone labs), Linear UM206 peptide or 
Cyclic UM206 peptide by carbodiimide activation as described in chapter 2. For IgG and 
RGD coated MNP, 1mg of MNP (per ligand) were activated for 1h as stated previously. 
After washing, the particle suspensions were re-suspended in 0.1M MES buffer containing 
either 20μg/mg of MNP of anti-rabbit IgG antibody (Abcam) or 50μg/mg of MNP of RGD 
tri-peptide (Sigma). The particle suspensions were continuously mixed overnight at 4oC. 
Particle suspensions were then blocked, washed and re-suspended in 0.1% BSA (Fisher) in 
PBS (Sigma) as stated previously. 
3.2.4 Cell labelling with MNP 
Cells were labelled with MNP as described in chapter 2. Briefly, Cells were washed with 
PBS then cultured in basal serum-free media before addition of MNP at approximately 
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3g MNP/cm2 of culture surface area. Cells were incubated for a further 1.5h with 
intermittent agitation, then unbound particles were removed by washing with PBS before 
addition of fresh media. Serum free basal media was used in western blotting 
experiments, basal media with 2.5% FBS was used in luciferase experiments, basal media 
with 10% FBS was used for gene expression experiments.  
3.2.5 Magnetic stimulation 
Magnetic field stimulation was applied using the magnetic force bioreactor (MICA 
Biosystems) described in chapter 2. Magnetic field treatment was applied in 1hr and 3h 
sessions at a frequency of approximately 1Hz. 
3.2.6 Total Protein assay 
 Total protein was assessed using a BCA assay kit (Fisher). Lysates were diluted 2x with 
d.H2O and 25μL of each sample was aliquoted into 96 well plates. Samples were 
incubated with a working solution of BCA assay reagent as detailed in chapter 2. The total 
protein concentration of the samples was determined using a standard curve of BSA 
dissolved in Luciferase lysis buffer (for luciferase samples) or RIPA buffer (for Western 
blotting samples) (see appendix B).      
3.2.7 Western blotting 
Cells were lysed with RIPA buffer containing a mixture of protease and phosphatase 
inhibitors (Sigma) (See appendix C). Cell Lysates were clarified and the total protein of 
each sample using a BCA assay kit (Thermo). The total protein concentration of the 
samples was determined using a standard curve of BSA dissolved in RIPA buffer. For 
PAGE, 25-30g of protein was mixed with LDS sample buffer with added -
mercaptoethanol (both Invitrogen). Samples were then heated for 10mins at 70oC and 
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briefly centrifuged before being loaded onto a Tris-Glycine 4-20% gel in Tris-Gly running 
buffer (NuSep) and subjected to PAGE. Proteins were transferred to 0.4μm PVDF 
membrane (Thermo) which was then blocked with 5% milk powder (Co-operative) in TBST 
buffer (Sigma) (5% BSA in TBST used for GAPDH probe). Membranes were then incubated 
with anti-LRP6 (New England Biolabs) (1:1000), anti (Ser1490) phospho-LRP6 (New 
England Biolabs) (1:1000), anti-LRP5 (New England Biolabs) (1:1000), anti-phospho-LRP5 
(Abnova) (1:1000), anti-Frizzled 2 (Santa Cruz) (1:500) or anti-GAPDH (Abcam) (1:1000, in 
5% BSA/TBST). All antibodies were diluted in 5% Milk in TBST unless stated otherwise. All 
blots were incubated overnight at 4oC with constant mixing. Membranes were washed 
with TBST 3x before incubation with anti-rabbit-HRP, anti-Mouse-HRP (Abcam) or anti-
Goat-HRP (Santa Cruz) respectively. All secondary antibodies were diluted 1:1000 in 5% 
Milk/TBST and mixed for 1h at room temp. Membranes were washed 5x in TBST and 
chemiluminescence developed using a PicoWest chemiluminescent kit (Thermo Pierce) 
followed by image capture using a Protein Simple Flourchem M imaging system. 
3.2.8 Immunocytochemistry 
For -catenin mobilisation experiments cells were seeded onto glass cover slips (SLS). At 
24h post treatment media was aspirated, cells washed with PBS (Sigma), then fixed with 
ice cold (90%) methanol (Fisher) for 10mins. Cells were permeabilised with 0.1% triton-x 
in PBS (Sigma) for 10mins then then blocked in 2% BSA (Fisher) in PBS for 1h at room 
temp. Cells were then incubated with anti-active -catenin antibody (Millipore) 1:1000 
dilution in 0.1% BSA in PBS overnight at 4oC. Afterwards, cells were washed 3X with PBS, 
then incubated with anti-mouse-FITC conjugated secondary antibody (Sigma) in 0.1% BSA 
in PBS for 1h at room temp. Cells were then washed 3X in PBS and counterstained with 
DAPI (Sigma). Fluorescence microscopy was performed on Nikon Eclipse Ti-S microscope 
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with NIS elements software. All images are representative of 3 replicate samples. Pixel 
intensity analysis to assess nuclear -catenin staining was performed using ImageJ v1.48s 
3.2.9 Luciferase reporter assays 
Luciferase activity was assessed 48-72h post-transfection. Experiments were performed in 
24-well plates with reduced serum (2.5%). For Wnt pathway blocking experiments cells 
were cultured in reduced serum (2.5%) media containing either 0.1g/mL Dkk1 or 50M 
iCRT14 (R&D Systems). At each time point, media samples were taken and analysed for 
secreted Gaussia luciferase activity using a luciferase flash assay kit (Thermo Pierce). 20μL 
of sample was aliquoted into opaque 96 well plates then 50μL of luciferase assay reagent 
consisting of Coelenterazine diluted 100x in luciferase assay buffer (Thermo Pierce) was 
injected into each well using an automatic injection system. Luminescence measurements 
were acquired immediately after addition of Coelenterazine using a Biotek Synergy 2 
plate reader controlled by Gen5 software. Luciferase activity was normalised to the total 
protein content of the cell lysates taken at the experimental end-point. Cells were lysed in 
100μL of Luciferase lysis buffer (Fisher) for 10mins. Fold changes for each treatment were 
calculated relative to the cells only control. 
3.2.10 Reverse transcription PCR 
At each time-point, total RNA was extracted using an RNAeasy extraction kit (Qiagen) 
according to the manufacturer’s instructions (see appendix C). Reverse transcription was 
performed on 600ng RNA using a high capacity reverse transcription kit (Applied 
Biosystems) according to the manufacturer’s instructions (see appendix C). RT-PCR 
reaction mixes were prepared using diluted cDNA mixed with PCR master mix (Applied 
Biosystems) and commercially available primers for Frizzled 2 (Hs_FZD2_1_SG) and 
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GAPDH (Hs_GAPDH_2_SG) (both Qiagen), (see appendix C). Thermocycling was 
performed on a Stratagene MX3000P. 10μL of PCR products were mixed with 2.5μL of 
loading buffer (Sigma), loaded and run on a 2% Agarose gel for 1h at 100v. Gels were 
imaged on a GelDoc-It2 imager system (UvP). 
3.2.11 Quantitative reverse transcription PCR 
At each time-point, media was aspirated, cells washed with PBS then lysed using TRI 
reagent (Sigma), total RNA was extracted using the chloroform / isopropanol extraction 
method according to the manufacturer’s instructions (see appendix C). Reverse 
transcription was performed on 500ng total RNA (120ng for 1h samples) using a high 
capacity reverse transcription kit (Applied Biosystems). Quantitative PCR reaction mixes 
were prepared using 5L of diluted sample mixed with 10μL of q-PCR master mix 
consisting of 7.5μL of SYBR-Green master mix (Applied Biosystems), 1.5μL of H2O and 1μL 
of commercial primers for either COX2 (Hs_PTGS2_1_SG), c-Myc (Hs_MYC_1_SG), NF- 
(Hs_NFKB1_1_SG) or GAPDH (Hs_GAPDH_2_SG) (all Qiagen) (see appendix C).  
Quantitative PCR was performed over 40 cycles using a Stratagene MX3000P system with 
MxPro software. Gene expression was normalised to GAPDH and fold change in gene 
expression was calculated using the delta-delta Ct method.  
3.2.12 Statistical analysis 
All data is presented as means ±SEM. Statistical significance at 95% confidence level was 
determined using 1-way ANOVA with post-hoc Tukey tests using Mini-tab (v16) software. 
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3.3 Results 
3.3.1 Expression of Frizzled 2 in hMSC 
Expression of Frizzled 2 in hMSC was determined at transcriptional and translational level 
using RT-PCR and Western blotting respectively (Figure 3.2). RT-PCR for the Frizzled 2 
gene indicated that gene expression was stable over 21 days in basal or osteogenic 
media. Western blotting was used to assess the level of Frizzled 2 expression at the 
translational level. In basal media Frizzled 2 expression appeared to increase over time 
with peak expression at Day 14. In osteogenic media clear expression was observed at 
Day 3 but then reduced until Day 21 where maximum expression was observed.  
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3.3.2 -catenin mobilisation studies 
To determine if Frizzled 2 targeted MNP were causing Wnt signalling activation 
downstream of Frizzled, the mobilisation and nuclear localisation of the intracellular 
messenger -catenin was investigated using immunocytochemistry.  
3.3.2.1 -catenin is mobilised in response to Fz-MNP and L-UM206-MNP 
-catenin localisation was studied in hMSC after treatment with anti-Frizzled-MNP (Fz-
MNP), Linear UM206-MNP (L-UM206-MNP) or Cyclic UM206-MNP (C-C-UM206-MNP). 
Figure 3.2. hMSC express Frizzled 2. 
RT-PCR gels and Western blots showing Frizzled 2 expression in hMSC. RT-PCR for Frizzled 2 
mRNA expression (A) indicated that Frizzled 2 is expressed in Basal and Osteogenic media 
over the course of 21 days. Western blotting for Frizzled 2 confirmed expression of Frizzled 2 
at the protein level (B), GAPDH is used as a housekeeping gene. 
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Samples were also treated with magnetic field stimulation to determine the effects of 
added mechanical stimulation on β-catenin mobilisation. Wnt3a conditioned media (Wnt-
CM) was used as a positive control in these experiments (Figure 3.3). Non-treated cells 
displayed negligible -catenin nuclear localisation after 24h. When cells were treated with 
anti-Fz MNP, L-UM206-MNP and to a lesser extent C-C-UM206-MNP (without magnetic 
field), clear nuclear localisation of -catenin was observed and pixel intensity analysis of 
the cell nuclei confirmed a significant increase in nuclear localisation compared to non-
treated control (non-significant increase for C-C-UM206-MNP). Magnetic field stimulation 
of Fz-MNP or L-UM206-MNP labelled cells caused a further increase in -catenin 
mobilisation, whereas magnetic stimulation of C-C-UM206-MNP labelled cells resulted in 
a marginal increase in β-catenin mobilisation. Pixel intensity analysis also confirmed a 
significant increase in nuclear staining by Fz-MNP and L-UM206-MNP compared to cells 
with magnet control (Figure 3.4). Cells treated with Wnt-CM showed noticeable nuclear 
localisation after 24h which was again significant over the non-treated control according 
to pixel intensity analysis.  
3.3.2.2 Control-MNP do not mobilise β-catenin 
Control particles coated with IgG (IgG-MNP) or the RGD peptide (RGD-MNP) both caused 
overall minor increases in -catenin activation (not significant) but no additive effect was 
observed when cells were treated with either control MNP with addition of magnetic field 
(Figure 3.5). Pixel intensity analysis confirmed that control-MNP had no overall effect on 
β-catenin mobilisation with or without magnetic field (Figure 3.6). 
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Figure 3.3. Frizzled-MNP and L-UM206-MNP promote β-catenin activation and mobilisation. 
Fluorescent images showing localisation of active β-catenin (Green) after 24h, DAPI was used to visualise cell nuclei (Blue), Merged 
images show location of β-catenin in relation to cell nuclei. Non-treated cells (A) showed negligible β-catenin localisation. Treatment with 
anti-Frizzled magnetic nanoparticles (Fz-MNP) or L-UM206-MNP without magnet (A) showed notable nuclear localisation with an added 
effect when these particles were used in conjunction with magnetic field (B). Treatment with Wnt-conditioned media (A) also showed 
notable nuclear β-catenin after 24h. In contrast treatment with C-C-UM206 MNP resulted in a negligible increase in β-catenin localisation 
with and without magnetic field. Representative images, n=3, scale bar = 50μm. 
 120 
 
 
 
Figure 3.4. Quantification of Fz-MNP and L-UM206-MNP β-catenin mobilisation. 
Quantification of nuclear pixel intensity (A) indicated levels of nuclear (active) β-
catenin. Treatment with magnetic field alone or C-C-UM206-MNP (with or without 
magnetic field) caused negligible increases in levels of nuclear β-catenin whereas 
treatment with Fz-MNP, L-UM206-MNP or Wnt-CM all increased β-catenin 
mobilisation to similar levels. An added effect was observed when Fz-MNP or L-
UM206-MNP were used in conjunction with magnetic field. Average pixel 
intensities shown, n=3, error bars represent SEM, * denotes p<0.05 
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Figure 3.5. Control MNP do not mobilise β-catenin. 
Fluorescent images showing localisation of active β-catenin (Green) after 24h, DAPI was used to visualise 
cell nuclei (Blue), Merged images show location of β-catenin in relation to cell nuclei. Cells treated with 
IgG-MNP or RGD-MNP (A) resulted in minor increases in nuclear localisation, and addition of magnetic 
field (B) had no overall effect. Representative images, n=3, scale bar = 50μm. 
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3.3.3 TCF/LEF reporter studies 
A Gaussia luciferase reporter under control of a TCF/LEF promoter was then used to 
directly asses the transcriptional activity of Wnt target genes over 24 hours in response to 
UM206 peptides and antibody/UM206 functionalised MNP. Wnt3a-conditioned media 
was used as a positive control. Samples were also treated with magnetic field stimulation 
for 3 hours to determine the effects of added mechanical stimulation on TCF/LEF reporter 
activity. The activation mechanisms of the treatments were also probed using different 
Wnt pathway blockers to determine through which control nodes pathway activity was 
signalling through. 
Figure 3.6. Quantification of control-MNP β-catenin mobilisation.  
Quantification of nuclear pixel intensity indicated levels of (active) β-catenin. 
Treatment with magnetic field alone, IgG-MNP or RGD-MNP (with or without 
magnetic field) all caused similar (non-significant) increases in the levels of active 
nuclear β-catenin. Average pixel intensities shown, n=3, error bars represent 
SEM. 
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3.3.3.1 Wnt3a activates TCF/LEF signalling 
Transfected hMSC showed a 3-fold increase in Wnt reporter activity 6h after treatment 
with Wnt-conditioned media (Wnt-CM) with maximal reporter activity observed after 24h 
(Figure 3.7). Wnt-CM mediated pathway activation was successfully blocked at both time-
points using Dkk1 which inhibits LRP co-receptor activation at the cell membrane. 
Pathway activation was also successfully blocked with iCRT14 which blocks downstream 
Wnt pathway activation by inhibiting -catenin interaction with TCF/LEF transcription 
factors and subsequent Wnt target gene expression.  
3.3.3.2 UM206 peptides alone do not activate TCF/LEF signalling 
Treatment of transfected hMSC with 1μg/mL of UM206 in the linear conformation (L-
UM206-peptide) had no overall effect on reporter activity at 6h or 24h after treatment 
(Figure 3.8). However, treatment with 1μg/mL UM206 in the cyclic conformation (C-C 
UM206-peptide) decreased reporter activity after 6h but after 24h reporter activity 
remained similar to the control.  
 124 
 
Figure 3.7. Wnt3a-CM activates a TCF/LEF reporter.  
TCF/LEF reporter activity from transiently transfected hMSC 6h and 24h after treatment. Treatment of hMSC with Wnt3a-conditioned 
media (Wnt-CM) resulted in a 3 fold increase in luciferase reporter activity after 6h (A) which significantly increased to approximately 
20 fold after 24h (B). Treatment with the Wnt blocker Dkk1, which blocks LRP co-receptor activation by Wnt, restricted reporter 
activity to basal levels over both time-points. Treatment with the Wnt blocker iCRT14, which blocks end-point Wnt activation by 
disrupting TCF/LEF binding, also restricted reporter activity to basal levels over both time-points. Values represent mean fold change 
in luciferase activity relative to cells only with luciferase activity normalised to total protein. Error bars represent SEM, n=4, * denotes 
p<0.05 
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Figure 3.8. UM206 peptides alone do not activate a TCF/LEF reporter. 
TCF/LEF reporter activity from transiently transfected hMSC 6h and 24h after treatment. Treatment with 1μg/mL L-UM206  peptide had 
no effect on reporter activity after 6h (A) or 24h (B). Treatment with 1µg/mL C-C-UM206 peptide reduced reporter activity after 6h (A) 
but no overall effect was observed after 24h (B). Treatment with Wnt-CM had no effect on reporter activity after 6h (A) but increased 
reporter activity after 24h (B). Values represent mean fold change in luciferase activity relative to cells only. Luciferase activity 
normalised to total protein. Error bars represent SEM, n=4, * denotes p<0.05. 
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3.3.3.3  Fz-MNP activate TCF/LEF signalling 
Transfected hMSC showed a notable 3-fold increase (not statistically significant) in 
luciferase reporter activity 6h after treatment with MNP coated with antibodies targeted 
to Frizzled 2 (Fz-MNP) (Figure 3.9). A similar level of activity was observed when cells 
were treated with Wnt-conditioned media. An added 6-fold increase in reporter activity 
was observed when cells were treated with Fz-MNP with magnetic field. The increase in 
reporter activity by Fz-MNP (with or without magnetic field) was unaffected by the LRP 
co-receptor blocker Dkk1 but was reduced to basal levels when cells were treated with 
downstream Wnt blocker iCRT14 that disrupts TCF/LEF activity. After 24h, Fz-MNP treated 
cells showed a moderate increase in reporter activity (not significant) but a 17 fold 
increase in reporter activity (significant) was observed when magnetic field stimulation 
was applied in conjunction with Fz-MNP. A similar level of reporter activity was observed 
in the Wnt-CM control group after 24h. Treatment with Dkk1 again had no effect on Fz-
MNP induced reporter activity which remained elevated but reporter activation was again 
successfully blocked using the downstream inhibitor iCRT-14 after 24h. Magnetic field 
treatment alone caused non-significant changes in reporter activity at both time-points. 
3.3.3.4 L-UM206-MNP activate TCF/LEF signalling 
Transfected hMSC showed a significant 4-fold increase in luciferase reporter activity at 6h 
after treatment with MNP coated with Linear UM206 peptides alone (L-UM206-MNP) 
(Figure 3.10). A similar level of activity was observed when cells were treated with Wnt-
conditioned media. An added 8-fold increase in reporter activity was observed when cells 
were treated with L-UM206-MNP with magnetic field stimulation. The increase in 
reporter activity by L-UM206-MNP (with or without magnetic field) was unaffected by the 
LRP co-receptor blocker Dkk1 but was reduced to basal levels when cells were treated 
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with downstream Wnt blocker iCRT14 that disrupts TCF/LEF activity.  At 24h, L-UM206-
MNP treated groups showed a moderate increase in reporter activity (not statistically 
significant) but an added 20-fold increase in reporter activity (significant) was observed 
when magnetic field stimulation was also applied with L-UM206-MNP. A similar level of 
reporter activity was also observed in the Wnt-CM control group at 24h. Treatment with 
Dkk1 again had no effect on reporter activity at 24h when used in conjunction with L-
UM206-MNP which remained elevated but reporter activation was again successfully 
blocked using the downstream inhibitor iCRT-14 after 24h. Magnetic field treatment 
alone caused minor increases in reporter activity (not significant).  
3.3.3.5 C-C UM206-MNP do not activate TCF/LEF signalling 
Treatment of transfected hMSC with MNP coated with the Cyclic UM206 peptide (C-C-
UM206-MNP) had no effect on reporter activity after 6h and no effect was observed 
when cells were treated in conjunction with magnetic field stimulation (Figure 3.11). After 
24h, C-C-UM206-MNP marginally increased reporter activity (not significant) but again no 
effect was observed when used in conjunction with magnetic field treatment. In contrast 
Wnt-CM significantly increased reporter activity after 24h treatment.
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Figure 3.9. Anti-Fz MNP activate a Wnt TCF/LEF reporter. 
TCF/LEF reporter activity from transiently transfected hMSC 6h and 24h after treatment. Magnetic field alone (Cells + Mag) 
increased reporter activity at both time points (not significant) (A,B). Treatment with anti-Frizzled MNP (Fz-MNP) alone caused a 3 
fold increase in reporter activity after 6h (A) and remained elevated after 24h (B) (not statistically significant). An added significant 6 
fold increase in reporter activity was observed after 6h when magnetic field with Fz-MNP treatment was applied (A) with reporter 
activity remaining high after 24h (B). Addition of the Wnt signalling blocker Dkk1 which inhibits LRP5/6 activation failed to prevent 
reporter activation by Fz-MNP. However activation was successfully blocked using iCRT14, a downstream inhibitor which blocks 
TCF/LEF activity. Treatment with Wnt-Conditioned Media (Wnt-CM) increased reporter activity to a similar level as Fz-MNP alone 
after 6h (A), with maximum activity observed after 24h (B). This effect was successfully blocked using Dkk1 or iCRT14 with reporter 
activity being reduced to basal levels. Values represent mean fold change in luciferase activity relative to cells only. Luciferase 
activity was normalised to total protein. Error bars represent SEM, n=4 , * denotes p<0.05 
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Figure 3.10. L-UM206-MNP activate a TCF/LEF reporter.  
TCF/LEF reporter activity from transiently transfected hMSC 6h and 24h after treatment. Treatment with L-UM206-MNP alone significantly 
increased reporter activity by 4 fold after 6h (A) and remained elevated after 24h (B). An added significant 8 fold increase in reporter 
activity was observed after 6h when magnetic field with L-UM206-MNP was applied (A) with reporter activity remaining elevated after 24h 
(B). L-UM206-MNP mediated reporter activation was unaffected by the LRP5/6 blocker Dkk1 but was successfully blocked using the 
downstream Wnt pathway inhibitor iCRT14 at both time-points. Treatment with Wnt-conditioned media (Wnt-CM) increased reporter 
activity to similar levels as L-UM206-MNP alone at 6h(A) with maximum activity observed after 24h (B). Treatment with magnetic field 
alone marginally increased Wnt reporter activity at both time-points (not significant). Values represent mean fold change in luciferase 
activity relative to cells only. Luciferase activity normalised to total protein. Error bars represent SEM, n=4, * denotes p<0.05. 
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Figure 3.11. C-C-UM206-MNP do not activate a TCF/LEF reporter 
TCF/LEF reporter activity from transiently transfected hMSC 6h and 24h after treatment .Treatment with C-C-UM206 MNP had no 
overall effect on reporter activity compared to controls over both-time-points  and no overall effects on were observed with 
magnetic field treatment. Values represent mean fold change in luciferase activity relative to cells only with luciferase activity 
normalised to total protein. Error bars represent SEM, n=4, * denotes p<0.05  
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3.3.3.6 Control MNP have no effects on TCF/LEF reporter activity 
Treatment of transfected hMSC with control MNP which were coated with generic IgG 
antibodies (IgG-MNP) or RGD tri-peptide (RGD-MNP) had no overall effect on reporter 
activity 6h or 24h after treatment (Figure 3.12). Furthermore no added effects on 
reporter activity were observed when cells were treated with either of the control MNP 
with the addition of magnetic field stimulation 6h or 24h after treatment. 
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Figure 3.12. Control MNP have no effect on TCF/LEF reporter activity.  
TCF/LEF reporter activity from transiently transfected hMSC 6h and 24h after treatment. Magnetic field alone caused minor 
increases in reporter activity at both time points (not significant) (A,B). Treatment with Control particles coated with either anti-
Rabbit-IgG (IgG-MNP) or RGD peptide (RGD-MNP) caused no increase in reporter activity at 6h (C) or 24h (D) and no added effects 
were observed when with the addition of magnetic field stimulation. Values represent mean fold change in luciferase activity relative 
to cells only. Luciferase activity was normalised to total protein. Error bars represent SEM, n=4. 
 133 
 
3.3.4 Fz-MNP and L-UM206-MNP signal through an LRP5/6 independent mechanism 
Western blotting was used to elucidate the mechanism of Wnt signalling activation by Fz-
MNP and L-UM206-MNP. This was assessed by probing for the active (phosphorylated) 
forms of the Wnt co-receptor Low density lipoprotein (LDL) receptor-related protein 5 
and 6 (LRP5/6) which is an indicator of co-receptor activation (Figure 3.13). Untreated 
cells showed a low basal level of LRP6 phosphorylation as did treatment with Fz-MNP or 
L-UM206-MNP. Whereas treatment with Wnt conditioned media resulted in a clear 
increase in LRP6 phosphorylation which was mostly blocked with the addition of the LRP6 
inhibitor Dickkopf 1 (Dkk1). In the case of LRP5, non-treated cells displayed a clear basal 
level of phosphorylation and this was shown to be unaffected by either Fz-MNP, L-
UM206-MNP or Wnt-CM. Treatment with Dkk with Wnt-CM did result in a marginal 
decrease in LRP5 phosphorylation. GAPDH was used as a loading control.  
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Figure 3.13. MNP signal through an LRP-independent mechanism. 
(A) Non-treated cells displayed negligible LRP6 phosphorylation. Treatment of hMSC with 
anti-Frizzled-MNP (Fz-MNP) or L-UM206-MNP had no effect on LRP6 co-receptor 
phosphorylation. In contrast Wnt conditioned media (Wnt-CM) caused clear LRP6 
phosphorylation which was blocked using the Wnt inhibitor Dkk 1. (B) Non-treated cells 
displayed a basal level of Wnt co-receptor LRP5 phosphorylation (B). Treatment of hMSC 
with Fz-MNP, L-UM206-MNP or Wnt conditioned media (Wnt-CM) all had no overall effect 
LRP5 phosphorylation levels. Treatment with Dkk and Wnt-CM marginally decreased LRP5 
phosphorylation. Black lines denote none adjacent lanes. GAPDH and total LRP6 are shown 
as loading controls. 
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3.3.5 Fz-MNP alter stress response gene expression 
Gene expression analysis for stress response genes c-Myc, Cox2 and NF- was also 
examined over early time-points. These investigations were performed to determine the 
levels of mechano-stimulatory response of cells to Fz-MNP and Wnt-3a. The stress gene 
response to Fz-MNP was compared to control particles anti-TREK1-MNP (Trek-MNP) 
which are known to induce a cellular mechanical stress response (Figure 3.14).  As 
predicted, treatment with control particles Trek-MNP caused a significant up-regulation in 
NF- expression after 1h followed by a down-regulation in expression after 3h when 
compared to cells + magnet control groups.  All other groups showed small but not 
significant levels of elevation at 1 and 3 hours compared to the TREK labelled response to 
magnetic field. 
Investigations of responses in two other early response genes c-Myc and Cox2 showed 
low level variations in expression but none to the same extent as the NF- response 
observed to TREK coated particles with oscillating magnetic field. Small elevations in c-
Myc  expression was observed in all groups at 1 hour which fell by 3 hours with the most 
significant again observed in the TREK activated magnetic particle group.  Similar levels of 
elevation were observed in Wnt3A activation as with particles alone, particles with 
magnetic field and magnetic field alone. 
A similar low level pattern of response was observed in the expression of Cox2.  Again 
small elevations in Cox2 were observed in all groups after 1 hour which fell after 3 hours 
with the greatest variation seen to magnetic field alone and magnetic field with Fz-MNP. 
No significant difference was observed between experimental groups at one hour after 
treatment.
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Figure 3.14. Fz-MNP alter expression of mechanosensitive genes. 
Gene expression analysis of mechano responsive genes (Nf-β, c-Myc, Cox 2) in 
response to anti-frizzled particles (Fz-MNP) or control particles (Trek-MNP) and 
magnetic field stimulation was evaluated using quantitative real-time PCR after 
1h and 3h treatment. NF-β gene expression (A) was increased by Trek-MNP 
(compared to cells + magnet control) after 1h. Magnetic field treatment alone 
also increased Nf-β expression (compared to cells only control) after 3h. 
Treatment with Fz-MNP or Wnt 3A both showed similar but minor shifts in Nf-β 
gene expression. Expression of c-Myc (B) was increased after 1h treatment with 
magnetic field alone (cells + magnet) with an added increase when used in 
conjunction with Trek-MNP. Treatment with Fz-MNP or Wnt 3A again both 
showed similar but negligible shifts in c-Myc expression. Expression of COX 2 (C) 
was shown to be significantly increased after 1hr by magnetic field treatment 
alone but a decrease in expression was observed after 3h. Treatment with Fz-
MNP (without magnet) or Wnt 3A both caused significant decreases in COX 2 
expression after 3h treatment. Treatment with Fz-MNP (with magnet) was 
shown to significantly increase COX 2 expression when compared to Cells + 
magnet control after 3h. Figures show mean fold change in gene expression 
normalised to GAPDH, Error bars represent SEM, n=4, ANOVA p < 0.05 for all 
genes, * denotes p <0.05 
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3.4 Discussion 
Wnt signalling is a crucial pathway controlling stem cell behaviour and has become an 
attractive target for modulation with potential applications in stem cell therapies. The 
results in this chapter have demonstrated the feasibility of using antibody and small 
peptide functionalised magnetic nanoparticles to specifically target and stimulate Frizzled 
2 receptors expressed by hMSC for the activation of Wnt / -catenin signalling pathways. 
3.4.1 Frizzled 2 expression in hMSC 
Expression of Frizzled 2 in hMSC was confirmed at the gene and protein level by RT-PCR 
and Western blotting respectively. Frizzled 2 was shown to be stably expressed over 21 
days in either basal or osteogenic media. This agrees with previous work which has also 
shown that Frizzled 2 is expressed in hMSC (Etheridge et al., 2004), (Okoye et al., 2008).  
3.4.2 Effects of MNP on β-catenin mobilisation 
To determine if magnetic oscillation of Fz-MNP, L-UM206-MNP or C-C-UM206 were 
capable of causing downstream Wnt signalling activation, -catenin mobilisation in 
response to MNP treatment was studied. It was shown that Fz-MNP and L-UM206-MNP 
but not C-C-UM206-MNP were capable of activating -catenin mobilisation to the 
nucleus. Furthermore, oscillation of Fz-MNP or L-UM206-MNP in magnetic fields also led 
to increased β-catenin nuclear mobilisation.  -catenin mobilisation to the nucleus is a 
hallmark of active Wnt -catenin signalling and a precursor to transcription of Wnt 
responsive genes.  This phenomenon is frequently used as a qualitative indicator of active 
Wnt signalling (Ehrlich et al., 2010) (Cong et al., 2003).  These results suggest that the 
binding action of Fz-MNP or L-UM206-MNP to Frizzled receptors is enough to initialise 
Wnt signalling and cause mobilisation of -catenin. Furthermore, magnetic field 
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stimulation of MNP labelled cells caused a further increase in -catenin mobilisation and 
nuclear localisation. This suggests that there is an enhanced mechanoactivation of 
Frizzled receptors caused by torque of the functionalised MNP in the magnetic field. Cells 
treated with Wnt-CM also showed noticeable nuclear localisation after 24h which was 
again significant over the non-treated control according to pixel intensity analysis of the 
nuclear -catenin staining. These observations agree with the findings of other groups 
who have showed that treatment with Wnt causes -catenin mobilisation after 24h 
(Carthy et al., 2011), (Staal et al., 2002). A low level of background mobilisation of -
catenin was also observed in control groups suggesting basal levels of Wnt signalling are 
present in MSC, this is in agreement with Liu et al 2009 who also showed MSC express 
endogenous Wnt signalling activity (Liu et al., 2009).   
3.4.3 Effects of MNP on TCF/LEF reporter activity 
The critical downstream pathway of Wnt signalling has been shown to be transcriptional 
activation of TCF/LEF responsive genes (Schuijers et al., 2014, Nusse, 1999). In this work it 
was shown that treatment with Wnt-CM results in an elevation of the TCF/LEF reporter 
constructs in transiently transfected hMSC. Furthermore it was demonstrated that 
mechanical activation via Fz-MNP or L-UM206-MNP (but not C-C-UM206-MNP) resulted 
in similar levels of activation of the downstream reporter. This observation confirms that 
Fz-MNP and L-UM206-MNP activate Wnt-responsive elements after a short time period 
and have similar effects as Wnt-CM on pathway activity. The increase in Wnt luciferase 
reporter activity by Wnt-CM was potently blocked using the Wnt LRP5/6 co-receptor 
blocker Dkk1; this can be expected as signalling activation by Wnt protein requires LRP 
co-activation. However, in these experiments Dkk1 had no effect on the blocking of 
reporter activity (at both time-points) when cells were activated through the oscillating 
 140 
 
Fz-MNP or L-UM206-MNP. This suggests that functionalised MNP are signalling through 
an LRP independent mechanism. This result is in agreement with the Western blotting 
data which showed no noticeable increase in LRP5/6 phosphorylation after treatment 
with Fz-MNP or L-UM206-MNP which would indicate receptor activation. This again 
suggests an alternative mode of Wnt/-catenin activation by functionalised MNP which 
warrants further investigation. At 24h Fz-MNP and L-UM206-MNP treated groups 
remained elevated. This is further evidence of a level of mechanoactivation of Wnt 
signalling and demonstrates that functionalised MNP are capable of causing sustained 
Wnt pathway activation. Treatment with Wnt-CM also significantly activated reporter 
activity to comparable levels as the functionalised MNP (with magnet). Taken together, 
this would suggest that a lag phase or threshold exists after stimulation with Wnt-CM that 
must be overcome before Wnt signalling activity peaks. This observation is again in 
agreement with results from Carthy et al who showed activation of a Wnt TCF reporter 
after 24h treatment with recombinant Wnt 3A (Carthy et al., 2011). Although Dkk1 was 
unable to block Wnt pathway activation by functionalised MNP, reporter activation by Fz-
MNP, L-UM206-MNP and Wnt-CM was successfully blocked using a downstream Wnt 
signalling blocker- iCRT-14, which acts by disrupting -catenin’s association and 
interaction with TCF transcription factors which is required for the expression of Wnt 
target genes.  
3.4.4 Contrasting effects of Linear and Cyclic UM206 
Interestingly, in these experiments MNP coated with C-C-UM206 peptides had no effect 
on reporter activity. These data also agree with the β-catenin mobilisation data which 
indicated a negligible effect of C-C-UM206-MNP on β-catenin mobilisation. These 
observations suggest that C-C-UM206-MNP may not bind to Frizzled 2 receptors with 
 141 
 
sufficient affinity to activate downstream signalling. Also, L-UM206 or C-C UM206 
peptides alone were found to have no activating effects on reporter activity despite a 
comparatively high peptide dose of 1µg/mL. In fact cyclic UM206 (C-C-UM206) was 
actually found to have a mild but significant inhibitory effect on reporter activity after 6h 
treatment. These findings are in contrast with Blankesteijn et al who observed clear 
agonistic and antagonistic activities of C-C UM206 and L-UM206 respectively at a dose of 
1µg/mL in HEK293 cells (Blankesteijn Wessel Matthijs, 2010). In that study HEK293 cells 
were engineered to over-express Frizzled 2. It is therefore possible that the stoichiometry 
of the interaction between UM206 peptide binding and frizzled receptors is different 
between these systems which may alter pathway responsiveness to peptide stimulation. 
Another possibility is that the signalling kinetics between MSC and HEK293 or HEK293 
over-expressing Frizzled 2 are inherently different which may result in different outcomes 
in Wnt pathway activation between these cell types.  
3.4.5 Control MNP do not activate Wnt/β-catenin signalling 
Finally, Control MNP coated with IgG antibodies or the tri-peptide RGD were also used to 
assess the effects of generic and integrin mediated membrane stimulation on Wnt 
pathway activation. In these experiments both control MNP types were found to have no 
activating effects on either β-catenin mobilisation or Wnt reporter activity over 24h. This 
indicates that generic or Integrin mediated mechano-stimulation is not enough to activate 
Wnt signalling in hMSC at the magnitude of forces applied in these experiments. 
3.4.6 Effects of MNP on LRP co-receptor activation 
The mechanism of Wnt signalling by MNP was also investigated. Treatment of hMSC with 
the Wnt pathway activating particles (Fz-MNP or L-UM206-MNP) resulted in no 
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noticeable changes in LRP5/6 phosphorylation. This indicates that these MNP are not 
activating and signalling through LRP co-receptors. The canonical Wnt signalling co-
receptor Low density lipoprotein (LDL) receptor-related protein 5/6 (LRP5/6) forms an 
active signalling complex with Frizzled and a Wnt ligand (Brown et al., 1998). Upon 
receptor activation, LRP is successively phosphorylated at multiple sites by kinases such as 
GSK. This process is part of downstream Wnt signal transduction which occurs through 
Axin (Zeng et al., 2005).  Phosphorylation of LRP in response to Wnt 3A has been shown 
previously (Grumolato et al., 2010). In contrast Wnt conditioned media resulted in clear 
phosphorylation of LRP6 after 3h which was partially blocked with the addition of the 
LRP6 inhibitor Dickkopf 1 (Dkk1). In the case of LRP5 co-receptor signalling, a basal level 
of LRP5 phosphorylation in untreated cells was observed which was not altered by Fz-
MNP, L-UM206-MNP or indeed Wnt-CM. This suggests that LRP5 is not the main co-
receptor for transduction of Wnt signals in hMSC. This is in agreement with Perobner et 
al. who showed that LRP6 is indispensable for canonical Wnt signalling in hMSC and not 
LRP5 (Perobner et al., 2012). Altogether, this suggests that Fz-MNP and L-UM206-MNP 
are activating Wnt signalling via a different mechanism to Wnt protein. One explanation 
for this observation could be receptor clustering and dimerization of Frizzled receptors 
caused by functionalised MNP which results in pathway activation. This mechanism has 
been shown to be an alternative route for Frizzled receptor activation by Carron et al. 
who showed that dimerization of Frizzled receptors is enough to activate Wnt/β-catenin 
signalling (Carron et al., 2003). LRP independent signalling has also been shown to be 
involved with increased murine osteoblast proliferation in response to strain in vitro 
(Javaheri et al., 2012). Further work could involve the investigation of the 
 143 
 
phosphorylation and activation status of LRP6 after targeting and stimulation with anti-
LRP6 functionalised MNP to determine if this also leads to Wnt signalling activation.  
3.4.7 Effects of MNP on Stress response gene expression 
Finally, gene expression analysis for stress response genes previously shown to respond 
to generic mechano-stimulation at early time-points were investigated. C-Myc is an 
oncogene associated with stress response; it has also been identified as a Wnt responsive 
gene (He et al., 1998). Overall low levels of up-regulation in all groups were observed 
after one hour of treatment and both Fz-MNP treatment (with or without magnetic field) 
and Wnt 3a treatment all up-regulate c-Myc expression after 1h to similar levels. This is 
comparable to results from Gujral et al who showed that c-Myc expression increases in 
the first 3h after Wnt stimulation in HEK293 cells (Gujral and MacBeath, 2010). 
Furthermore, in this experiment the expression profile of Fz-MNP matches the expression 
profile produced by Wnt 3a closely, whereas treatment with control particles targeted to 
the Trek-1 ion channel (Trek-MNP) produced a broadly different expression profile to 
Wnt3A and Fz-MNP with Magnet (at 1h time-points). This is an indication that the Fz-MNP 
and Wnt 3a are having a similar effect on c-Myc gene expression. COX2 expression has 
also been shown to increase in response to cytotoxic stress e.g. cytokines, endotoxins, -
radiation (Feng et al., 1995) (Steinauer et al., 2000). Recent evidence has also shown that 
the COX-2 promoter harbours TCF/LEF response elements and that activation of canonical 
Wnt signalling by lithium or Wnt 3A results in increased COX2 mRNA expression  (Nuñez 
et al., 2011). The results again showed low levels of expression elevation at 1 hour in all 
experimental groups without a clear expression pattern emerging.  However, once again 
Fz-MNP alone and Wnt3a both induced a similar expression pattern whilst Fz-MNP with 
magnet and Trek induced different levels of Cox2 expression, particularly after 3h. In 
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contrast, investigation of the levels of NF- show a clear elevation in response to the 
control group labelled with TREK particles. NF-β is a stress response gene activated 
when cells are subjected to physiological stresses e.g. mechanical stimulation (Mercurio 
and Manning, 1999), (Kumar and Boriek, 2003). The expression profile of NF- is similar 
when cells are treated with either Wnt 3A or Fz-MNP without magnet with these 
treatments causing slight increases in NF- expression (trend only). In contrast, 
treatment with control particles (Trek-MNP) caused a significant up-regulation in NF- 
expression after 1h when compared to cells plus magnet control group. This again 
demonstrates the differing outcomes when cells are treated with either Fz-MNP or Trek-
MNP. Although Fz-MNP had no clear effects on stress-response gene expression over the 
early time-points studied here, expression of other stress response genes in response to 
other MNP types should be investigated over later time-points in order to reveal any 
longer term effects of MNP stimulation on gene expression. 
 
3.5 Conclusions 
Wnt signalling pathways are important for the regulation of cell behaviour and there is 
increasing interest in the development of modulators of Wnt signalling. These modulation 
tools may have therapeutic potential in fields such as stem cell science, development, cell 
and tissue engineering and cancer.  One way of controlling cell signalling is by using bio-
functionalised MNP. To date no one has attempted to locally target and stimulate Wnt 
receptors in order to modulate Wnt signalling. The work presented in this chapter has 
shown that it is possible to tag Frizzled receptors expressed by hMSC with antibody or 
peptide-functionalised nanoparticles and use an oscillating magnetic field to impart 
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focused mechanical stimulation onto the receptors to enhance receptor signalling. This 
strategy has enabled unconventional, co-receptor independent activation of Wnt 
signalling pathways in hMSC. By initialising Wnt-Frizzled signalling in a co-receptor 
independent manner, functionalised-MNP can override many of the top-level inhibitors of 
Wnt signalling. Furthermore, it has been shown that the magnetic activation process can 
be enhanced or reduced by operating an external magnetic switch, which affords a 
degree of external control and temporal regulation of Wnt pathway activation. In these 
experiments Immunofluorescence showed clear mobilisation of the Wnt signalling 
messenger -catenin and activation of a Wnt signalling reporter construct was also 
observed in response to Fz-MNP and L-UM206-MNP. Gene expression analysis also 
showed different expression of stress response genes in response to Fz-MNP and Wnt 
compared to treatment with control MNP. Taken together, these results suggest that Fz-
MNP and L-UM206-MNP are acting via different mechanisms to Wnt protein to activate 
Wnt -catenin signalling. The mechanism behind Wnt signalling activation by 
functionalised MNP may include receptor clustering or alternative co-receptor 
recruitment and requires further investigation. Furthermore, the effects on hMSC fate 
and applications in tissue engineering should also be studied. Finally, the remote 
stimulation of other Frizzled receptors and co-receptors for the modulation of Wnt 
pathways using MNP technology should be investigated. The development of this 
technology raises the possibility of remotely controlling Wnt signalling and consequently 
the control of stem cell behaviour for therapeutic purposes. 
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4 Chapter 4: Remote control of hMSC 
differentiation using MNP
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4.1 Introduction 
Human mesenchymal stem cells (hMSC) are a promising cell source for autologous 
cellular therapies, particularly for orthopaedic tissue engineering (Oreffo et al., 2005), 
(Ling et al., 2009). The differentiation of hMSC into osteoblasts results from an array of 
signalling cascades which are triggered by growth factors including Wnts and Bone 
Morphogenetic Proteins (BMPs, as well as environmental conditions such as physical 
stimuli. These signalling networks interact with each other and form feedback loops to 
regulate cell differentiation (Augello and De Bari, 2010), (James, 2013). The Wnt pathway 
is known to be a pivotal regulator of hMSC fate and hMSC have been shown to express a 
range of Wnt proteins and receptors (Etheridge et al., 2004). Some researchers have 
suggested that Wnt signalling acts as a master regulator of osteoblast differentiation 
(Milat and Ng, 2009). The modulation of the Wnt pathway in hMSC could therefore be 
beneficial in bone tissue engineering.  
Wnt signalling pathways have a multitude of effects on cell behaviour including changes 
to polarity, proliferation and differentiation. These effects are shown to be highly 
dependent on cell type and Wnt protein concentration (Rao and Kuhl, 2010), (Quarto et 
al., 2010), (de Boer et al., 2004a). Activation of canonical signalling by Wnt3A has been 
shown to promote hMSC proliferation, preserve multipotency and inhibit differentiation 
(De Boer et al., 2004b), (Boland et al., 2004), (Cho et al., 2006). However, in calvarial 
osteoblasts Wnt3A has been shown to promote bone formation (Quarto et al., 2010).  In 
vitro, both overexpression of the canonical Wnt co-receptor LRP6 and stabilised active β-
catenin have been shown to promote osteogenic differentiation of hMSC (De Boer et al., 
2004b), (Gong et al., 2001), (Qiu et al., 2007). In vivo, Wnt 3A has been shown to enhance 
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the proliferation and differentiation of skeletal progenitor cells causing accelerated bone 
repair in sensitised (Axin2 knockout) mice (Minear et al., 2010).  
Despite the significant role of Wnt in directing tissue formation, its  in vivo use for bone 
repair has so far been limited as a consequence of the complicated and costly production 
methods required to produce pharmacological quantities of bioactive protein (Gothard et 
al., 2014), (Coudreuse and Korswagen, 2007). In addition, the multiple Wnt ligands have 
varying biological potencies which complicate standardised dosing. Therefore, there is 
considerable interest in developing synthetic Wnt analogues in order to 
pharmacologically regulate Wnt signalling pathways in hMSC for therapeutic use. The 
synthetic peptide UM206, introduced in chapter 3, is a specific ligand for Frizzled 2 
receptors whose signalling activity is conformational dependent (Blankesteijn Wessel 
Matthijs, 2010). In chapter 3 the efficacy of remotely activating Wnt signalling using anti-
Frizzled 2 antibodies (Fz-MNP) or linear UM206 (L-UM206) peptide coated MNP targeted 
against Frizzled receptors was demonstrated. Due to supplier issues that limited 
availability of the anti-Frizzled 2 antibody, UM206 was taken forward and used as the 
Frizzled 2 targeting strategy for MNP in these experiments.  
The aims of this chapter were to investigate the potential of the UM206-mediated 
magnetic Wnt pathway activation approach for the regulation of osteogenesis and bone 
formation. This approach was first assessed in vitro by investigating the osteogenic 
response of hMSC in monolayer to both Linear and Cyclic UM206-MNP respectively. 
Secondly, the potential in vivo aspects of this magnetic activation approach were 
evaluated using an ex vivo foetal chick femur model of bone development adopted by 
Smith et al. (Smith et al., 2013), (Smith et al., 2014a), (Smith et al., 2014b). Using this 
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model, microinjection of hMSCs pre-labelled with UM206-MNP into organotypically 
cultured chick femurs was demonstrated.   
 
4.2 Methods 
4.2.1 Cell culture  
hMSC were sourced and processed as detailed in chapter 2. Cells were expanded in basal 
media (high glucose DMEM, 10% FBS, 1% L-glutamine and 1% penicillin/streptomycin) 
(Lonza) with media changes performed twice per week. Osteogenic media consisted of 
basal media supplemented with 0.2mM Ascorbic acid, 10mM sodium β-glycerophosphate 
and 0.1μM Dexamethasone. Cells were cultured for up to 28 days with two media 
changes per week. For Wnt-treated control groups diluted Wnt3A conditioned media 
collected from Wnt3A overexpressing L-M (TK-) cells (LGC standards) was used. Cells 
between passage 1 and 5 were used in all experiments.  
4.2.2 Magnetic nanoparticle coating and cell labelling.  
250nm SPIO carboxyl functionalised magnetic nanoparticles (Micromod) were covalently 
coated with UM206 peptide by carbodiimide activation and cells were labelled as 
described in chapter 2.    
4.2.3 Magnetic stimulation.  
Magnetically stimulated groups were treated using the magnetic force bioreactor as 
described in chapter 2. Treatment was performed in 3x 3h weekly sessions for in vitro 
studies. For chick femur cultures all femurs were stimulated with 5x 1h sessions per week 
for 2 weeks. Stimulations were performed at a frequency of approximately 1Hz. Non-
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stimulated control groups were kept in identical conditions (without magnetic field 
stimulation). 
4.2.4 Biochemical assays 
At each time-point cells were washed with PBS then lysed for 10 mins in 0.1% Triton-X 
100 in dH2O containing 10μM Pepstatin A, 1mM Phenylmethanesulfonyl fluoride (PMSF) 
and a protease inhibitor cocktail (All Sigma) diluted 10x in RIPA buffer. The ALP activity of 
cell lysates was assessed using a 4-MUP assay (Sigma). 50μL of lysate was mixed with 
50μL of 1M DEA buffer containing 0.5mM MgCl. Reactions were started with the addition 
of 50μL of 4-MUP substrate and incubated at 37oC for 30mins. Reactions were stopped 
using 50μL of 1M NaOH. The fluorescence of each sample was measured on a Biotek 
synergy 2 plate reader using an excitation wavelength of 360nm and emission wavelength 
of 440nm. The amount of 4-MU produced was determined using a standard curve of 4-
MU dissolved in DEA buffer (see appendix B). The total protein concentration of cell 
lysates was determined using a BCA assay kit (Thermo Fisher) according to the protocol 
described in chapter 2. Protein concentration was determined using a standard curve of 
BSA dissolved in d.H20. The DNA content of cell lysate samples was also determined using 
a PicoGreen assay kit (Invitrogen). 20μL of lysate was mixed with 100μL of PicoGreen 
reagent dissolved 200x in 1x Tris-EDTA (TE) buffer. Samples were mixed for 10mins. and 
fluorescence was determined on a Biotek synergy 2 plate reader using an excitation 
wavelength of 480nm and emission wavelength of 520nm. DNA concentrations were 
determined using a standard curve of DNA dissolved in 1x TE buffer (see appendix B).  
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4.2.5 Immunocytochemistry.  
After 28 days of culture cells were fixed with 90% Methanol and blocked as above before 
incubation with anti-Osteocalcin or anti-Osteopontin (R & D systems) diluted 1:2000 in 
1% BSA / PBS overnight at 4oC. Cells were washed 3x with PBS and incubated with anti-
Mouse-FITC secondary antibody (Sigma) diluted 1:1000 in 1% BSA / PBS for 1h at room 
temp. Cells were washed 3x in PBS, and counterstained with DAPI. Fluorescence 
microscopy was performed on an Olympus IX83 confocal microscope operating Flourview 
10 software. All images are representative of n=3. 
4.2.6 Chick foetal femur culture.  
Foetal chick femur extraction was performed by Dr J. Henstock (Keele University). Intact 
femurs were removed from freshly-killed Dekalb white chick foetuses after 11 days 
incubation and carefully cleaned of all muscle tissue by rolling on sterile tissue paper. 
Femurs were cultured ex vivo on porous polycarbonate membrane inserts (Millipore) in 
cell culture plates as described by (Kanczler et al., 2012). Femurs were cultured in 
osteogenic media consisting of alpha-MEM containing 1% penicillin-streptomycin and 150 
μg/ml ascorbic acid, 2mM sodium β-glycerophosphate and 10-8M dexamethasone (Sigma) 
for 14 days at 37°C in a 5% CO2 humidified incubator. Media changes were performed 
every 24h. 
4.2.7 Micro-injection.  
Micro-injection of hMSC was performed with the assistance of Dr J. Henstock (Keele 
University). Cells were first fluorescently tagged with a DiO membrane tracker before 
labelling with magnetic nanoparticles at a concentration of 25µg MNP/2x105 cells. Cells 
were introduced into three sites in the femur; both cartilaginous epiphyses and the mid-
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point of the diaphyseal bone collar using a 1ml syringe microinjection system (Linton 
Instrumentation, UK) and a glass capillary needle with a ~70µm tip diameter. 20nl of 
solution was injected into each site, equating to approximately 103 cells per injection. Co-
injections of cells and BMP2 microparticles consisted of a suspension of cells mixed with 
microspheres. Microinjections were performed under sterile conditions with the aid of a 
Leica MZ10F dissecting microscope. 
4.2.8 BMP2 microparticle encapsulation. 
BMP2 microparticles were prepared and provided by Dr O. Qutachi (University of 
Nottingham). Poly vinyl alcohol (PVA, molecular weight: 13000 – 23000 Da, 87-89% 
hydrolysed), human serum albumin (HSA), Poly (DL-lactide-co-glycolide), (PLGA) polymers 
with lactide: glycolide ratios of 50:50 (DLG 4.5A 59 kDa) were all purchased from 
Surmodics (Birmingham, USA). Recombinant human BMP-2 (BMP-2) was purchased from 
Professor Walter Sebald (University of Wurzburg, Germany). Poly (DL-lactide-co-glycolide) 
microparticles were formed using a water-in-oil-in-water (w/o/w) emulsion method as 
previously described by (Kirby et al, 2011). Briefly, triblock copolymer was added to PLGA 
to provide weight percentages of 30% (w/w) of the 1g total mass in 5 ml 
dichloromethane. BMP-2 and HSA (human serum albumin) solution were prepared at a 
ratio of 1:9 for a 1% w/w loading in the microparticles. In order to manufacture 
microparticles, the aqueous solution of HSA and BMP-2 was added to a solution of PLGA-
tri block copolymer. These phases were homogenised for two minutes at 4,000 rpm in a 
Silverson L5M homogeniser (Silverson Machines, UK) to form the water-in-oil emulsion. 
This primary emulsion was transferred to 200 ml 0.3% (w/v) PVA solution and was 
homogenised for a second time at 9,000 rpm. The resultant double emulsion was stirred 
at 300 rpm on a Variomag 15-way magnetic stirrer for a minimum of 4h to facilitate DCM 
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evaporation. Microparticles were then washed and lyophilized until dry (Edwards 
Modulyo, IMA Edwards, UK). 
4.2.9 X-ray microtomography.  
X-ray microtomography analysis of chick femurs was performed by Dr J. Henstock (Keele 
University). End-point femur density and volume were assessed by X-ray 
microtomography (µCT) using a Scanco µCT40 (beam energy: 55 kVp, beam intensity: 
145µA, 200ms integration time, spatial resolution: 10µm). Femurs were analysed at two 
density thresholds (50/1000 and 120/1000), firstly to determine the total size, volume 
and average density of each femur following treatment and secondly at a higher 
threshold to determine the mineralised portion of the femur in the diaphysis (bone collar) 
and its average density. These thresholds were conserved throughout the experiments, 
allowing for comparison of bone formation across the investigation. All analysis on the 
reconstructions was performed using Scanco software tools. 
4.2.10 Histological staining.  
Cells were washed and fixed as described above then stained with 1% (w/v) Alizarin red in 
d.H2O or 1% (w/v) for 10mins followed by 3x washes with d.H2O or Sirius red dissolved in 
1.3% Picric acid solution (Sigma) for 45mins followed by 3x washes with d.H20. Samples 
were imaged on a Leica DMIL microscope with LAS software. After imaging, Alizarin red 
dye was extracted by incubating samples with 10% (w/v) CPC solution for 10mins on an 
orbital shaker. Samples of extracted dye were quantified by measuring absorbance at 
562nm. Sirius red staining was extracted by incubating samples with 1M NaOH solution 
for 15mins on an orbital shaker. Samples of extracted dye were quantified by measuring 
absorbance at 540nm. For chick femur experiments, femurs were fixed, stained with 
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Alizarin Red and imaged. This was performed by Dr J. Henstock (Keele University). Femurs 
were fixed in 4% paraformaldehyde for 48h and washed in PBS. Whole mount histological 
staining for calcium deposition was performed by immersing the femurs in 1% Alizarin red 
for 1h followed by washing in PBS. Femurs were imaged using a Leica S6D dissection 
microscope fitted with a Nikon D500 digital camera. For sectioning, samples were first 
dehydrated in increasing concentrations of Industrial methylated spirits (IMS), followed 
by clearing in xylene. Samples were embedded in wax overnight then 7µm sections of 
femurs were obtained using a Microtome (Thermo-Shandon AS325). Tissue sections were 
re-hydrated by immersing in xylene for 2mins followed by decreasing concentrations of 
IMS (2mins each) and rinsed in water for 2mins. Sections were then stained for Calcium or 
Collagen using Alizarin Red or Sirius red respectively as described above. sGAG were 
stained for 10mins using 1% (w/v) Alcian blue dissolved in Acetic acid for 10mins followed 
by 3x d.H20 washes.     
4.2.11 Immunohistochemistry  
Femurs were processed for histological staining as above. Antigen retrieval on re-
hydrated sections was first performed by incubating samples with Proteinase K solution 
(20μg/mL) dissolved in TE/Triton buffer for 20mins at 37oC (Sigma). Sections were then 
blocked with 1%BSA / TBS for 1h and incubated with anti-Osteocalcin (Abcam) diluted 
1:200 in 1%BSA / TBS-Triton overnight at 4oC. Sections were washed 2x with TBS-Triton. 
Endogenous peroxidase activity was then blocked with 0.3% H2O2 in TBS for 15mins at 
room temperature. Secondary antibody incubation and DAB staining was then performed 
using ABC staining system (Santa Cruz). Stained sections were dehydrated, cleared and 
mounted using DPX (Sigma). Sections were imaged using an Olympus CKX41 microscope 
operating with Image Pro Insight software.   
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4.2.12 Statistical analysis  
All data is presented as means +/- SEM. Statistical significance at 95% Confidence level 
was determined using 1-way ANOVA with post-hoc Tukey tests using Mini-tab. μCT data 
was analysed by 1-way ANOVA with post-hoc Dunnett’s test, all groups were compared to 
the Sham injection control group. 
 
4.3 Results 
The effects of UM206-MNP stimulation on the osteogenic differentiation of hMSC 
cultured in monolayer and in an ex vivo foetal chick femur model were investigated. For 
monolayer experiments cells were labelled with L-UM206-MNP or C-C-UM206-MNP and 
cultured for up to 28 days in osteogenic media with intermittent sessions of magnetic 
stimulation and studied for indicators of differentiation.  
4.3.1 Biochemical analysis 
Cell lysates were obtained from cells treated with MNP with and without magnetic field at 
three time-points (day 7, 14, 21) and samples were assayed for ALP activity, total protein 
and DNA content. 
4.3.1.1 ALP activity 
ALP activity was unaffected by magnetic field treatment alone at each time-point (Figure 
4.1) whilst treatment with L-UM206-MNP or C-C-UM206-MNP alone marginally increased 
ALP activity at each time-point (not significant).  Treatment with L-UM206-MNP in 
conjunction with magnetic field stimulation led to an added increase in ALP activity at all 
time-points with the most prominent effects observed after 7 and 21 days respectively 
(significant). Treatment with C-C-UM206-MNP and magnetic field also significantly 
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increased ALP activity after at all time points. Treatment with Wnt-CM caused increases in 
ALP activity at day 7 (Not significant) and day 14 (Significant) to similar levels as L-UM206-
MNP and C-C-UM206-MNP, whilst a significant decrease in ALP activity was observed 
after 21 days. 
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Figure 4.1. UM206-MNP increase ALP activity. 
Magnetic field alone had negligible effects on ALP activity at all time points (not 
significant). Treatment with L-UM206-MNP or C-C-UM206-MNP (without magnetic 
field) marginally increased ALP activity at all time-points (not significant). Treatment 
with L-UM206-MNP (with magnetic field) increased ALP activity at day 7 and day 21 
(significant) and treatment with C-C-UM206-MNP with magnetic field increased ALP 
activity at all time-points (significant). Treatment with Wnt-Conditioned media (Wnt-
CM) increased ALP activity at day 7 (not-significant) and day 14 (significant), but 
significantly reduced ALP activity at day 21. n=4, values represent average ALP activity, 
error bars represent SEM, * represents p<0.05.  
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4.3.1.2 Total protein production 
Total protein production was marginally raised by magnetic field treatment after 7 days 
(not significant) and remained similar to the non-treated control group after 14 days and 
21 days respectively (Figure 4.2).  Treatment with L-UM206-MNP or C-C-UM206-MNP 
alone also resulted in elevated total protein at day 7 (not significant) and remained 
similar to the non-treated control group at day 14 and day 21 respectively. Treatment 
with L-UM206-MNP with magnetic field resulted in marginal increases in total protein 
production after 7 and 21 days respectively (not significant), but no overall effect was 
observed after 14 days treatment. Treatment with C-C-UM206-MNP with magnetic field 
stimulation significantly raised total protein production at all time-points with most 
notable increase at later time-points. Treatment with Wnt-conditioned media (Wnt-CM) 
also significantly increased total protein production at all time-points.  
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Figure 4.2. Effects of UM206-MNP on Total Protein content. 
Magnetic field alone caused an increase in Total protein content at day 7 (not 
significant) and was not affected at day 14 or day 21. Treatment with L-UM206-MNP 
or C-C-UM206-MNP (without magnetic field) increased ALP activity at day 7 (not 
significant)  and had no effect at day 14 or day 21. Treatment with L-UM206-MNP 
(with magnetic field) marginally increased Total protein at day 7 and day 21 
compared to the non-treated control (not significant) and no effect was observed 
after 14 days. Treatment with C-C-UM206-MNP and magnetic field significantly 
increased Total protein content at all time-points, with most notable increases at day 
14 and day 21. Treatment with Wnt-Conditioned media (Wnt-CM) significantly 
increased Total protein content at all time-points. n=4, values represent average 
total protein content of cell lysates, error bars represent SEM, * represents p<0.05.  
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4.3.1.3 DNA content 
The DNA content of cell lysates was also assessed. Magnetic field treatment alone was 
found to have no effect on DNA content at each time-point (Figure 4.3). Treatment with 
L-UM206-MNP or C-C-UM206-MNP alone had no effect on DNA content at day 7 and day 
14, whilst a minor increase in DNA content was observed after 21 days treatment 
compared to the non-treated control group (not significant). Treatment with L-UM206-
MNP in conjunction with magnetic field resulted in a significant increase in DNA content 
after 7 days only but no effect was observed after 14 and 21 days respectively. Treatment 
with C-C-UM206-MNP resulted in a significant increase in DNA content after 7 and 21 
days with a marginal increase  in DNA content observed after 14 days (not significant). 
Treatment with Wnt-conditioned media (Wnt-CM) elevated the DNA content of cell 
lysates at all time-points with a significant increase observed after 14 days only.    
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Figure 4.3. Effects of UM206-MNP on DNA content. 
Treatment with magnetic field alone had no overall effect on DNA content at each 
time-point studied. Treatment with L-UM206-MNP or C-C-UM206-MNP had no effect 
of DNA content at day 7 and day 14, a marginal increase in DNA content was observed 
after 21 days (not significant). Treatment with L-UM206-MNP with magnetic field 
stimulation caused a significant increase in DNA content at day 7, no effect was 
observed at day 14 or day 21. Treatment with C-C-UM206-MNP and magnetic field 
stimulation caused a significant increase in DNA content at day 7 and day 21, no effect 
was observed after 14 days. Treatment with Wnt-conditioned media (Wnt-CM) 
increased DNA content at each time-point (significant at day 14 only). n=4, values 
represent average DNA content of cell lysates, error bars represent SEM,* represents 
p<0.05.  
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4.3.1.4 ALP/DNA ratio 
The ALP activity of cell lysates was also normalised to the DNA content of the respective 
lysates to account for changes in cell numbers between groups (Figure 4.4). Treatment 
with magnetic field alone caused minor non-significant increases in the ALP/DNA ratio at 
day 7 and day 14, whilst no effect was observed at day 21. Treatment with either L-
UM206-MNP or C-C-UM206-MNP alone caused relative increases in the ALP/DNA ratio at 
day 7 and 14 respectively (not significant) whilst no effect observed at day 21. An additive, 
but non-significant increase in ALP/DNA was observed when cells were treated with L-
UM206-MNP with magnetic field stimulation at all time-points. Treatment with C-C-
UM206-MNP with magnetic field stimulation also caused minor, non-significant increases 
in the ALP/DNA ratio at day 7 and day 14, whilst a decrease was observed at day 21 (not 
significant). Treatment with Wnt-conditioned media (Wnt-CM) transiently increased 
ALP/DNA at Day 7 (not significant), but a reduction was observed after 14 days (not 
significant) with a significant reduction in ALP/DNA observed after 21 days treatment.  
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Figure 4.4. Effects of UM206-MNP on ALP/DNA ratio. 
Treatment with magnetic field alone caused minor increases in the ALP/DNA ratio at 
day 7 and day 14 (not significant), no effect was observed after 21 days. Treatment 
with L-UM206-MNP or C-C-UM206-MNP alone caused increases in ALP/DNA at day 7 
and day 14 (not significant) with no effect observed at day 21. Treatment with L-
UM206-MNP with magnetic field stimulation increased ALP/DNA at all time-points 
(not significant). Treatment with C-C-UM206-MNP and magnetic field increased 
ALP/DNA at day 7 and day 14 (not significant) and a decrease in ALP/DNA was 
observed at day 21 (not significant). Treatment with Wnt-conditioned media (Wnt-
CM) increased ALP/DNA at day 7 (not significant), whilst decreases in ALP/DNA were 
observed after 14 days (not significant) and 21 days (significant). n=4, values 
represent averages of ALP activity normalised to DNA content of cell lysates.  Error 
bars represent SEM,* represents p<0.05. 
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4.3.2 In vitro histological analysis 
4.3.2.1 Collagen deposition 
Treatment with magnetic field, L-UM206-MNP or C-C-UM206-MNP alone all caused 
marginal changes in collagen production as shown by Picro-Sirius red staining for collagen 
(Figure 4.5). Whilst treatment with either type of UM206-MNP in conjunction with 
magnetic field appeared, by microscopic analysis, to increase localised collagen 
production. However quantification of the total collagen production after dye extraction 
with NaOH indicated that collagen content remained similar to the non-treated control 
for each treatment (Figure 4.6). In contrast, treatment with Wnt-CM clearly increased 
collagen production which was confirmed after quantification.  
4.3.2.2 Calcium deposition 
Treatment with magnetic field or L-UM206-MNP alone appeared to cause marginal 
increases in calcium deposition as shown by Alizarin red staining for calcium (Figure 4.7), 
whilst C-C-UM206-MNP alone had no overall effect on calcium deposition. Treatment 
with either L-UM206-MNP or C-C-UM206-MNP in conjunction with magnetic field 
appeared to increase localised calcium deposition by microscopic analysis. Although again 
quantification of the total calcium production after dye extraction with CPC indicated that 
the calcium content of the samples remained similar to the non-treated control for each 
treatment (Figure 4.8). In contrast, treatment with Wnt-CM caused a noticeable decrease 
in calcium deposition. This effect was also shown after quantification although was found 
not to be statistically significant. 
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Figure 4.5. UM206-MNP enhance localised Collagen production. 
Treatment with Magnetic field alone or L-UM206-MNP (without magnetic field) had a negligible effect on collagen deposition compared 
to the non-treated control (A). Whereas an increase in localised local collagen deposition was observed after treatment with L-UM206 
with magnetic field compared to the magnetic field only control group. Treatment with Wnt-CM caused a clear increase in collagen 
deposition after 28 days. High magnification images are shown in (B) Images representative of n=4. Scale bar represents 200μm. 
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Figure 4.6. UM206-MNP do not affect total Collagen production. 
Quantification of total Collagen deposition after dye extraction with NaOH 
indicated that Collagen deposition across the wells was broadly similar 
across all groups apart from the Wnt-CM treated group which displayed a 
significant increase in total Collagen deposition after 28 days. Error bars 
represent SEM, n=4, * represents p<0.05 
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Figure 4.7. UM206-MNP enhance local mineralisation. 
Treatment with Magnetic field alone or UM206-MNP (without magnetic field) resulted in minor increases of localised bone nodule 
formation compared to the non-treated control (A). Treatment with L-UM206-MNP (with magnetic field) caused a noticeable increase in 
localised nodule numbers compared to the magnetic field alone control group. In contrast treatment with Wnt-CM for 28 days caused a 
clear decrease in nodule formation. High magnification images are shown in (B) Images representative of n=4. Scale bar represents 200μm. 
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4.3.3 In vitro matrix marker expression 
Matrix production was assessed by immunostaining for bone markers Osteocalcin and 
Osteopontin. 
4.3.3.1 Osteocalcin 
Treatment with magnetic field or either L-UM206-MNP or C-C-UM206-MNP alone 
appeared to increase overall Osteocalcin production after 28 days (Figure 4.9).  An added 
increase was observed when cells were treated with either C-C-UM206-MNP or in 
particular L-UM206-MNP when subjected to magnetic field stimulation. Treatment with 
Wnt-CM also marginally increased Osteocalcin production after 28 days. 
Figure 4.8. UM206-MNP do not affect total mineralisation. 
Quantification of total calcium deposition after CPC extraction indicated 
that calcium deposition across the wells was broadly similar across all 
groups apart from the Wnt-CM treated group which displayed a significant 
decrease in total calcium deposition after 28 days. Error bars represent 
SEM, n=4.  
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4.3.3.2 Osteopontin  
Treatment with magnetic field or either L-UM206-MNP or C-C-UM206-MNP alone 
appeared to have no overall effect on Osteopontin production after 28 days (Figure 4.10).  
Whilst a marginal increase in Osteopontin production was observed after treatment with 
L-UM206-MNP or C-C-UM206-MNP in conjunction with magnetic field stimulation. 
Treatment with Wnt-CM also marginally increased Osteopontin production after 28 days.
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Figure 4.9. UM206-MNP enhance Osteocalcin production. 
Treatment with Magnetic field alone (B) or either L-or C-C-UM206-MNP without magnetic field (C,E) caused increases in Osteocalcin 
expression relative to the non-treated control group (A). Treatment with L-UM206-MNP with magnetic field (D) caused a notable increase in 
Osteocalcin expression after 28 days.  Treatment with C-C-UM206-MNP with magnetic field (F) or Wnt-CM (G) caused minor increases in 
Osteocalcin expression. Images representative of n=3. Scale bar represents 200μm. 
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Figure 4.10. UM206-MNP do not affect Osteopontin production. 
Treatment with Magnetic field alone (B) or with either L-UM206 or C-C-UM206-MNP without magnetic field (C, E) had a negligible effect on 
Osteopontin expression compared to the non-treated control (A). Treatment with L-UM206-MNP or C-C-UM206 MNP with magnetic field 
(D, F) caused negligible increases in Osteopontin expression. Treatment with Wnt-CM (G) had no overall effect on Osteopontin production. 
Images representative of n=3. Scale bar represents 200μm. 
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4.3.4 Effects of L-UM206-MNP on ex vivo bone production 
The effects of L-UM206-MNP, magnetic field treatment and synergistic effects of BMP2 
on bone formation were investigated in an ex vivo foetal chick femur model. Delivery of 
cells to femurs was confirmed by fluorescent microscopy which showed fluorescence of 
tagged-cells in the epiphyseal regions 24h after injection, sham injected femurs displayed 
background auto-fluorescence only (Figure 4.11). Injection of hMSC alone or hMSC pre-
labelled with L-UM206-MNP into the foetal femur resulted in the formation of secondary 
mineralisation sites in the injected epiphysis and evidence of extension of the bone collar 
was also observed after 14 days (Figure 4.12). This effect was also observed when hMSC 
with or without labelling with L-UM206-MNP were co injected with BMP2-releasing 
microspheres which provided controlled release of BMP2. 
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Figure 4.11. Microinjection of MSC into foetal femurs. 
Fluorescence dissection microscopy images showing delivery of injected hMSC 
into foetal chick femurs 24h post-injection (Top). Auto-fluorescence of sham 
injected femur is shown in the bottom image. Arrows indicate injection sites. 
Representative images from MSC injection and Sham injection groups are shown. 
N=8, scale bar represents 1mm. 
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Figure 4.12. UM206-MNP and BMP releasing microparticles increase bone 
formation in foetal femurs. 
Whole mount dissection microscopy images showing calcium deposition 
(Alizarin red staining) primarily in the bone collar in all groups including the 
control sham injection group (A). In treated groups secondary mineralisation 
sites were observed at the microinjected regions in epiphyses injected with 
hMSC alone (B) , hMSC with BMP2-releasing microparticles (C) hMSC labelled 
with L-UM206 and (D) and L-UM206-labelled hMSC with BMP2 microparticles  
(E). Images representative of n=8. Scale bar represents 1mm. 
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4.3.5 Micro-computed tomography analysis 
4.3.5.1 Total Bone density and volume 
The bone density and volume of foetal femurs was determined by μCT analysis (Figure 
4.13). Injection of hMSC alone caused a minor decrease in total femur volume whilst total 
femur density was marginally increased (not significant). In contrast, injection of hMSC 
with BMP2 microparticles resulted in a significant increase in total bone volume, mainly 
as a result of increased mineralisation at the diaphyseal bone collar but overall a minor 
decrease in total bone density was observed (not significant). Injection with L-UM206-
MNP labelled MSC with and without BMP2 releasing microparticles had no overall effect 
on the total bone volume or density of femurs. 
4.3.5.2 Bone Collar density and volume 
The density and volume of the diaphyseal bone collars were also analysed (Figure 4.14). 
Injection of hMSC alone or hMSC pre-labelled with L-UM206-MNP (with or without 
BMP2) all caused minor decreases in bone collar volume whilst bone collar density was 
marginally increased in these groups (not significant). Injection of hMSC with BMP2 
releasing microparticles resulted in a minor increase in bone collar volume (not 
significant) but no effect was observed on bone collar density. The highest collar density 
was observed in femurs co-injected with hMSC with L-UM206-MNP and BMP2 although 
this was not found to be statistically significant.  
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Figure 4.13. UM206-MNP do not affect total bone volume or density. 
Microinjection of hMSC, hMSC labelled with UM206-MNP or UM206-MNP with BMP2 
had no overall effect on Total bone volume (A) or total density (B). In contrast micro-
injection of hMSC with BMP2 releasing micro-particles caused an overall increase in 
the total volume of bone formed (A) but did not affect the total bone density (B). A 
scatter plot of bone volume and bone density is shown in (C). N=8, error bars 
represent SEM, * represents p<0.05. 
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Figure 4.14. UM206-MNP increase Bone collar density in foetal femurs. 
Microinjection of hMSC, hMSC labelled with UM206-MNP or UM206-MNP with BMP2 
had no overall effect on Bone collar volume (A) but did increase bone collar density 
(trend only) with highest collar density observed in UM2060-MNP with BM2 injection 
group (B). Injection with BM2 caused a minor (not significant) increase in Collar volume 
(A) but had no effect on collar density (B). A scatter plot of bone collar volume and 
collar density is shown in (C). N=8, error bars represent SEM. 
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4.3.5.3 Relative Bone Collar density and volume 
In order to control for differences between femurs, the bone collar volume and density of 
each femur was normalised to the total bone volume and density of each respective 
femur (Figure 4.15). Injection of hMSC alone appeared to increase relative collar volume 
(not significant) whilst no effect was observed on relative collar density. Injection of hMSC 
with BMP2 releasing microparticles with or without L-UM206-MNP caused a marginal 
decrease in relative collar volume (not significant) and no effect was observed on femurs 
injected with L-UM206-MNP labelled hMSC alone. However injection with hMSC and 
BMP2 microparticles, or L-UM206-MNP labelled MSC both resulted in increases in relative 
collar density with the highest relative collar density observed in L-UM206-MNP and 
BMP2 injected femurs (significant). 
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Figure 4.15. UM206-MNP increase relative Bone collar density in foetal femurs. 
Microinjection of hMSC alone caused a minor (not significant) increase in relative collar 
volume (A) but had no effect on relative collar density (B). Injection of BMP2 
microparticles caused a minor decrease (not significant) in relative collar volume (A) but 
caused an increase (not significant) in relative collar density (B). Injection of L-UM206-
MNP labelled MSC with or without BMP2 microparticles had no overall effect on relative 
collar volume but did increase relative collar density (Significant for L-UM206-MNP & 
BMP2). A scatter plot of relative bone collar volume and relative collar density is shown 
in (C). N=8, error bars represent SEM, * represents p<0.05. 
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4.3.6 Ex vivo histological analysis 
Injected femurs were sectioned and subjected to histological analysis in order to 
investigate the observed secondary mineralisation sites after alizarin red staining. The 
degree of tissue remodelling at the injection site was also investigated using histological 
staining.  
4.3.6.1 Calcium deposition 
Femurs injected with hMSC (with or without BMP2 and UM206-MNP) all displayed 
evidence of secondary mineralisation at the injection sites as shown by Alizarin red 
staining for calcium indicating the presence of mineralised matrix (Figure 4.16). In 
contrast, negligible mineralisation apart from normal bone deposition at the bone collar 
was observed at the injection sites in the sham injected control femurs.  
4.3.6.2 sGAG and collagen deposition 
Femur sections were also stained with Alcian blue and Sirius red to reveal sGAG and 
collagen deposition respectively. This allows the degree of tissue remodelling at the 
injection sites of the femurs to be assessed. Femurs injected with hMSC (with or without 
BMP2 and UM206-MNP) all showed a degree of increased collagen or sGAG deposition at 
the injection sites (Figure 4.17) indicating a level of tissue remodelling after treatment. In 
contrast negligible tissue remodelling was observed in the sham injected control femurs. 
4.3.6.3 Osteocalcin production 
Immunocytochemistry was also performed on femur sections to probe for the presence 
of Osteocalcin which is an indicator of mature bone matrix (Figure 4.18). Once again 
femurs injected with hMSC (with or without BMP2 and UM206-MNP) all displayed 
evidence of Osteocalcin expression at the injection sites which was most noticeable at the 
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epiphyseal regions of the femurs. In contrast sham injected femurs were negative for 
epiphyseal osteocalcin expression. 
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Figure 4.16. Secondary mineralisation sites after L-UM206-MNP injection. 
Alizarin red staining showing calcium deposition in femur histology sections. Sham injected (control) femurs (A) showed little evidence 
of epiphyseal mineralisation at injection sites. In contrast Injection of hMSC alone (B), hMSC with BMP2 microparticles (C), hMSC 
labelled with L-UM206-MNP (D) and L-UM206-MNP co-injected with BMP2 microparticles (E) resulted in formation of secondary 
mineralisation sites. Higher magnification images are shown in the bottom row. Scale bars represent 300 μm (top row) and 120μm 
(bottom row) respectively, Images representative of n=8 shown. 
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Figure 4.17. Tissue remodelling after L-UM206-MNP injection. 
Alcian blue and Sirius red staining showing Glycosaminoglycan (GAG) and Collagen deposition in femur histology sections. Sham 
injected (control) femurs (A) showed little evidence of epiphyseal tissue remodelling after injection. In contrast Injection of hMSC 
alone (B), hMSC with BMP2 microparticles  (C), hMSC labelled with L-UM206-MNP (D) and L-UM206-MNP co-injected with BMP2 
microparticles (E) resulted in increased collagen deposition and tissue remodelling at the injection sites . Higher magnification images 
are shown in the bottom row. Scale bars represent 300 μm (top row) and 120μm (bottom row) respectively, Images representative of 
n=8 shown. 
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Figure 4.18. Matrix formation after L-UM206-MNP injection. 
Immunohistochemistry staining for Osteocalcin in femur histology sections. Sham injected (control) femurs (A) showed little evidence 
of epiphyseal osteocalcin production after injection. In contrast Injection of hMSC alone (B), hMSC labelled with L-UM206-MNP (C) 
and L-UM206-MNP co-injected with BMP2 microparticles (D) resulted in increased Osteocalcin deposition at the injection sites . 
Higher magnification images are shown in the bottom row. Images representative of n=8 shown. 
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4.4 Discussion 
4.4.1 Role of Wnt signalling in Osteogenesis 
The complex role of Wnt signalling on the regulation of hMSC fate is well known. Wnt has 
been shown to have contradictory actions on MSC fate with both inhibitory and 
promoting effects on MSC osteogenesis. Previous work has shown that Wnt3a promotes 
MSC proliferation and maintains multipotency  (Boland et al., 2004) whilst other groups 
have shown that high doses of exogenous Wnt3a can promote MSC osteogenesis, and for 
MSC which are already committed to the osteogenic lineage Wnt has also been shown to 
stimulate their differentiation (Ling et al., 2009), (De Boer et al., 2004b). In this chapter 
the effects of MNP mediated Wnt stimulation on hMSC osteogenesis was explored in 
vitro by examining expression of osteogenic and matrix associated markers. Finally, the 
effects of MNP stimulation coupled with BMP2 released from microspheres were 
investigated on bone formation in an ex vivo foetal femur model.  
4.4.2 Effects of MNP on Alkaline phosphatase activity 
Alkaline phosphatase (ALP) is an established marker of osteogenesis (Aubin, 2001)  and is 
a widely used indicator of osteogenic differentiation and a predictor of the osteogenic 
potential of hMSC (Kulterer et al., 2007), (Birmingham et al., 2012). In these experiments 
treatment of cells with either Linear UM206-MNP (L-UM206-MNP) or Cyclic UM206-MNP 
(C-C UM206-MNP) alone resulted in minor elevations in ALP activity over 21 days. Whilst 
a further increase was observed when these MNP were applied in conjunction with 
magnetic field stimulation. This indicates a positive role of UM206-MNP on MSC 
osteogenesis and highlights the enhancing effects when magnetic field stimulation of 
MNP is used. Treatment with Wnt-conditioned media also elevated ALP activity at the 
earlier time-points but was reduced after 21 days. ALP activity is known to fluctuate 
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during hMSC osteogenesis (Jaiswal et al., 1997), particularly in the presence of 
mechanical forces (Yourek et al., 2010). The differences observed between UM206-MNP 
mediated ALP activity and the effects observed by Wnt-Conditioned media may be 
explained by the differing effects of mechanoactivation by UM206-MNP and the dose-
response effects of Wnt signalling on MSC osteogenesis (Ling et al., 2009), (Janeczek et 
al., 2016). Continual Wnt pathway stimulation by Wnt-conditioned media may therefore 
be resulting in reduced end-point osteogenic differentiation of hMSC.    
4.4.3  Changes in DNA and total protein content in response to MNP 
The DNA and total protein content of cells are commonly used as indicators to assess 
changes in cell proliferation. In these experiments treatment of hMSC with L-UM206-
MNP or C-C UM206-MNP both caused increases in DNA content at the early time-point 
when applied with magnetic field stimulation. Cyclic UM206-MNP (C-C-UM206-MNP) also 
increased DNA at the later time-point, whereas treatment with Wnt-CM consistently led 
to increases in DNA content over all time-points. Increased cell proliferation is a known to 
be both a response to Wnt signalling and part of the osteogenic induction process 
(Hoffman and Benoit, 2015), (Luu et al., 2009). Increased hMSC proliferation in response 
to UM206-MNP or Wnt may therefore be an indicator of increased hMSC osteogenesis. In 
the case of total protein, treatment with Linear UM206-MNP (L-UM206-MNP) caused 
minor changes on total protein production whilst Cyclic UM206-MNP (C-C-UM206 MNP) 
with magnetic field in particular led to increased protein production at all time-points. 
Total protein production was also increased by Wnt-Conditioned media (Wnt-CM) at each 
time-point. These trends may be linked to the increased cell numbers which were evident 
by the increased DNA content of the Cyclic UM206-MNP and Wnt-conditioned media 
groups.  When ALP activity was normalised to DNA content, to account for changes in cell 
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proliferation, an enhancement of early ALP activity was observed in both UM206-MNP 
and Wnt conditioned media treated groups in particular. At later time-points L-UM206-
MNP continued to elevate relative ALP activity whilst Wnt-conditioned media reduced 
relative ALP activity. These results suggest that MNP-mediated stimulation and Wnt 
stimulation of hMSC have different effects on the progression of hMSC osteogenesis.  
Overall these results suggests that MNP treatment is having a positive effect on cell 
proliferation and ALP activity in a manner that may be more beneficial than prolonged 
and constant treatment with Wnt3a alone.  
4.4.4 Effects of MNP on in vitro monolayer MSC osteogenesis 
The effects of UM206-MNP stimulation on matrix production and mineralisation were 
also investigated. It was found that intermittent stimulation of hMSC with L-UM206-MNP 
over 28 days resulted in some increases in collagen synthesis, matrix maturation as 
shown by Osteocalcin (and to a lesser extent Osteopontin) staining and matrix 
mineralisation. All of these markers are indicative of a differentiated osteoblast 
phenotype (Marom et al., 2005), (Birmingham et al., 2012), (Delaine-Smith et al., 2012). In 
contrast treatment with Wnt-CM over 28 days resulted in marked increase in collagen 
synthesis but a decrease matrix mineralisation. The discrepancy between the outcomes of 
L-UM206-mediated and Wnt-mediated pathway activation on hMSC osteogenesis could 
again be explained by the apparent differential dose-response effects of Wnt signalling 
which was also seen with ALP activity. The results from chapter 3 suggest that Wnt 
pathway activation through L-UM206-MNP is a transient stimulus which, in the context of 
MSC osteogenic differentiation, is initially beneficial for lineage commitment to 
osteogenesis but enables terminal differentiation after signal dissipation. This agrees with 
the findings of Ling et al. and Janeczek et al. who also showed that Wnt is beneficial for 
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hMSC commitment to the osteogenic lineage but Wnt withdrawal is ultimately required 
for terminal osteoblast differentiation and robust bone formation  (Ling et al., 2009), 
(Janeczek et al., 2016) 
4.4.5 Application of MNP in an ex vivo femur model 
This chapter introduces the foetal chick femur which is an established model of 
endochondral bone development. Delivery of MSC was confirmed by fluorescent tracking 
of the tagged cells 24h after injection. The effects of combined stimulation of Wnt 
transduction via L-UM206-MNP and BMP2 release from polymer microparticles on bone 
formation were then investigated over 14 days. This combinatorial strategy utilising 
controlled release of growth factors is particularly relevant and has applications in tissue 
engineering approaches for regenerating bone defects (Kirby et al., 2011). In this model, 
injection of BMP2 releasing microparticles with MSC increased total bone volume across 
the whole femur. This can be expected due to the well-known anabolic properties of 
BMP2 on bone formation (Chen et al., 2007). Interestingly, no overall effect on total bone 
volume or density was seen when BMP2 was injected in conjunction with hMSC labelled 
with L-UM206-MNP but this treatment had the greatest effect on bone collar density. 
This highlights the complex nature of Wnt and BMP2 signalling cross-talk and suggests 
that tight regulation of pathway activity is required for optimal bone formation. When 
bone collar volume and density were compared relative to the total bone volume and 
density, bone formation at the bone collar was found to be increased by injection of 
BMP2 and L-UM206-MNP and resulted in increases in bone density. This indicates the 
presence of a more mature, functional bone matrix and suggests enhanced bone 
development in response to MNP mediated Wnt activation and BMP2 signalling. This was 
confirmed by histological staining for calcium which showed clear evidence of 
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mineralisation and IHC for osteocalcin production both of which were observed at the 
injection sites. Future work should interrogate other non-collagenous bone markers 
expressed in the foetal femur injection sites such as Alkaline phosphatase and 
Osteopontin. The differential effects of MNP and/or BMP2 on bone volume and density 
observed at the diaphysis or epiphyses suggest that the complex spatial and temporal 
signalling and the different cell types present across the femur may be impacting on the 
degree of hMSC and chick cell induced bone formation in these zones. Previous work 
from (Smith et al., 2013) have shown that different cell populations isolated from distinct 
zones of the chick femur have different morphologies and phenotypes; it is therefore 
plausible that injection of cells into different zones of the femur is resulting in different 
outcomes in terms of tissue generation.  
4.4.6 Cross-talk between Wnt and BMP2 signalling in bone formation 
The interactions between Wnt and other cell signalling pathways in stem cells are 
complex. Amongst these interactions, a clear relationship between Wnt and BMP2 
signalling in the regulation of bone formation has been observed. For example Wnt and 
BMP2 have been shown to act reciprocally to regulate osteoblastic differentiation of both 
hMSC (Cook et al., 2014) and mouse C3H10T1/2 cells (Bain et al., 2003). There is also 
evidence to suggest that BMP induced osteoblast differentiation is dependent on Wnt 
pathway activity (Chen et al., 2007), (Rawadi et al., 2003). Other studies have found that 
BMP2 signalling resulted in the upregulation of Wnt antagonists Sfrp2 (secreted frizzled 
related protein 2) and Wif1 (Wnt inhibitory factor 1) in the late phase of MSC 
differentiation (Vaes et al., 2005). Evidence also exists for the activation of TCF/LEF 
response elements by both BMP/TGF and Wnt signalling during development 
(Letamendia et al., 2001). In the experiments presented here the ability of L-UM206-MNP 
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with BMP2 to trigger bone formation may be attributed to the reciprocal relationship 
between Wnt and BMP signalling where L-UM206-MNP act to initially trigger lineage 
commitment via Wnt signalling before promotion of terminal differentiation by BMP2. 
This may explain why the combination of L-UM206-MNP and BMP2 resulted in the 
greatest enhancement of relative bone formation in this model. In these experiments an 
enhancement of bone formation mediated by L-UM206-MNP was seen in the ex vivo 
femur model compared to in vitro bone formation by cells cultured in monolayer. This 
observation underlines how the complexity of relevant models which consist of multiple 
cell types and signalling gradients arranged in 3-dimentions are all needed to obtain 
optimum tissue engineered constructs.    
 
4.5 Conclusions 
The role of Wnt signalling in stem cell maintenance, differentiation and tissue 
development is well established. The results presented here indicate that the use of 
conjugated magnetic nanoparticle technology coupled with magnetic fields to activate 
Wnt signalling may be useful in modulating signal transduction with positive outcomes on 
cell differentiation and bone formation. This strategy has applications both as an in vitro 
research tool and potentially as a future clinical treatment in orthopaedics. Due to the 
expense and difficulty in preparing recombinant Wnt protein, easily synthesised ligands 
conjugated to magnetic nanoparticles present a viable method for activating Wnt 
pathways for the control of cell signalling and direction of stem cell differentiation. The 
results from this chapter show  that UM206 peptide functionalised MNP can modulate 
Wnt pathway activation and that these MNP can modestly augment  end-stage hMSC 
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osteogenesis with subsequent promotion of localised bone and matrix formation in an ex 
vivo foetal femur model. Importantly, this magnetic activation approach has also been 
shown to work in synergy with the controlled release of bone promoting growth factors 
such as BMP2, which already have proven relevance in the clinic. As such, the applications 
of this approach for the magnetic activation of stem cells for tissue engineering are 
apparent and indicate a positive step forward in the development of injectable cell 
therapies. 
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Chapter 5: Engineering the stem cell 
niche with Wnt
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5.1 Introduction 
The previous chapters of this thesis have focused on the use of magnetic nanoparticles 
for the remote modulation of Wnt signalling. The application of magnetic nanoparticles in 
this manner essentially allows remote control of signalling magnitude and duration. 
However the spatial and directional control of signalling at the cellular level using this 
approach is somewhat limited due to the fact that MNP must be applied in solution. One 
of the most important roles of Wnt signalling is the regulation of adult tissue homeostasis 
and the maintenance of the stem cell niche. Part of the mechanism behind this role 
involves  maintaining  the balance between promoting stem cell self-renewal and 
orchestrating lineage commitment (Clevers et al., 2014), (Baksh and Tuan, 2007). One 
particularly important aspect of Wnt mediated niche maintenance is the role of spatial 
Wnt gradients which have been shown to be critical for properly controlled and normal 
tissue development (Heller and Fuchs, 2015). There is now great interest in the 
application of Wnt proteins in stem cell research and tissue engineering. Current research 
utilising Wnt proteins revolves around the use of purified and soluble recombinant Wnt 
protein. Consequently, soluble Wnt often requires storage in detergents to preserve the 
bio-activity of the protein (Willert et al., 2003). The perceived benefit of this is that it 
allows the generalised and global application of Wnt protein to a cell population at 
relatively high concentrations. However application of Wnt in this manner excludes the 
spatial and directional presentation of Wnt gradients to target cells. This limitation is also 
a factor to consider in the current system for the magnetic activation approach 
introduced in the previous chapters. Recent work by Habib et al. has shown that spatial 
orientation of Wnt signalling using Wnt-3a immobilised on beads can initiate asymmetric 
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division of embryonic stem cells. In this system the daughter cell proximal to the Wnt 
signal retained a stem cell phenotype whilst the daughter cell distal to the Wnt signal 
expressed markers of differentiation (Habib et al., 2013). This highlights the crucial role of 
spatially presented and localised Wnt signalling on stem cell fate.  
As discussed in the previous chapters there is a clear role for human mesenchymal stem 
cells (hMSC) in tissue engineering. Furthermore, there is a clear role for Wnt signalling as 
a critical regulatory pathway affecting MSC self-renewal and osteogenic lineage 
commitment (De Boer et al., 2004b). Wnt signalling also plays a role in regulating the 
migratory capacity of MSC. Wnt pathway activation using Wnt3a or LiCl has been shown 
to promote MSC migration through human ECM coated Transwell filters in vitro (Neth et 
al., 2006), (Kollar et al., 2009). Therefore, there is a demonstrable role for the modulation 
of Wnt signalling and, in particular, Wnt gradients for the control of MSC osteogenic 
differentiation for tissue engineering purposes. 
The primary aim of this chapter was to introduce a novel tissue engineering platform 
which utilises Wnt protein immobilised on glass slide surfaces. These slides can be 
overlaid with cells and biocompatible scaffold materials such as Collagen 1 hydrogels. This 
system can then be used as a screening tool to develop putative tissue engineered 
constructs whilst allowing the investigation of the role of localised Wnt gradients in the 
maintenance of the stem cell niche and stem cell differentiation in a bone tissue 
engineering context.  
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5.2 Methods 
5.2.1 Preparation of immobilised Wnt sides 
Wnt3a immobilised slides were prepared and provided by Dr S. Habib (Kings College 
London). Recombinant Wnt-3A was acquired from Drosophila S2 cells expressing Wnt-3A. 
Wnt protein was purified by Blue sepharose affinity and gel filtration. Alternatively, 
commercially available Wnt 3A (R&D systems) was reconstituted in 0.1% BSA to 40ng/μL. 
This was diluted in PBS to a final volume of 40uL per drop and used to cover a working 
area of 64mm2 on VSS25 Vantage Silylated Aldehyde Slides (CEL Associates) with a Wnt3A 
concentration range of 10-40ng. Wnt coated slides were incubated for 1h at room 
temperature. The biological activity of immobilised Wnt3a was confirmed using a 
SuperTOPFlash reporter system expressed in L cells using a luciferase reporter assay (data 
not shown). Control surfaces (consisting of inactivated Wnt3a) were prepared by 
incubating Wnt3a coated slides with 20mM DTT for 30mins at room temperature. All 
coated surfaces were washed 3x with PBS and incubated with basal media for 10mins 
before seeding with cells. 
5.2.2 Cell culture 
hMSC were sourced and processed as detailed in chapter 2. Cells were expanded in basal 
media (10% FBS, 1% L-glutamine and 1% penicillin/streptomycin) (Lonza) with two media 
changes performed per week. Cells were passaged once per week and cells between 
passage 2 and 5 were used in all experiments. Cells were seeded onto the Active Wnt 3a 
or DTT treated control substrates at 80000/cm2 and cultured for 24h after which 100µL of 
1mg/mL rat tail Collagen 1 (BD biosciences)  pre-neutralised with 1M NaOH (25µL per mL 
of gel) and diluted in serum-free media was laid over the cell monolayer. Samples were 
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incubated overnight at 37oC, 5% CO2 to complete gelation. Media was then changed to 
Osteogenic inducing media consisting of basal media with the addition of Dexamethasone 
(0.1µM), β-Glycerophosphate (β-GP) 10mM, Ascorbic Acid (50µM) and non-essential 
amino acids (NEAA) 1x v/v. Samples were cultured for 7 days with 2 media changes 
performed. A diagram depicting the experimental setup is shown in Figure 5.1. 
 
 
 
5.2.3 Immunocytochemistry 
Media was aspirated and cells washed with PBS (Sigma), then fixed with 4% PFA (Sigma) 
in PBS for 10mins. Cells were permeabilised with 0.1% Triton-X in PBS (Sigma) for 10mins 
then then blocked with 2% BSA (Fisher) in PBS for 2h at room temp. Cells were then 
incubated with Anti-Human Stro1 (R&D systems) diluted 1:50 in 1% BSA in PBS overnight 
at 4oC. Samples were washed 3x 5mins with PBS before incubation with Anti-Mouse-FITC 
(Sigma) 1:1000 in 1% BSA in PBS for 1hr at room temperature. Samples were washed 3x 
5mins with PBS. This procedure was repeated for Osteocalcin staining where cells were 
re-blocked with 2% BSA in PBS for 2h before incubation with Anti-Human Osteocalcin 
Figure 5.1. Schematic of Wnt slide. 
Schematic representation of the Wnt slide.  Wnt protein is immobilised onto glass 
slides. Cells are seeded onto the Wnt-coated surface then overlaid with collagen 
gel. Cell migration and phenotype can then be monitored throughout the system.  
 197 
 
(R&D systems) diluted 1:1000 in 1% BSA in PBS overnight at 4oC. Cells were washed 3x 
5min with PBS before incubation with Alexa Flour Anti-Mouse-647 (Life Technologies) 
1:2000 in 1% BSA in PBS for 1hr at room temperature. Samples were washed 3x 5mins 
with PBS and counterstained with DAPI (Sigma) diluted to 1µg/mL in PBS for 10mins at 
room temperature. DAPI solution was aspirated and samples stored in PBS at 4oC before 
imaging.  
5.2.4 Imaging 
Imaging was performed on an inverted axio-imager fluorescence microscope (Zeiss) using 
Zen 2 (Bleu edition) software. Z-stacks were obtained with a step size of 1.5µm obtained 
from a total of 8 regions across two gels for each condition.  
5.2.5 Image Analysis 
The gels were separated into three layers in the z-dimension, a lower layer constituting 
the lower 46% (up to 72µm) from the gel base, a middle layer constituting up to 85% (up 
to 132µm)  from the gel base and an upper layer constituting up to 100% (up to 156µm) 
from the gel base.  The total number of migrating cells (cells across all migration layers) 
was determined from 8 regions across the gels along with the average cell number per gel 
layer to assess differences in migration patterns. To overcome the variation in cell 
number across the gel and high levels of fluorescence intensity in the base where cells 
were most confluent, the background corrected average Stro1 and Osteocalcin staining 
intensity per cell for the base layer and the three identified migration layers was 
determined using ImageJ (v1.48s).     
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5.2.6 Histological staining 
Samples were stained with 1% w/v Alizarin Red S solution (in d.H2O) for 10mins at room 
temperature then washed 5x 5mins with d.H2O. Samples were imaged using a Leica S6D 
dissection microscope fitted with a Nikon D500 digital camera. 
5.2.7 Statistical analysis 
The cell migration per gel layer was assessed using 1-way ANOVA with post-hoc Tukey 
tests with statistical significance at 95% confidence level determined using Mini-tab (v16).  
Stro1 and Osteocalcin staining intensity was assessed using Kruskal-Wallis with statistical 
significance at 95% confidence level. Post-hoc Mann-Whitney tests were used to 
determine statistically significant differences between groups. 
 
5.3 Results 
5.3.1 Wnt 3A increases hMSC migration 
The effects of immobilised Wnt on hMSC migration through collagen gel were monitored 
using immunocytochemistry. MSC were seeded onto immobilised Wnt surfaces at 
confluent density, overlaid with collagen gel and cultured in osteogenic media for 7 days. 
Confocal microscopy of the DAPI stained cells revealed a clear increase in the migratory 
capacity of the cells in response to the active Wnt3a surface (Figure 5.2). In contrast, cells 
cultured on the control surface consisting of inactivated Wnt 3a displayed a basal level of 
cell migration. Quantification of the total numbers of cell migration after 7 days 
confirmed the migratory capacity of cells cultured on the Wnt surface (151 migrated cells) 
compared to the control surface where a total of 13 migrated cells were observed across 
8 regions. This increase in the migratory capacity of MSC was also reflected in the spatial 
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location of cells in the gels where a significant 4 fold increase in average cell numbers 
were observed in the lower section of the gels when cells were cultured on the Wnt 
surface compared to the inactive Wnt control surface (Figure 5.3).  This trend continued 
in the middle section and even in to the upper section of the gel (up to 156 µm from the 
Wnt3a surface) where increased cell migration was observed in response to the active 
Wnt surface. Whilst on the control surface lower cell numbers were observed in the 
middle section and no migrated cells were observed in the upper section of the gels. 
 200 
 
Figure 5.2. Wnt3a increases MSC migration in Collagen gel. 
Confocal images of DAPI stained cells (Blue) 7 days after treatment. Fluorescent imaging was used to locate migrated cells through 
collagen gels. MSC cultured on Inactive Wnt 3A surfaces (Control) showed basal levels of cell migration. When MSC were cultured 
on active Wnt 3A surfaces (Bottom image) cell migration was noticeably increased with cells migrating further upwards through 
the gels. Representative images of 8 regions for each condition are shown. Scale bar represents 100µm.    
 201 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3. Quantification of hMSC migration in collagen gels. 
Quantification of hMSC migration through Collagen gels after 7 days. The 
average number of cells per layer of the gels was determined. Cells cultured on 
the active Wnt3A substrate resulted in increased cell migration into the lower 
(up to 72µm / 46% gel), middle (up to 132µm, 85% gel) and upper layers (up to 
156µm, 100% gel) of the gel . No cells were observed in the upper gel layers of 
the control groups. Values represent average cell counts counted across 8 
regions from 2 gels, error bars represent SEM, * denotes p<0.05. 
 202 
 
5.3.1 Wnt3a gradient influences MSC stemness and differentiation 
Immunostaining of MSC was then performed for Stro1, a stemness marker for MSC and 
Osteocalcin, a mature marker of the osteogenic lineage in order to ascertain if the 
immobilized Wnt surface recapitulated the inversely correlated gradient of Stro1 and OCN 
which is seen in vivo. In this system Osteocalcin expression was found to increase as the 
cells migrated upward with peak Osteocalcin expression observed in cells located in the 
upper gel layer. This was in contrast to Stro1, which was mainly expressed in the base and 
lower migration layer nearest to the Wnt signal and then decreased as the cells migration 
upward (Figure 5.4).  This effect was reduced on control surfaces where Osteocalcin and 
Stro1 expression both remained at basal levels. Quantification of the staining intensity of 
each marker was also performed and confirmed that Osteocalcin expression increased as 
cells migrated upwards with significant increases in Osteocalcin expression observed in 
the Middle and Upper gel layers (Figure 5.5). In contrast significant Stro1 expression was 
observed in the base and lower gel layers and decreased to approximately basal levels in 
the middle and upper gel layers. In the control groups both Osteocalcin and Stro1 
expression remained around basal levels in each region of the gel.  
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Figure 5.4. Wnt3a modulates Osteocalcin and Stro1 expression in migrating cells. 
Fluorescent immunostaining for Stro1 (green), and osteocalcin (red) expression in hMSC in collagen gels after 7 days in culture on active 
Wnt 3A and inactive wnt3A (control) substrates. Merged images show spatial pattern of staining in relation to cell nuclei (blue) (a). Levels 
of osteocalcin expression were higher in upper levels of the gel (up to 156µm, 100% gel), whilst cells cultured on the inactive Wnt3a 
(control) substrate showed basal levels of expression. Cells cultured on the active Wnt3a substrate showed a progressive decrease in Stro1 
expression through the gel with peak expression observed in the base and lower gel layers (up to 72µm / 46% gel) closest to the Wnt 
source, whilst cells cultured on the inactive Wnt3a (control) substrate showed overall  reduced levels of Stro1 expression. Representative 
images shown from 8 regions of interest from two gels, scale bar represents 100μm. 
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Figure 5.5. Quantification of Osteocalcin and Stro1 expression in migrating cells. 
Quantitation of image pixel intensity relative to cell number for osteocalcin (A) and 
Stro1 (B). Levels of osteocalcin expression were significantly increased in middle and 
upper layers of the gels (up to 156µm, 100% gel), whilst cells cultured on the inactive 
Wnt3a (control) substrate showed basal levels of expression (A). In contrast, cells 
cultured on the active Wnt3a substrate showed maximum Stro1 expression in the 
Base level and lower gel layer (up to 72µm / 46% gel) closest to the Wnt signal with a 
progressive decrease in Stro1 expression in the middle and upper gel layers, whilst 
cells cultured on the inactive Wnt3a (control) substrate showed overall  reduced 
levels of Stro1 expression (B). Values represent average fluorescence intensities per 
cell, error bars represent SEM,  * denotes p<0.05. 
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5.3.2 Wnt3a promotes early bone nodule formation   
Assessment of mineralised nodule formation was also determined histologically using 
Alizarin red to visualise early stage calcium deposits. Cells cultured on the Wnt3a surface 
were shown to form putative mineralised nodules after 7 days of treatment in two out 
four of the gels whilst no evidence of nodule formation was observed in the gels of 
control surfaces (Figure 5.6). 
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Figure 5.6. Wnt3a induces early mineralised nodule formation. 
Histological staining for calcified nodule formation after 7 days of culture. Alizarin red staining indicated early formation of mineralised 
nodules in 2/4 gels in response to Active Wnt 3A substrates (right panels) whilst no mineralised nodules were observed in the control group 
(Left panels). n=4, Scale bar = 100μm. 
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5.4 Discussion 
5.4.1 Migration inducing effects of Wnt 
The results presented in this chapter indicate that there is a clear role of Wnt signalling in 
stimulating hMSC migration. There was a clear increase in the number of migratory cells 
on the active Wnt surface compared to control surfaces, and these cells migrated further 
into collagen gels than cells cultured on the surfaces. The migration promoting effects of 
Wnt have been observed in previous work, for example Neth et al. observed that Wnt3A 
or LiCl prompted MSC to migrate through Transwell filters coated with human ECM (Neth 
et al., 2006). The MSC in this system were seeded on top of a surface functionalised with 
Immobilised Wnt protein, this means that only the basal surface of the cells would be 
presented with an exogenous Wnt stimulus. Previous work has shown that localised Wnt 
stimuli asymmetrically imparted onto embryonic stem cells using Wnt coated beads 
results in asymmetric cell division. In this scenario the daughter cell proximal to the Wnt 
signal displayed pluripotency markers and the distal daughter cell expressed markers of 
differentiation (Habib et al., 2013). Therefore an asymmetric cell division response to 
localised Wnt stimuli may be a contributing factor behind the increased MSC migration 
that was seen in these experiments. It should also be noted that a basal level of migration 
was also seen on the control surfaces. This phenomenon could be expected due to the 
unsorted, heterogeneous population of MSC which was used in these experiments. 
Previous work has shown that subpopulations of hMSC that exhibit high endogenous Wnt 
pathway activity are present in heterogeneous, unsorted populations of MSC. Therefore 
the limited migration of cells in the control group may be a reflection of the high Wnt 
signalling capacity of these MSC sub-populations. 
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5.4.2 Role of Wnt gradients in MSC osteogenic differentiation 
The role of Wnt gradients in maintaining adult tissue homeostasis is well-known, and 
these signalling gradients are known to play a role in regulating the MSC niche (Kim et al., 
2015). As discussed in the previous chapter, Wnt signalling plays a pivotal role in 
maintaining the self-renewal of MSC whilst withdrawal of Wnt signals is known to allow 
progression of MSC differentiation down the osteogenic lineage. A dose-response 
relationship between Wnt pathway activity and MSC differentiation has previously been 
observed whereby a reduction of Wnt signalling is required to enable MSC differentiation 
in vitro (Ling et al., 2009), (Janeczek et al., 2016). In the work presented here, a clear 
increase in Stro1 expression was observed at the basal layer closest to the Wnt signal 
indicating maintenance of the stem cell population. Whilst the inverse relationship was 
observed in Osteocalcin expression, a mature bone cell marker. Here, Osteocalcin 
expression increased as cells migrated away from the Wnt signal, which indicates a more 
differentiated phenotype of these cells. This inverse expression pattern of stem cell 
markers such as Stro1 and mature bone markers as cells progress from a stem cell 
phenotype to a differentiated bone cell phenotype has been observed before. Previous 
work has demonstrated that human osteoblast-like cells extracted from trabecular bone 
and human bone marrow stromal cells have different bone marker expression and 
capacities for bone generation depending on the expression of their surface markers. 
Cells that were expressing Stro1 were shown to have a limited bone forming capacity and 
expressed lower levels of bone markers whilst ALP+ cells displayed higher expression of 
bone markers and had a higher bone forming capacity (Gronthos et al., 1999), (Stewart et 
al., 1999). Another factor to consider is the mitogenic effects of Wnt stimulation on 
osteo-progenitor cell proliferation. Previous work has suggested that Wnt enhances 
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osteo-progenitor proliferation. This suggests that Wnt activity is an important driver of 
bone formation (Baksh et al., 2004), (Kato et al., 2002). The work presented in this 
chapter also supports this hypothesis. An increase in migratory cell numbers were 
observed in response to Wnt 3A, this may be explained by enhanced migration followed 
by proliferation of these osteo-progenitors before dissipation of the Wnt signal which 
allowed differentiation of the migrated cells. This hypothesis requires further 
investigation. 
Finally, the collagen gel constructs were stained for calcium to determine if the Wnt 
surfaces could affect osteogenic differentiation and end-stage mineralised nodule 
formation, which is an indicator of terminally differentiated osteoblasts. In this 
experiment, clear evidence of early stage mineralised nodule formation was observed in 
2/4 of the Wnt3a gels whilst no nodules were observed in the control gels.  This indicates 
a clear role of Wnt signalling gradients in MSC osteogenesis and formation of mineralised 
nodules. As discussed previously, the effects of Wnt signalling on MSC differentiation in 
vitro are often contradictory depending on the experimental conditions and cell lines 
used but it is clear that regulated Wnt signalling is required for bone development. 
Overall, these results suggest that the immobilised Wnt system presented here is 
potentially capable of maintaining and recapitulating the stem cell niche whilst promoting 
migration and then differentiation of stem cells further away from the Wnt signal. Further 
work is needed to fully dissect the phenotype of both basal layer cells and migrated cells. 
The level of Wnt pathway activity in these populations should also be determined in order 
to confirm the effects of Wnt gradients on MSC maintenance and differentiation. In the 
broader context of this thesis, it could also be postulated that Wnt gradients and 
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asymmetric cell division may be contributing factors governing hMSC osteogenesis 
mediated through MNP induced Wnt pathway activation described in chapter 4. The role 
of asymmetric cell division in MNP-mediated direction of MSC fate should be investigated 
to assess this.  
 
5.5 Conclusions 
The role of Wnt in maintaining the stem cell niche is well-known. One important aspect of 
niche regulation is the formation of spatial signalling gradients which regulates cell fate 
depending on the presentation and directionality of signalling proteins to cells. The 
results presented here demonstrate the importance of spatial presentation of Wnt in the 
regulation of the MSC niche which has been shown to be important for MSC migration 
and subsequent commitment to the osteogenic lineage. The immobilised Wnt platform 
may be able to improve the sustainability of the Wnt signal compared to the use of 
soluble Wnt whilst providing a localized basal Wnt stimulus to cells. This strategy has clear 
implications for the control of growth factor delivery that should inform the development 
of tissue engineered solutions for regenerative medicine. 
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6.1 The importance of Wnt signalling: from stem cells to bone 
The role of Wnt signalling in the regulation of stem cell maintenance and differentiation is 
well known. These pathways also play critical roles in regulating bone development from 
the limb bud to adult bone formation. The control of Wnt signalling for therapeutic 
purposes is therefore of particular relevance in a tissue engineering context. 
Manipulation of these pathways can be used to regulate stem cell fate in order to 
augment tissue development. It was hypothesised that magnetic activation of Wnt 
signalling could have beneficial effects on stem cell differentiation in a bone tissue 
engineering context. This thesis has introduced prototype engineering platforms which 
have been developed to explore the role of Wnt signalling as a regulator of the stem cell 
niche in bone development. Stimulation of hMSC using Wnt receptor targeting MNP was 
shown to activate Wnt/β-catenin signalling. Although signalling activation in this manner 
had modest effects on hMSC differentiation in vitro, combining this approach with BMP 
was subsequently shown to have a beneficial effect on bone formation in an ex vivo 
model of bone development. The results presented in earlier chapters suggest an 
important and beneficial role of Wnt signalling gradients in the control of stem cell 
migration and differentiation. This aspect of signalling regulation raises important 
implications for the development of future tissue engineering strategies.  
 
6.2 Wnt signalling and regulation of the stem cell niche 
Many studies utilising Wnt proteins for cell and tissue engineering purposes focus on the 
general application of different Wnt doses to a cell population.  One often overlooked 
aspect in tissue engineering is the spatial role of signalling gradients which are required 
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for normal tissue development in vivo (Heller and Fuchs, 2015). This thesis has briefly 
highlighted the importance of Wnt gradients in the regulation of the MSC niche using an 
immobilised Wnt platform. This approach has been shown to be beneficial in maintaining 
a stem cell phenotype in cells proximal to the Wnt signal whilst promoting migration in a 
collagen gel and subsequent enhancement of differentiated markers in the cells distal to 
the Wnt signal. One mechanism behind this observation may be Wnt induced asymmetric 
cell division. This process has been shown to be an important factor regulating ES cell fate 
and results in maintained stemness in the daughter cell proximal to the Wnt signal whilst 
promoting differentiation markers in the cell distal to Wnt (Habib et al., 2013). In the 
hMSC system presented here, asymmetric cell division may be one of the mechanisms 
influencing cell migration and differentiation. Taken together, these results highlight the 
advantages of controlled and patterned delivery of growth factors in tissue engineering 
approaches allowing the development of functional tissues. This aspect of patterned 
growth factor delivery should inform future studies and be investigated further. 
 
6.3 Remote modulation of Wnt signalling using MNP 
The work presented in this thesis has demonstrated the possibility of remotely targeting 
and activating Wnt signalling pathways using MNP targeted to Frizzled receptors at the 
cell membrane. With the use of oscillating magnetic fields, this has allowed the 
application of targeted mechanical stimulation of Frizzled receptors for remote activation 
of Wnt signalling pathways. This level of control of cell signalling is a promising 
development that brings distinct advantages over traditional drug delivery techniques 
that apply systemic and generalised drug doses. This is particularly important in the 
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context of Wnt signalling where systemic delivery of therapeutic agents is complicated 
due to the critical roles this pathway plays in development and disease in many tissues. 
Therefore the control afforded by magnetic activation is particularly advantageous for 
avoiding unwanted side-effects of aberrant Wnt pathway activation. 
6.3.1 Conformation dependent activities of UM206 
The main MNP targeting strategy in this work involved the use of the Frizzled binding 
peptide UM206. This peptide is derived from a fragment of the amino acid sequence from 
Wnt3a and Wnt5a and exists in two conformations. In the linear conformation, UM206 
has been shown to antagonise Wnt signalling in HEK293 cells. UM206 can also be induced 
into a cyclic conformation, which is formed by disulphide bond formation between two 
cysteine residues in the peptide. In the cyclic conformation UM206 has been shown to act 
as an agonist of Wnt signalling in HEK293 cells (Blankesteijn Wessel Matthijs, 2010). The 
experiments presented here suggest that the signalling ability of UM206 to act as an 
agonist or antagonist of Wnt signalling is different in hMSC compared to HEK293 cells. 
This may be due to many factors. One possible explanation is that the signalling dynamics 
may be different between HEK293 cells and MSC as a result of different expression 
patterns of Wnt receptors, inhibitors or intracellular mediators. Indeed the 
conformational dependent activity of UM206 was originally observed in HEK293 cells 
which were engineered to overexpress Frizzled 2 receptors, whilst the studies presented 
here used hMSC with endogenous Frizzled receptor expression. As a result this may alter 
the binding kinetics or affinity of UM206 to bind Frizzled receptors endogenously 
expressed in comparison to Frizzled overexpressing cells. A thorough study comparing the 
expression profile of Wnt components in hMSC and HEK293 cells would help to test this 
hypothesis. Interestingly linear-UM206 was found to activate signalling when bound to 
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MNP whereas cyclic-UM206-MNP did not. There are multiple possible reasons for this 
observation. Firstly, the cyclic peptide is known to have a lower affinity for Frizzled 
receptors and displays lower bio-activity. In HEK293 TCF/LEF reporter cells the EC50 value 
of the cyclic peptide was measured to be 2.10-8M, in contrast the linear peptide displayed 
an IC50 value of 10-10M (Blankesteijn Wessel Matthijs, 2010). These differences suggest 
that the linear peptide binds more efficiently to Frizzled receptors and so may be more 
potent in activating signalling. Secondly, the activating activity of Linear-UM206-MNP may 
be expected if the mechanism of pathway activation involves the simultaneous binding 
and formation of multiple Frizzled dimers which has been suggested previously (Carron et 
al., 2003). It is therefore plausible that the mechanical forces exerted by addition of 
magnetic field stimulation enhances peptide-receptor binding or causes further receptor 
clustering. This hypothesis could be investigated using Fluorescence Resonance Energy 
Transfer based assays. With respect to the inactivity of C-C-UM206-MNP, it is possible 
that the MNP and Cyclic-UM206 conjugation process may be inducing changes to the 
conformation of the cyclic peptide which could result in diminished Frizzled binding 
affinity. It is also possible that the Cyclic peptide-MNP conjugation process is not as 
efficient, which was suggested by the coating efficiency studies presented in chapter 2. 
Furthermore, the conjugation of multiple cyclic peptides to MNP may be inducing steric 
hindrance effects, which may also reduce the binding efficiency to Frizzled 2. This 
hypothesis could be explored further using binding assays to quantify the degree of MNP 
binding to cells when MNP are coated with Linear or Cyclic UM206. Another explanation 
could be related to the natural oxidising effects of the iron oxide core of MNP. This 
property of iron oxide could be inducing di-sulphide bond formation in Linear UM206. 
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Hypothetically, this could switch the linear peptide to the cyclic conformation and 
therefore alter its bioactivity. 
6.4 Use of Magnetic Nanoparticles 
Magnetic nanoparticles have emerged as extremely useful and adaptable tools in science, 
engineering and medicine. There is now a large scope for the application of nanoparticles 
of different sizes and functionality in many fields (Bao et al., 2015), (Salata, 2004). One 
particularly useful attribute of MNP is the ability to track them using various imaging 
modalities. For instance, the introduction of fluorescent tags to the matrix of MNP is 
easily achieved and enables convenient visual tracking of nanoparticles, which is a 
particular advantage in studies requiring MNP or cell tracking. There is also a clear role for 
different sized nanoparticles. Modifications to MNP size alters the rate of internalisation 
and changes the magnitude of the forces imparted by them (Hughes et al., 2005). In turn, 
this can have different effects on cell behaviour depending on the target and cell type. In 
the context of MNP-mediated mechanoactivation, the application of varied forces and 
stimulation regimes may result in differential signalling responses and changes in cell 
behaviour.  
6.4.1 Forces applied by MNP 
The forces imparted by MNP are measured in the order of piconewtons (pN). These are 
relatively low magnitude forces in comparison to other mechanical loading techniques. 
However, when considered that these forces are applied directly to proteins, it is not 
surprising that forces of this magnitude lead to changes in protein activity. This principle 
is shown by previous work utilising optical tweezers to impart load to cells and proteins. 
For instance, Cecconi et al discovered that application of 5.5pN forces is capable of 
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causing partial unfolding of RNase H in E-coli (Cecconi et al., 2005). Also, Walker et al 
demonstrated that 7pN loading of the cell bodies of individual bone cells resulted in 
changes in intracellular calcium signalling  (Walker et al., 1999). In terms of magnetic 
particle mediated activation, both nano- and micro-sized MNP have been shown to be 
capable of initiating the same cellular signalling responses. This suggests that just the 
direct application of pN forces to protein targets is required to elicit a biological response 
(Hughes et al., 2008). In any case, the low magnitude forces imparted by MNP have 
distinct advantages in tissue engineering systems unable to accommodate larger 
magnitude and/or global loading profiles. One such application is the mechanical loading 
of cell seeded hydrogel scaffolds which have shown promise in tissue engineering. 
Hydrogel scaffolds have particular advantages over denser scaffold materials such as the 
capability to directly control cell seeding, scaffold shape / volume and mechanical 
properties (El-Sherbiny and Yacoub, 2013). The benefits of MNP mediated stimulation in 
hydrogels has been demonstrated by Henstock et al who showed that MNP-mediated 
stimulation of Trek and integrin receptors on hMSC encapsulated in Collagen hydrogel 
resulted in increased bone formation and hydrogel density (Henstock et al., 2014). 
 
6.5 Magnetic Force Bioreactor 
Conditioning of cells and tissues using Bioreactor systems has become mainstream 
practice in Biomedical engineering. This work has centred on the use of an oscillating 
magnetic force bioreactor to impart magnetic field stimulation to magnetic nanoparticles 
for remote and targeted mechanical stimulation of cells and tissues. The use of this type 
of system brings numerous advantages for stem cell conditioning. Firstly, this system 
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affords a high degree of control of treatment parameters, for example the magnetic field 
dose can be modified to suit the level of force required by altering the magnetic arrays 
used or the distance of the arrays from the samples. The technology is also scalable, for 
instance the number of magnets on the array can be modified depending on 
experimental conditions allowing the capability for high-throughput assays. The fact that 
the forces applied are remote allows is also advantageous in that it permits a unique way 
of controlling cell signalling and, in a tissue engineering context, it permits conditioning of 
cells and softer scaffolds in a sterile environment. As a result this system has 
demonstrated its value both as a high throughput screening tool and as a non-invasive 
cell and tissue conditioning bioreactor for tissue engineering. 
 
6.6 Applications of magnetic stimulation in bone tissue engineering 
The use of functionalised MNP and magnetic fields for the stimulation and activation of 
stem cells has emerged as a viable strategy for the promotion of bone formation both in 
vitro and in vivo. There are now numerous proof of concept studies demonstrating the 
potential of this strategy to modulate numerous mechanotransduction pathways for 
directing osteogenesis of stem cells for the enhancement of bone repair (Wimpenny et 
al., 2012), (Markides et al., 2015). This strategy has also been shown to be amenable and 
synergistic with a range of growth factors and biomaterials enabling mechanical 
conditioning of cell-seeded scaffolds for enhancement of bone formation (Hu et al., 
2013), (Henstock et al., 2014), (Hughes et al., 2007). In the context of the array of 
signalling pathways that have been shown to be responsive to mechanical stimulation, 
the work presented here suggests that Wnt signalling pathway may be another mechano-
 219 
 
responsive target that can be modulated for the promotion of bone formation when 
combined with other anabolic growth factors. This is particularly relevant to patients 
suffering from osteoporosis and neurodegenerative disorders where a decrease in Wnt 
signalling has been associated with disease progression (Hoeppner et al., 2009), 
(Terstappen et al., 2006). 
 
6.7 The foetal chick femur model  
This thesis has introduced the foetal chick femur as a model of early bone development. 
In this work, chick femurs were extracted at 11 days of gestation (E11). This is a 
comparatively early model of bone formation at approximately half-way through 
gestation. At this stage the tissue is mainly cartilaginous with only a mineralised bone 
collar present and is absent of blood vessel invasion. With this in mind, it is quite possible 
that a different outcome, in terms of tissue generation, may be expected if the magnetic 
activation strategy were to be applied to ex vivo femurs at later stages of development. 
One way to investigate this is to use later stage chick femurs e.g. gestation day E13-E17. 
Although femurs at this later stage do not display extensive vasculature, they are 
significantly more developed compared to the E11 stage and have robustly formed bone 
matrix (Smith et al., 2012), (Kanczler et al., 2012), (Smith et al., 2015), (Nowlan et al., 
2007). Vasculogenesis  is an instrumental process in bone development and repair 
(Kanczler and Oreffo, 2008). In this respect, one avenue for exploring the effects of 
vasculogenesis  on bone development is the Chorioallantoic membrane model (CAM), 
which has recently been utilised by Smith et al. (Smith et al., 2013). The CAM is a highly 
vascularised extraembryonic membrane surrounding chick embryos. In this model, tissue 
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engineering constructs can be cultured on a vascular bed which is accessible from a 
window excised from the egg shell. Culture of explants on the CAM allows vascular 
intrusion into the constructs; this model could allow the simultaneous evaluation of MNP 
stimulation and vasculogenesis on bone formation. However, one caveat is that this 
would require further development and modifications to the magnetic stimulation system 
before this study could take place.  
Despite the numerous similarities in the bone developmental processes between chick 
and human, there are also developmental differences which should be considered (Smith 
et al., 2013). Embryonic avian bones have a single ossification centre during gestation 
compared to the secondary ossification centres observed in mammals. Cartilage 
vascularisation is  also absent in the chick until mineralisation occurs which is in contrast 
with mammalian development (Nowlan et al., 2007). Also, the avian growth plate is not 
as ordered and substantially increases in thickness during development whilst the 
mammalian growth plate remains a constant thickness (Roach, 1997). These factors may 
influence the apparent efficacy of cell based tissue engineered strategies in chick models 
and therefore the translational potential of such treatments. Therefore, the efficacy of 
these novel cell and MNP therapies would need to be fully assessed in other animal 
models first.   
 
6.8 Future work 
6.8.1 Development of the Magnetic force bioreactor 
Bioreactors have been demonstrated to be incredibly useful platforms for cell 
conditioning and engineering tissue constructs. This work has focused on mechanical 
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stimulation of cells and tissues using magnetic nanoparticles coupled with an innovative 
magnetic force bioreactor. There is scope for the future development of this system. The 
magnetic force bioreactor utilised in these experiments relied upon the magnetic field 
produced by permanent rare earth magnets on a platform driven by a drive shaft. This 
results in heavy apparatus which requires cooling during operation which raises potential 
safety problems if this technology is to be translated into the clinic. An improvement to 
this system could be the replacement of heavy permanent magnets with electromagnets. 
This would make the system lighter, more controllable and negate the need for constant 
cooling.    
6.8.2 Improving MNP functionalisation 
The MNP functionalisation process used in this work is based on carbodiimide activation 
of carboxyl groups on MNP. This reaction results in formation of a peptide bond between 
the MNP carboxyl group and amine groups present on the protein ligands. Although 
peptide bond formation results in very stable bonding between molecules (Montalbetti 
and Falque, 2005), (Radzicka and Wolfenden, 1996),  non-specific cross-linking between 
MNP and ligands could lead to high density packing of biomolecules on the MNP surface. 
This may lead to steric hindrance and limit the targeting capabilities of the bio-ligands. 
One way of off-setting this potential issue is through the use of molecular spacers such as 
organic linkers. This would increase the molecular spacing between ligands potentially 
allowing the correct orientation of ligands to occur which in turn may improve targeting 
efficiency. One commonly used spacer is poly ethylene glycol (PEG), this has been shown 
to improve ligand/receptor interactions in a targeting therapy for tumour imaging 
(Varasteh et al., 2014) and for folate-receptor targeted liposomes for drug delivery in 
cancer models (Kawano and Maitani, 2011).  
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6.8.3 Investigating alternative nanoparticles 
These experiments were underpinned by the application of one type of super 
paramagnetic nanoparticle. It is possible that other types of nanoparticle may influence 
the magnitude of the effects on cell signalling activation. MNP of different sizes have 
different magnetic properties and impart different mechanical loads which in turn may 
augment or reduce signalling activation. The application of other types of nanoparticles 
should therefore be investigated to study this possibility. Further to this, different 
magnetic stimulation regimes with different doses of MNP may be better suited to 
different targets or when stimulating different cell types. A thorough investigation into 
magnetic stimulation regimes and a dose-response study of MNP is also needed in order 
to fully optimise the protocol for controlling cell differentiation.     
6.8.4 Exploring the mechanism behind magnetic activation of Wnt pathways 
There are multiple mechanisms through which Wnt/β-catenin signalling can be induced. 
Wnt proteins act through Frizzled and co-receptors whilst pharmacological activation 
through small molecules such as LiCl acts on the intracellular mediator GSK-3β (Freland 
and Beaulieu, 2012). Mechano-activation of Wnt signalling has also been previously 
demonstrated. Norvell et al, showed that fluid shear stress is capable of mobilising 
cadherin associated β-catenin with the subsequent activation of Wnt signalling (Norvell et 
al., 2004). The results from chapter 3 suggest that magnetic activation of Wnt signalling 
also occurs through a different mechanism to Wnt protein in a way that is co-receptor 
independent. As MNP are known to torque and induce forces in response to magnetic 
fields it is therefore possible that this mechanical stimulation could induce a cadherin 
mobilising effect similar to the effects of shear stress when the MNP are bound to the cell 
surface. Frizzled clustering and dimerisation has also been shown as another mechanism 
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of Wnt pathway activation. This has been demonstrated both experimentally and by 
mathematical modelling (Carron et al., 2003), (Voronkov et al., 2008). When considering 
that MNP functionalised with peptides and antibodies will contain multiple ligands per 
particle, it is therefore feasible that these MNP are inducing receptor clustering that 
causes subsequent pathway activation. Both of these mechanisms should be investigated 
further to determine the precise mechanism of MNP mediated Wnt activation.  
6.8.5 Targeting other Wnt pathway receptors 
There are multiple receptors involved in Wnt signalling at the cell membrane. The 
targeting strategy used in this work has used antibodies and peptides that interact with 
one of the Frizzled receptors. There are nine other Frizzled receptors in humans along 
with a plethora of other co-receptors which control other aspects of Wnt signalling 
pathways. If targeting strategies can be developed for these other targets, the mechano-
responsiveness of these receptors and downstream effects on Wnt signalling could be 
investigated and may even allow greater control of pathway activity which may influence 
the outcome on cell fate. This work has focused on the effects of functionalised MNP on 
canonical Wnt signalling. However there is growing evidence that the non-canonical Wnt 
signalling pathways are also involved in MSC fate including the promotion of osteogenic 
differentiation of MSC (Arnsdorf et al., 2009), (Chang et al., 2007), (Baksh and Tuan, 
2007). Therefore the effects of targeted MNP on non-canonical pathway activity in MSC 
and effects on cell fate should also be investigated.  
6.8.6 Interplay between growth factor and MNP-mediated signalling 
Wnt signalling acts in concert with a wide array of other signalling pathways during 
development. The cross-talk between these signalling networks is crucial for properly 
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controlled bone development. This work has given a snapshot into the synergistic roles of 
Wnt and BMP signalling for bone generation using a foetal chick femur model. Future 
work should interrogate the cross-talk with other signalling pathways and the molecular 
mechanisms underpinning them (e.g. gene expression analysis) in order to elucidate the 
optimum signalling environments for bone generation. The effects of spatial gradients 
and the temporal nature of signalling pathways are also important considerations in bone 
development and require investigation. 
6.8.7 Optimising cell targets for differentiation 
It is clear that the effects of Wnt signalling on stem cell proliferation and differentiation 
are complex and tight regulation of this pathway is ultimately required to optimise stem 
cell differentiation and tissue development. This thesis has examined the role of 
intermittent Wnt signalling activation on the osteogenic differentiation of MSC for bone 
formation. However, Wnt signalling is known to play roles in most cells types of the 
osteogenic lineage ranging from osteoprogenitor cells to osteocytes and osteoblasts 
(Leucht et al., 2008) and has been shown to have different effects on cell function 
depending on the differentiation state of the target cells (Quarto et al., 2010).  In this 
case, targeting other cells at other stages of differentiation should also be investigated to 
ascertain if bone formation can be driven more efficiently by targeting these cell types. 
6.8.8 Re-creating the stem cell niche 
The work presented in this thesis has also hinted at the advantages of developing 
localised Wnt signalling gradients to promote MSC migration and regulate MSC 
osteogenic differentiation in migrated cells. Future work should interrogate the 
phenotype of the cells at different levels of migration. This could be achieved by looking 
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at other MSC markers of stemness in basal cell layers closest to the Wnt signals such as 
CD73, CD90 and CD105 whilst examining other differentiation markers in migrated cells 
which are further from the Wnt signal such as RUNX2, Osteopontin and Collagen 1. The 
level of Wnt pathway activity in migrated MSC and the role of asymmetric cell division in 
these processes are other exciting avenues for future research.  
 
6.9 Final conclusions 
The work presented in this thesis has shown that it is possible to engineer magnetic 
nanoparticles to target cell surface receptors and activate the Wnt signalling pathway in 
hMSC, a clinically relevant stem cell type. It has also been demonstrated that this strategy 
can have beneficial effects on hMSC osteogenic differentiation in ex vivo bone formation 
models particularly when used in conjunction with other growth factors. Importantly, this 
strategy was shown to be complementary to BMP2 signalling in supporting bone 
development. A table summarising the effects of MNP and hMSC stimulation on Wnt 
signalling and osteogenesis is presented in tables 6.1, 6.2 and 6.3. 
 
 
 
 
Table 6.1. Summary of the effects of MNP on Wnt pathway activation. 
+ denotes increased effect, - denotes decreased effect, = denotes no change 
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This work also demonstrates the multiple advantages to using magnetic nanoparticles to 
apply forces to cells and tissues. The fact that MNP can be produced relatively easily at 
different sizes with different magnetic properties and functionality enables their use to be 
tailored and their dose to be scaled to the desired application. Furthermore, the fact that 
the mechanical forces provided by MNP are translated directly to cells allows a high 
degree of control over the magnitude of the forces applied which can be altered by 
changing the MNP dose or stimulation regime. This also means that cells can be 
mechanically conditioned on a wider array of scaffolds including softer scaffolds unable to 
accommodate direct mechanical loading. This work has also touched upon the benefits of 
creating directional Wnt signalling gradients which are important for the maintenance of 
the stem cell niche in bone. This approach has been shown to have beneficial effects on 
the regulation of MSC osteogenic differentiation.   
Table 6.3. Summary of the effects of MNP on in vitro MSC osteogenesis. 
+ denotes increased effect, - denotes decreased effect, = denotes no change 
Table 6.2. Summary of the effects of MNP on ex vivo bone formation. 
+ denotes increased effect, - denotes decreased effect, = denotes no change 
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In conclusion, this work has shown the benefits of remote stem cell activation and 
directional application of Wnt gradients for the regulation of stem cell differentiation and 
bone formation. One key advantage of this approach is that it is cell therapy based; this 
allows the possibility of developing a treatment that could be administered with a simple 
injection. Added to this, the use of nanoparticles targeted to specific cell receptors 
effectively allows for a controlled dose of cell activation which could be administered with 
the application of an externally controlled magnetic field. With further development, the 
techniques applied here could conceivably be adapted to produce a minimally invasive 
cell therapy which could be readily translated to the clinic. 
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A. Appendix A: hMSC characterisation 
 
Figure A.1. hMSC surface marker characterisation. 
MSC surface marker expression was analysed by flow cytometry to confirm the 
presence of MSC markers CD73, CD90 and CD105 and the absence of CD14, CD19, 
CD44, CD45 and HLA-DR. Each marker displays the result of a minimum of 5X104 
events. This experiment was performed by J. Price (Keele University)  
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Figure A.2. hMSC marker expression. 
Immunofluorescence images for CD marker expression showing bone-marrow derived hMSC are positive for hMSC markers 
CD73 (A), CD90  (B) and CD105 (C). Cells were negative for haematopoietic markers CD14, CD20, CD34 and CD45 (D). IgG Isotype 
controls were also negative (E). Cells nuclei are shown by DAPI staining (F-J), Merged images are shown K-O. Representative 
images of n=3 shown, scale bar represents 100µm.  
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Figure A.3. hMSC tri-lineage histological staining. 
Histological staining of hMSC after 21 days culture in differentiation media. Cells 
cultured in adipogenic differentiation media were positive for lipid droplets as 
shown by Oil red O staining (A). Cells cultured in chondrogenic media were 
positive for GAG’s as shown by Alcian blue staining (B). Cells cultured in 
osteogenic media were positive for calcium as shown by Alizarin Red S staining 
(C). Representative images of n=3 shown. This experiment was performed by S. 
Moise (Keele University). 
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B. Appendix B: Standard curves 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B.1. Standard curve for DNA in TE buffer using PicoGreen assay. 
Figure B.2. Standard curves of Bovine Serum Albumin acquired in different 
buffers. 
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Figure B.3. Standard curve of 4-Methylumbelliferone in Diethanolamine buffer for 
the quantification of Alkaline Phosphatase activity. 
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C. Appendix C: Extended Methods 
Extraction of total RNA using RNAeasy kit 
Cells were lysed with addition of 350μL of buffer RLT for 10mins. 350μL of 70% EtOH was 
added to each well and mixed. Lysates were then transferred to RNAeasy mini-spin 
columns and centrifuged at 8000g for 15s, the flow through was discarded. 700μL of 
Buffer RW1 was added to the columns and samples centrifuged at 8000gfor 15s, the flow 
through was discarded. 500μL of Buffer RPE was added to each column and samples 
centrifuged at 8000gfor 15s, the flow through was discarded. Another 500μL of Buffer 
RPE was added to each column and samples were centrifuged at 8000g for 2mins, the 
flow through was discarded. Centrifugation was repeated at 12,000rpm for 1mins, the 
flow through was discarded. 17μL of H20 was added to each  column and centrifuged at 
8000g for 1min to elute the RNA. The flow through was added back to the column and re-
centrifuged at 8000g for 1min to complete RNA elution. RNA quality and concentration 
was determined by spectrophotometric analysis using absorbance at 260 nm and 280 nm 
respectively. 
Extraction of total RNA using TRI reagent 
Cells were lysed using 1mL of Tri reagent per well for 10mins. Lysate was homogenised by 
passing through a pipette several times collected in sample tubes and vortexed for 15s. 
Samples were incubated for 5mins. 0.2mL of chloroform was added to each sample then 
vortexed for 15s. Samples were incubated for 5mins then centrifuged at 12000g for 
15mins at 4oC. The upper colourless aqueous phase was transferred to a new sample 
tube. RNA was precipitated with the addition of 0.5mL of 2-Propanol per sample. Samples 
were incubated 10mins then centrifuged at 12000g for 10mins at 4oC. The supernatant 
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was removed and the RNA pellet was washed with 1mL of 75% EtOH. Samples were 
mixed then centrifuged at 12000g for 5mins at 4oC. The supernatant was removed and 
samples allowed to air dry for 5mins. RNA was dissolved in 17μL H2O. RNA quality and 
concentration was determined by spectrophotometric analysis using absorbance at 260 
nm and 280 nm respectively. 
cDNA synthesis using High capacity cDNA Reverse transcription kit 
(Applied Biosystems) 
A reverse transcription (RT) master mix was prepared on ice as detailed below: 
Component Volume per reaction (μL) 
10x Reverse Transcription buffer 2 
25x dNTP mix 0.8 
10x Reverse Transcription random primers 2 
Reverse Transcriptase 1 
H20 4.2 
Total 10 
Table C.1. Reverse Transcription master mix components 
10μL of RT master mix was aliquoted into reaction tubes. The appropriate amounts of 
extracted RNA were added to the RT master mix. Tubes were sealed and samples kept on 
ice until thermocycling. Reverse transcription was performed under the conditions 
detailed below. Samples were stored at -20oC until further use.    
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 Step 1 Step 2 Step 3 Step 4 
Temperature (oC) 25 37 85 4 
Time (mins) 10 120 5 Hold 
Table C.2. Reverse Transcription thermocycling conditions 
RT-PCR and qPCR primer details 
Primer Catalogue 
no. 
Gene Detected Transcript Amplicon 
length 
Hs_FZD2_1_SG QT00208208 FZD2 NM_001466 (3834 bp) 141 bp 
Hs_GAPDH_2_SG QT01192646 GAPDH NM_002046 (1421 bp) 
NM_001289745 (1513 bp) 
119 bp  
211 bp 
Hs_PTGS2_1_SG QT00040586 PTGS2 NM_000963 (4507 bp) 68 bp 
Hs_MYC_1_SG QT00035406 MYC NM_002467 (2379 bp) 129 bp 
Hs_NFKB1_1_SG QT00063791 NFKB1 NM_001165412 (4090 bp) 
NM_003998 (4093 bp) 
XM_005263029 (4007 bp) 
XM_006714229 (3642 bp) 
68 bp 
68 bp 
68 bp 
68 bp 
Table C.3. Qiagen primer details 
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Western blotting lysis buffer recipe 
Component Working Concentration 
Pepstatin A (Sigma) 1μM 
PMSF (Sigma) 1mM 
Protease inhibitor cocktail mix (Sigma) 1x 
Sodium vanadate 1mM 
Sodium Fluoride 40mM 
RIPA buffer (Sigma) 1x 
Table C.4. Western blotting cell lysis buffer components 
Preparation of Wnt 3A conditioned media 
Mouse L-M(TK-) cells that overexpress Wnt 3A (LGC standards) were seeded into T75 
flasks and cultured in 10mL of basal media (High Glucose DMEM, 10% FBS, 1% Pen/Strep, 
1% L-Glutamine) until confluent. The media was then removed and stored. 10mL of fresh 
media was added to the flasks and cells cultured for a further 3 days. The media was 
removed, mixed with the first batch of media 1:1, sterile filtered and stored at -20oC until 
further use.  
 
 
 
